


Covid-19

Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update April 5 - April 11, 2021,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 14 2021

1078 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashbord](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford Universtiy Press](#)

[Cambridge Univeristy Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[German \(ICU\) bed capacity](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[COVID reference \(Steinhauser Verlag\)](#)

[Retracted papers](#)

[COVID-19 risk tools - Apps](#)

[Web app for SARS-CoV2 mutations](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

[COVID-19 prevention network](#)

[Covid-Plex trial - \(plasma exchange & convalescent plasma trial\)](#)

**Re: Plasma exchange and convalescent plasma in COVID-19 patients with
multi-organ failure –**

The COVID-19 PLEX + Convalescent Plasma trial –

Enrollment initiated

The Covid-Plex trial is an investigator initiated, multicenter, parallel-group, open-label randomized clinical trial aiming to randomize patients with severe COVID-19 to standard care or standard care plus plasmapheresis and convalescent plasma.

If you are interested to participate Please contact Wladimir Szpirt, Nicholas Carlson Anders, or Perner Bo Feldt-Rasmussen. Depts. Of Intensive Care Therapy and Nephrology, Copenhagen University Hospital Rigshospitalet, Denmark

[Covid-Plex trial](#)

Mainstream Media

[New York Times - Corona update](#)

[Vaccines Won't Protect Millions of Patients With Weakened Immune Systems](#)

[Can the Covid Vaccine Protect Me Against Virus Variants?](#)

[C.D.C. Panel Keeps Pause on Use of J&J Vaccine, Need to Assess Potential Risks](#)

[Nearly half of Republicans say they don't want a Covid vaccine.](#)

[Empty middle seats reduce virus risk on planes, a new study says](#)

[What the Coronavirus Variants Mean for Testing](#)

[What Women Need to Know About the Covid Vaccine](#)

[Regular Exercise May Help Protect Against Severe Covid](#)

[What Are the Roadblocks to a 'Vaccine Passport'?](#)

[Washington Post - Corona update](#)

[Annual vaccine booster shots may be needed, potentially stretching supply.](#)

[How travelers can find vaccines on the road](#)

[Why Biden health officials decided to pause J&J's coronavirus vaccine](#)

[Cleaning with regular soap and water is often good enough to fight covid-19](#)

[A vaccine study in college students help determine when it's safe to take masks off](#)

[Why covid arm and other post-vaccine rashes might actually be a 'good thing'](#)

[CDC ramps up scrutiny of rare post-vaccination 'breakthrough infections'](#)

[Your questions about coronavirus vaccines, answered](#)

[Guardian - Corona update](#)

[Covid variant first detected in India is found in the UK](#)

[What is a lateral flow Covid test and how accurate is it?](#)

[Rapid Covid testing in England may be scaled back over false positives](#)

[US company illegally peddling 'miracle cure' bleach for new Covid variants](#)

Key Articles

1. **Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease.** Open Heart 2021; 8Tessitore E, Carballo D, Poncet A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833064>

History of CVD is a strong predictor of mortality and MACE in hospital admitted COVID-19 patients. In this study conducted in a Geneva university hospital, the risk for the composite endpoint of mortality and MACE occurred in 141/277 CVD patients (51%) vs. 83/562 patients (15%) in those without CVD.; OR:6.0 (4.3-8.4, $p<0.001$). Age, male sex, and elevated CRP were additional independent predictors of mortality

2. **COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER).** Vaccine 2021; Kochhar S, Dubé E, Graham J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836897>

This publication on vaccine safety questions for healthcare providers, shares a website link to the CANvax website (<https://canvax.ca/covid-19-vaccine-questionsand-answers-healthcare-providers>). This is a living document that is accredited by the WHO Vaccine Safety net. The Q&A's are available in English, French, Arabic, and Chinese. Additional languages will be added in the near future

3. **Novel coronavirus disease 2019 (COVID-19) pandemic: From transmission to control with an interdisciplinary vision.** Environ. Res. 2021;111126Anand U, Cabrerós C, Mal J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831411>

This article is helpful for those interested in a broad scientific review of relevant information on SARS-CoV2 and COVID-19. It includes information on virological characteristics, medical implications of the infection, human susceptibility, infection routes, and non-pharmacological interventions. The authors suggest establishing an international healthcare trans-multi-disciplinary workforce devoted to investigate, mitigate, and control current and future viral events.

4. **Current questions regarding Covid-19 vaccination for specific populations - an overview of the state of research.** MMW-Fortschritte der Medizin 2021; 163:48-49Sönmez S, Huenges B, Vollmar HC.

5. **Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.** Emerg Microbes Infect 2021:1-23Rockstroh A,

Wolf J, Fertey J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830901>

6. **Pathomechanism and Management of Stroke in COVID-19: Review of Immunopathogenesis, Coagulopathy, Endothelial Dysfunction, and Downregulation of ACE2.** J. Clin. Neurol. 2021; 17:155-163Rahmawati PL, Tini K, Susilawathi NM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835735>
7. **Assessment of COVID-19 deaths from cardiological perspective.** Acta Cardiol. 2021:1-8Omar T, Karakayalı M, Perincek G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823754>
8. **Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials.** Medwave 2021; 21:e8105Meza N, Pérez-Bracchiglione J, Pérez I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830976>
9. **COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography.** J. Thromb. Thrombolysis 2021; Maier CL, Sarker T, Szlam F, Sniecinski RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829396>
10. **Adverse effects of COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.** J Med Virol 2021; Kadali RAK, Janagama R, Peruru S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822361>
11. **Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USA.** BMJ Open 2021; 11:e047121Incerti D, Rizzo S, Li X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827848>
12. **Detecting COVID-19 from Breath: A Game Changer for a Big Challenge.** ACS Sens 2021; Giovannini G, Haick H, Garoli D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825440>
13. **Diabetes and COVID-19.** Open Life Sci 2021; 16:297-302Gazzaz ZJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817321>
14. **Obesity and its impact on COVID-19.** J. Mol. Med. (Berl.) 2021; de Leeuw AJM, Oude Luttikhuis MAM, Wellen AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824998>
15. **Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.** Clin Chem Lab Med

Basic Science (47 articles)

1. **A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing.** 3 Biotech 2021; 11:198Kumar SU, Priya NM, Nithya SR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816047>
2. **Structural biology of coronavirus ion channels.** Acta Crystallogr D Struct Biol 2021; 77:391-402Barrantes FJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825700>
3. **A time-delay COVID-19 propagation model considering supply chain transmission and hierarchical quarantine rate.** Adv Differ Equ 2021; 2021:191Yang F, Zhang Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815492>
4. **SARS-CoV-2: the "Uncensored" Truth about Its Origin and Adipose-Derived Mesenchymal Stem Cells as New Potential Immune-Modulatory Weapon.** Aging Dis 2021; 12:330-344Gentile P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815867>
5. **An Account of Immune Senescence in the Clinical Pathophysiology of COVID-19 Infection in Aging.** Aging Dis 2021; 12:662-670Jain S, Abrham E, Khan MN, Mathur R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815889>
6. **Investigation into molecular mechanisms and high-frequency core TCM for pulmonary fibrosis secondary to COVID-19 based on network pharmacology and data mining.** Ann Palliat Med 2021; Yu MX, Song X, Ma XQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832291>
7. **Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection.** Biochemistry (Mosc.) 2021; 86:257-261Letarov AV, Babenko VV, Kulikov EE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838638>
8. **Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay.** Bioorg. Med. Chem. 2021; 38:116119Sun H, Wang Y, Chen CZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831697>
9. **Development strategies of conducting polymer-based electrochemical biosensors for virus biomarkers: Potential for rapid COVID-19 detection.** Biosens. Bioelectron. 2021; 182:113192Tran VV, Tran NHT, Hwang HS, Chang M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819902>
10. **Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.** Biotechnol. Bioeng. 2021; Kiesslich S, Kim GN, Shen CF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837958>
11. **IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays.** BMC Infect. Dis. 2021;

21:325Shah J, Liu S, Potula HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827460>

12. **Bioinformatics and machine learning approach identifies potential drug targets and pathways in COVID-19.** Brief. Bioinform. 2021; Auwul MR, Rahman MR, Gov E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839760>
13. **Choice of assemblers has a critical impact on de novo assembly of SARS-CoV-2 genome and characterizing variants.** Brief. Bioinform. 2021; Islam R, Raju RS, Tasnim N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822878>
14. **Electrospun Aspirin/Eudragit/Lipid Hybrid Nanofibers for Colon-targeted Delivery Using an Energy-saving Process.** Chem. Res. Chin. Univ. 2021:1-7Wang Y, Tian L, Zhu T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814861>
15. **COVID-19 into Chemical Science Perspective: Chemical Preventive Measures and Drug Development.** ChemistrySelect 2021; 6:2010-2028Adhikari B, Sahu N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821213>
16. **Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 M(pro) for pharmacological interventions in COVID-19 pandemic.** Chronobiol. Int. 2021:1-15Sultan A, Ali R, Sultan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820462>
17. **Lung organoid simulations for modelling and predicting the effect of mutations on SARS-CoV-2 infectivity.** Comput Struct Biotechnol J 2021; 19:1701-1712Esmail S, Danter WR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815693>
18. **COVID-19 co-infection mathematical model as guided through signaling structural framework.** Comput Struct Biotechnol J 2021; 19:1672-1683Soni B, Singh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815692>
19. **The Main Receptors Involved with COVID-19: a Systematic Review and Meta-analysis.** Curr Med Chem 2021; Câmara AB, Brandão IA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820514>
20. **New insights into application of nanoparticles in the diagnosis and screening of novel coronavirus (SARS-CoV-2).** Emergent Mater 2021:1-17Tharayil A, Rajakumari R, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817553>
21. **E-cigarette Vape and Lung ACE2 Expression: Implications for coronavirus vulnerability.** Environ. Toxicol. Pharmacol. 2021:103656Lallai V, Manca L, Fowler CD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838329>
22. **The endless frontier of tRNA synthetases.** Enzymes 2020; 48:1-10Schimmel P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837700>
23. **Recent efforts for drug identification from phytochemicals against SARS-CoV-2: Exploration of the chemical space to identify druggable leads.** Food Chem. Toxicol. 2021:112160Joshi G, Sindhu J, Thakur S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823228>
24. **Is SARS-CoV-2 Spike glycoprotein impairing macrophage function via $\alpha 7$ -nicotinic acetylcholine receptors?** Food Chem. Toxicol. 2021:112184Tanmay S, Lambros D, Farsalinos K, Poulas K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838172>
25. **COVID-19-A Theory of Autoimmunity Against ACE-2 Explained.** Front. Immunol. 2021; 12:582166McMillan P, Dexhiemer T, Neubig RR, Uhal BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833750>

26. **Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19.** Front. Microbiol. 2021; 12:637430 Ventero MP, Cuadrat RRC, Vidal I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815323>
27. **An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies.** Gene Rep 2021;101122 Das A, Ahmed R, Akhtar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821222>
28. **Interferon-induced transmembrane protein-3 genetic variant rs12252 is associated with COVID-19 mortality.** Genomics 2021; Alghamdi J, Alaamery M, Barhoumi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838280>
29. **Design and Identification of Novel Annomontine Analogues Against SARS-CoV-2: An In-Silico Approach.** Heliyon 2021:e06657 Waidha K, Saxena A, Kumar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824915>
30. **Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach.** Indian J Med Res 2021; 153:132-143 Behera SK, Mahapatra N, Tripathy CS, Pati S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818470>
31. **An overview of preclinical animal models for SARS-CoV-2 pathogenicity.** Indian J Med Res 2021; 153:17-25 Munshi I, Khandvilkar A, Chavan SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818465>
32. **Phylogenetic classification of the whole-genome sequences of SARS-CoV-2 from India & evolutionary trends.** Indian J Med Res 2021; 153:166-174 Potdar V, Vipat V, Ramdasi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818474>
33. **COVID-19 vs influenza viruses: A cockroach optimized deep neural network classification approach.** Int J Imaging Syst Technol 2021; El-Dosuky MA, Soliman M, Hassanien AE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821096>
34. **Longitudinal Assessment of SARS-CoV-2 Anti-Nucleocapsid and anti-Spike-1-RBD Antibody Testing Following PCR-Detected SARS-CoV-2 Infection.** J Appl Lab Med 2021; El-Khoury JM, Schulz WL, Durant TJS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822964>
35. **Functional characterization of CD4+ T-cell receptors cross-reactive for SARS-CoV-2 and endemic coronaviruses.** J. Clin. Invest. 2021; Dykema AG, Zhang B, Woldemeskel BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830946>
36. **Genomic surveillance of Nevada patients revealed prevalence of unique SARS-CoV-2 variants bearing mutations in the RdRp gene.** J Genet Genomics 2021; Hartley PD, Tillett RL, AuCoin DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820739>
37. **The stability of an isolate of the SARS-CoV-2 B.1.1.7 lineage in aerosols is similar to three earlier isolates.** J Infect Dis 2021; Schuit M, Biryukov J, Beck K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822064>
38. **A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers.** J. Pharm. Biomed. Anal. 2021; 199:114057 Morsy MI, Nouman EG, Abdallah YM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831737>
39. **CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.** J Zhejiang Univ Sci B 2021; 22:253-

284Li C, Brant E, Budak H, Zhang B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835761>

40. **A mechanism for matrikine regulation in acute inflammatory lung injury.** JCI Insight 2021; 6Robison SW, Li J, Viera L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830084>
41. **Network bioinformatics analysis provides insight into drug repurposing for COVID-19.** Med Drug Discov 2021:100090Li X, Yu J, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817623>
42. **Could SARS-CoV-2 blocking of ACE2 in endothelial cells result in upregulation of CX3CL1, promoting thrombosis in COVID-19 patients?** Med. Hypotheses 2021; 151:110570Rivas-Fuentes S, Valdés VJ, Espinosa B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836338>
43. **A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice.** Mol. Ther. 2021; de Alwis R, Gan ES, Chen S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823303>
44. **Computational Insights of phytochemical Driven Disruption of RNA dependent RNA polymerase Mediated replication of Coronavirus: A Strategic Treatment Plan against COVID-19.** New Microbes New Infect 2021:100878Balkrishna A, Mittal R, Sharma G, Arya V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815808>
45. **Focused Role of Nanoparticles Against COVID-19: Diagnosis and Treatment.** Photodiagnosis Photodyn. Ther. 2021:102287Dheyab MA, Khaniabadi PM, Aziz AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836276>
46. **Robust antimicrobial photodynamic therapy with Curcumin-Poly (Lactic-co-Glycolic Acid) nanoparticles against COVID-19: A preliminary in vitro study in Vero cell line as a model.** Photodiagnosis Photodyn. Ther. 2021:102286Pourhajibagher M, Azimi M, Haddadi-Asl V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838311>
47. **Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property.** Phytother. Res. 2021; Palit P, Mukhopadhyay A, Chattopadhyay D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817867>

Biomarkers - Genetics (137 articles)

1. **Detecting COVID-19 from Breath: A Game Changer for a Big Challenge.** ACS Sens 2021; Giovannini G, Haick H, Garoli D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825440>
2. **Vertical Flow Cellulose-Based Assays for SARS-CoV-2 Antibody Detection in Human Serum.** ACS Sens 2021; Kim S, Hao Y, Miller EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822583>
3. **Electrochemical Resonance of Molecular Motion Enabling Label-, Antibody-, and Enzyme-Free Detection of SARS-CoV-2.** ACS Sens 2021; Zhou L, Hao P, Li H, Zhang Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823114>

4. **Rapid Antigen Detection Test for Severe Acute Respiratory Syndrome Coronavirus 2: How to Use It Properly?** Acta Med Indones 2021; 53:119-131 Loho T, Widodo D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818415>
5. **Genomic Insights into the Human Susceptibility to SARS-CoV-2 Infection.** Acta Med Port 2021; Magalhães AC, Pedro N, Pereira L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821785>
6. **Knowledge, attitude and practices of COVID-19 among medical laboratory professionals in Zambia.** Afr J Lab Med 2021; 10:1403 Chawe A, Mfuno RL, Syapiila PM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821204>
7. **Global Sex Disparity of COVID-19: A Descriptive Review of Sex Hormones and Consideration for the Potential Therapeutic Use of Hormone Replacement Therapy in Older Adults.** Aging Dis 2021; 12:671-683 Okpechi SC, Fong JT, Gill SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815890>
8. **Digital Droplet PCR for SARS-CoV-2 Resolves Borderline Cases.** Am J Clin Pathol 2021; Xu J, Kirtek T, Xu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822853>
9. **The role of the BUN/albumin ratio in predicting mortality in COVID-19 patients in the emergency department.** Am J Emerg Med 2021; 48:33-37 Küçükceran K, Ayrancı MK, Girişgin AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838471>
10. **Diagnostic accuracy estimates for COVID-19 RT-PCR and Lateral flow immunoassay tests with Bayesian latent class models.** Am. J. Epidemiol. 2021; Kostoulas P, Eusebi P, Hartnack S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823529>
11. **Joint testing of IgM and IgG has high value for ruling in SARS-CoV-2 infection.** Ann Intern Med 2021; Loeb M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819063>
12. **The challenges and risk of laboratory handling on a histology specimen during COVID-19 pandemic.** Ann Med Surg (Lond) 2021; 64:102242 Amri MF, Azizan N, Hussain FA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815787>
13. **Covid-19, hypokalaemia and the renin-angiotensin-aldosterone system.** Ann Med Surg (Lond) 2021:102261 Mandal AKJ, Wenban C, Heer RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815782>
14. **Sinonasal manifestations and dynamic profile of RT-PCR results for SARS-CoV-2 in COVID-19 patients.** Ann Palliat Med 2021; Jia X, Shao S, Ren H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832289>
15. **Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection.** Biochemistry (Mosc.) 2021; 86:257-261 Letarov AV, Babenko VV, Kulikov EE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838638>
16. **Development strategies of conducting polymer-based electrochemical biosensors for virus biomarkers: Potential for rapid COVID-19 detection.** Biosens. Bioelectron. 2021; 182:113192 Tran VV, Tran NHT, Hwang HS, Chang M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819902>
17. **Rapid visual detection of SARS-CoV-2 by colorimetric loop-mediated isothermal amplification.** Biotechniques 2021; Reynés B, Serra F, Palou A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820475>

18. **Urgent care center wait times increase for COVID-19 results in August 2020, with rapid testing availability limited.** BMC Health Serv. Res. 2021; 21:318Yousman LC, Khunte A, Hsiang W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33832506>
19. **Clinical and CT features of mild-to-moderate COVID-19 cases after two sequential negative nucleic acid testing results: a retrospective analysis.** BMC Infect. Dis. 2021; 21:333Rong Y, Wang F, Tian J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33832444>
20. **IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays.** BMC Infect. Dis. 2021; 21:325Shah J, Liu S, Potula HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827460>
21. **Detection of SARS-CoV-2 genomic and subgenomic RNA in retina and optic nerve of patients with COVID-19.** Br J Ophthalmol 2021; Casagrande M, Fitzek A, Spitzer M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836988>
22. **Monitoring of COVID-19 by extending existing surveillance for acute respiratory infections.** Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2021; Goerlitz L, Tolksdorf K, Buchholz U *et al.*
23. **The Canadian Pu0062lic Health Laboratory Network protocol for microbiological investigations of emerging respiratory pathogens, including severe acute respiratory infections.** Can. Commun. Dis. Rep. 2020; 46:205-209.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814986>
24. **Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.** Cardiovasc. Toxicol. 2021:1-6Ferrara F, Vitiello A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33835386>
25. **ABO Blood Group, SARS-CoV-2 Infection, and Risk of Venous Thromboembolism: Population-Based Cohort Study.** Clin. Appl. Thromb. Hemost. 2021; 27:10760296211008986Ray JG, Vermeulen MJ, Schull MJ, Park AL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33827287>
26. **Vitamin D and COVID-19 in an immunocompromised patient with multiple comorbidities-A Case Report.** Clin Case Rep 2021; Kralj M, Jakovac H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821193>
27. **COVID-19: which lessons have we learned?** Clin Chem Lab Med 2021; Banfi G, Lippi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823090>
28. **Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.** Clin Chem Lab Med 2021; Irsara C, Egger AE, Prokop W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837679>
29. **Laboratory medicine in the COVID-19 era: six lessons for the future.** Clin Chem Lab Med 2021; Plebani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826810>
30. **Clinical relevance of serum α -L-fucosidase activity in the SARS-CoV-2 infection.** Clin Chim Acta 2021; Liang EY, Li GH, Wang WG *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33826953>
31. **Serum levels of SARS-CoV-2 nucleocapsid antigen associate with inflammatory status and disease severity in COVID-19 patients.** Clin Immunol

2021:108720Perna F, Bruzzaniti S, Piemonte E *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33819577>

32. **Ultra-sensitive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection for the Diagnosis of Coronavirus Disease 2019 (COVID-19) in Upper Respiratory Samples.** Clin Infect Dis 2021; Wang H, Hogan CA, Verghese M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830203>
33. **Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19?** Clin Rheumatol 2021; Castillo-Martínez D, Torres Z, Amezcua-Guerra LM, Pineda C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826045>
34. **Coronavirus Disease Clinical and Laboratory Parameters: Dismembering the Values Reveals Outcomes.** Cureus 2021; 13:e13720Zehra T, Siddique SK, Aamir R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833931>
35. **A Mechanistic Link Between Selenium and Coronavirus Disease 2019 (COVID-19).** Curr Nutr Rep 2021:1-12Khatiwada S, Subedi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835432>
36. **Vitamin D Status: Can It Affect the Risk of Infection and the Severity of COVID-19 Symptoms?** Curr Trop Med Rep 2021:1-8Paiz N, Alonso P, Portillo AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816060>
37. **IL-6 and IL-10 are associated with disease severity and higher comorbidity in adults with COVID-19.** Cytokine 2021:155507Luporini RL, Rodolpho JMA, Kubota LT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839002>
38. **Impact of the vitamin D deficiency on COVID-19 infection and morality in Asian countries.** Diabetes Metab Syndr 2021; 15:757-764Jayawardena R, Jeyakumar DT, Francis TV, Misra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823331>
39. **Impact of the vitamin D deficiency on COVID-19 infection and mortality in Asian countries.** Diabetes Metab Syndr 2021; 15:757-764Jayawardena R, Jeyakumar DT, Francis TV, Misra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823331>
40. **Evaluation of simple and cost-effective immuno- haematological markers to predict outcome in hospitalized severe COVID-19 patients, with a focus on diabetes mellitus - A retrospective study in Andhra Pradesh, India.** Diabetes Metab Syndr 2021; 15:739-745Ramesh J, Reddy SLS, Rajesh M, Varghese J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819728>
41. **Letter to the Editor in response to article: Hypocalcemia is associated with severe COVID-19: A systematic review and meta-analysis (Martha et al.).** Diabetes Metab Syndr 2021; Siniorakis EE, Arvanitakis SG, Elkouris MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814294>
42. **The contrasting role of nasopharyngeal angiotensin converting enzyme 2 (ACE2) transcription in SARS-CoV-2 infection: A cross-sectional study of people tested for COVID-19 in British Columbia, Canada.** EBioMedicine 2021; 66:103316Nikiforuk AM, Kuchinski KS, Twa DDW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819740>
43. **Is sickle cell disease a risk factor for severe COVID-19 outcomes in hospitalized patients? A multicenter national retrospective cohort study.**

EJHaem 2021; Abdulrahman A, Wael M, AlAmmadi F *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821258>

44. **Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.** Emerg Microbes Infect 2021:1-23Rockstroh A, Wolf J, Fertey J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830901>
45. **New insights into application of nanoparticles in the diagnosis and screening of novel coronavirus (SARS-CoV-2).** Emergent Mater 2021:1-17Tharayil A, Rajakumari R, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817553>
46. **Vitamin D sufficiency and COVID-19: is vitamin D binding protein (and its polymorphism) the missing link?** Endocr. Pract. 2021; Speeckaert MM, Speeckaert R, Delanghe JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819636>
47. **Changes in drug use in European cities during early COVID-19 lockdowns - A snapshot from wastewater analysis.** Environ Int 2021; 153:106540Been F, Emke E, Matias J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838618>
48. **Simultaneous monitoring of SARS-CoV-2, bacteria, and fungi in indoor air of hospital: a study on Hajar Hospital in Shahrekord, Iran.** Environ. Sci. Pollut. Res. Int. 2021; Hemati S, Mobini GR, Heidari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837940>
49. **E-cigarette Vape and Lung ACE2 Expression: Implications for coronavirus vulnerability.** Environ. Toxicol. Pharmacol. 2021:103656Lallai V, Manca L, Fowler CD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838329>
50. **Accuracy of the serological detection of IgG and IgM to SARS-Cov-2: a prospective, cross-sectional study.** Eur J Clin Microbiol Infect Dis 2021; Pecoraro V, Cassetti T, Meacci M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839972>
51. **Virtual high throughput screening: Potential Inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) Proteases.** Eur. J. Pharmacol. 2021:174082Jade D, Ayyamperumal S, Tallapaneni V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823185>
52. **SARS-CoV-2 tracking in Tunisia through next-generation sequencing: lessons for the future.** EuroMediterr J Environ Integr 2021; 6:40Rebai A, Souissi A, Abid N, Masmoudi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824883>
53. **Is SARS-CoV-2 Spike glycoprotein impairing macrophage function via $\alpha 7$ -nicotinic acetylcholine receptors?** Food Chem. Toxicol. 2021:112184Tanmay S, Lambros D, Farsalinos K, Poulas K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838172>
54. **Genomic Variations in SARS-CoV-2 Genomes From Gujarat: Underlying Role of Variants in Disease Epidemiology.** Front Genet 2021; 12:586569Joshi M, Puvar A, Kumar D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815459>
55. **Initial Insights Into the Genetic Epidemiology of SARS-CoV-2 Isolates From Kerala Suggest Local Spread From Limited Introductions.** Front Genet 2021; 12:630542Radhakrishnan C, Divakar MK, Jain A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815467>
56. **Red Cell Distribution Width Upon Hospital Admission Predicts Short-Term Mortality in Hospitalized Patients With COVID-19: A Single-Center Experience.**

- [Front Med \(Lausanne\)](#) 2021; 8:652707Kaufmann CC, Ahmed A, Brunner U *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816532>
57. **Thymidine Phosphorylase Is Increased in COVID-19 Patients in an Acuity-Dependent Manner.** [Front Med \(Lausanne\)](#) 2021; 8:653773Li W, Yue H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33829029>
 58. **Detecting SARS-CoV-2 in the Breath of COVID-19 Patients.** [Front Med \(Lausanne\)](#) 2021; 8:604392Li X, Li J, Ge Q *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816516>
 59. **On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases.** [Front. Microbiol.](#) 2021; 12:646679Trunfio M, Longo BM, Alladio F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33815334>
 60. **Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19.** [Front. Microbiol.](#) 2021; 12:637430Ventero MP, Cuadrat RRC, Vidal I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815323>
 61. **Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression.** [Front Mol Biosci](#) 2021; 8:600881Cavalier E, Guiot J, Lechner K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816549>
 62. **The Looming Effects of Estrogen in Covid-19: A Rocky Rollout.** [Front Nutr](#) 2021; 8:649128Al-Kuraishy HM, Al-Gareeb AI, Faidah H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816542>
 63. **Comparing the Value of Cystatin C and Serum Creatinine for Evaluating the Renal Function and Predicting the Prognosis of COVID-19 Patients.** [Front. Pharmacol.](#) 2021; 12:587816Chen S, Li J, Liu Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828483>
 64. **Characteristics of Viral Shedding Time in SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis.** [Front Public Health](#) 2021; 9:652842Yan D, Zhang X, Chen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816427>
 65. **Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study.** [Future Sci OA](#) 2021; 7:Fso673Cerino P, Coppola A, Volzone P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33815819>
 66. **An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies.** [Gene Rep](#) 2021;101122Das A, Ahmed R, Akhtar S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821222>
 67. **Interferon-induced transmembrane protein-3 genetic variant rs12252 is associated with COVID-19 mortality.** [Genomics](#) 2021; Alghamdi J, Alaamery M, Barhoumi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838280>
 68. **Six-month follow-up of gut microbiota richness in patients with COVID-19.** [Gut](#) 2021; Chen Y, Gu S, Chen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833065>
 69. **Genomics in Patient Care and Workforce Decisions in High-Level Isolation Units: A Survey of Healthcare Workers.** [Health Secur](#) 2021; Gerber JE, Geller G, Boyce A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826422>
 70. **SARS-CoV-2 molecular identification and clinical data analysis of associated risk factors from a COVID-19 testing laboratory of a coastal region in**

- Bangladesh.** *Heliyon* 2021; 7:e06650Ali MR, Chowdhury MR, Mas-Ud MA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817359>
71. **The Socio-impact of COVID-19 positive patients in Bangladesh: A study on clinical data from a COVID-19 testing laboratory: SARS-CoV-2 molecular identification and clinical data analysis of associated risk factors from a COVID-19 testing laboratory of a coastal region in Bangladesh.** *Heliyon* 2021; 7:e06650Ali R, Chowdhury R, Mas-Ud A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817359>
72. **Performance evaluation of Truenat™ Beta CoV & Truenat™ SARS-CoV-2 point-of-care assays for coronavirus disease 2019.** *Indian J Med Res* 2021; 153:144-150Basawarajappa SG, Rangaiah A, Padukone S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33818471>
73. **Rapid chromatographic immunoassay-based evaluation of COVID-19: A cross-sectional, diagnostic test accuracy study & its implications for COVID-19 management in India.** *Indian J Med Res* 2021; 153:126-131Gupta A, Khurana S, Das R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818469>
74. **Phylogenetic classification of the whole-genome sequences of SARS-CoV-2 from India & evolutionary trends.** *Indian J Med Res* 2021; 153:166-174Potdar V, Vipat V, Ramdasi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818474>
75. **Feasibility, efficiency & effectiveness of pooled sample testing strategy (pooled NAAT) for molecular testing of COVID-19.** *Indian J Med Res* 2021; 153:227-232Prakash S, Prakash O, Mishra H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33818481>
76. **SARS-CoV-2 detection in sewage samples: Standardization of method & preliminary observations.** *Indian J Med Res* 2021; 153:159-165Sharma DK, Nalavade UP, Kalgutkar K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818473>
77. **Real world assessment of SARS-CoV-2 nasopharyngeal swab testing in a high burden COVID-19 region.** *Infect Control Hosp Epidemiol* 2021;1-10Sangal RB, Peaper DR, Rothenberg C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823949>
78. **CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity.** *Infection* 2021; Doehn JM, Tabeling C, Biesen R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825125>
79. **The first familial cluster of the B.1.1.7 variant of SARS-CoV-2 in the northeast of Italy.** *Infection* 2021; Lo Menzo S, Marinello S, Biasin M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33840038>
80. **Identification of COVID-19 subtypes based on immunogenomic profiling.** *Int Immunopharmacol* 2021; 96:107615Chen Z, Feng Q, Zhang T, Wang X.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33836368>
81. **Evaluation the relationship of left ventricular global longitudinal strain and laboratory parameters in discharged patients with COVID-19: a follow-up study.** *Int. J. Cardiovasc. Imaging* 2021; Baykiz D, Govdeli EA, Ozer PK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33826019>

82. **HOSTED-England's Household Transmission Evaluation Dataset: preliminary findings from a novel passive surveillance system of COVID-19.** Int J Epidemiol 2021; Hall JA, Harris RJ, Zaidi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837417>
83. **A deep learning model for mass screening of COVID-19.** Int J Imaging Syst Technol 2021; Dhaka VS, Rani G, Oza MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821094>
84. **Diagnostic value of plasma viscosity testing for patients with COVID-19.** Int. J. Lab. Hematol. 2021; Gleghorn DM, Olayiwola O, Omer A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817994>
85. **Early hematological indicators of severe COVID-19 disease in hospitalized patients: Data from a South Asian population.** Int. J. Lab. Hematol. 2021; Sharif F, Khan S, Junaid A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837662>
86. **Appointment attendance and patient perception of drive-up INR testing in a rural anticoagulation clinic during the COVID-19 pandemic.** J Am Coll Clin Pharm 2021; Zobeck B, Carson E, MacDowell M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821238>
87. **Longitudinal Assessment of SARS-CoV-2 Anti-Nucleocapsid and anti-Spike-1-RBD Antibody Testing Following PCR-Detected SARS-CoV-2 Infection.** J Appl Lab Med 2021; El-Khoury JM, Schulz WL, Durant TJS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822964>
88. **Serology testing demonstrates that antibodies to SARS-CoV-2 S1-RBD correlate with neutralization of virus infection of Vero E6 cells.** J Appl Lab Med 2021; Freeman J, Conklin J, Oramus D, Cycon K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822063>
89. **Evaluation of the clinical performance of seven serological assays for SARS-CoV-2 for use in clinical laboratories.** J Appl Lab Med 2021; Plaga A, Wei R, Olson E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825844>
90. **How SARS-CoV-2 Transformed the Clinical Laboratory: Challenges and Lessons Learned.** J Appl Lab Med 2021; Tsai JM, Tolan NV, Petrides AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822967>
91. **Functional characterization of CD4+ T-cell receptors cross-reactive for SARS-CoV-2 and endemic coronaviruses.** J. Clin. Invest. 2021; Dykema AG, Zhang B, Woldemeskel BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830946>
92. **Evaluation of a fully closed real time PCR platform for the detection of SARS-CoV-2 in nasopharyngeal swabs: a pilot study.** J. Clin. Pathol. 2021; De Luca C, Gragnano G, Conticelli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837109>
93. **Implementation of an in-house real-time reverse transcription-PCR assay for the rapid detection of the SARS-CoV-2 Marseille-4 variant.** J Clin Virol 2021; 139:104814 Bedotto M, Fournier PE, Houhamdi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836314>
94. **Vitamin D and COVID-19: is there a role?** J Diabetes Metab Disord 2021:1-8 Khan AH, Nasir N, Nasir N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816359>
95. **Vitamin D and Vitamin D binding protein: the inseparable duo in COVID-19.** J. Endocrinol. Invest. 2021; Speeckaert MM, Speeckaert R, Delanghe JR.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33840080>

96. **Retrospective analysis of vitamin D status on inflammatory markers and course of the disease in patients with COVID-19 infection.** J. Endocrinol. Invest. 2021; Ünsal YA, Gül Ö, Cander S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818731>
97. **Genomic surveillance of Nevada patients revealed prevalence of unique SARS-CoV-2 variants bearing mutations in the RdRp gene.** J Genet Genomics 2021; Hartley PD, Tillett RL, AuCoin DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820739>
98. **Effect of varying storage conditions on diagnostic test outcomes of SARSCoV-2.** J Infect 2021; Oguri S, Fujisawa S, Kamada K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823203>
99. **Effect of varying storage conditions on diagnostic test outcomes of SARS-CoV-2.** J Infect 2021; Oguri S, Fujisawa S, Kamada K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823203>
100. **Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment.** J Infect Chemother 2020; Tsuboi H, Kasamatsu Y, Matsubara S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814353>
101. **Does Macrophage Migration Inhibitory Factor predict the prognosis of COVID-19 disease?** J Infect Dev Ctries 2021; 15:398-403Dheir H, Yaylaci S, Sipahi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839715>
102. **The PaO2/FiO2 ratio on admission is independently associated with prolonged hospitalization in COVID-19 patients.** J Infect Dev Ctries 2021; 15:353-359Zinellu A, De Vito A, Scano V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839709>
103. **Differential T cell reactivity to endemic coronaviruses and SARS-CoV-2 in community and health care workers.** J Infect Dis 2021; da Silva Antunes R, Pallikkuth S, Williams E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822097>
104. **IgG immune complexes may contribute to neutrophil activation in the course of severe COVID-19.** J Infect Dis 2021; Mazzitelli I, Bleichmar L, Ludueña MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822045>
105. **The stability of an isolate of the SARS-CoV-2 B.1.1.7 lineage in aerosols is similar to three earlier isolates.** J Infect Dis 2021; Schuit M, Biryukov J, Beck K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822064>
106. **Inflammatory profiles and clinical features of COVID-19 survivors three months after discharge in Wuhan, China.** J Infect Dis 2021; Zhou M, Yin Z, Xu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822106>
107. **Sense and sensitivity: can an inaccurate test be better than no test at all?** J. Med. Ethics 2021; Pugh J, Wilkinson D, Savulescu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820853>
108. **Hypoalbuminemia in Patients Following Their Recovery from Severe Coronavirus Disease 2019.** J Med Virol 2021; Ali KM, Ali AM, Tawfeeq HM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830538>
109. **Association between the HLA genotype and the severity of COVID-19 infection among South Asians.** J Med Virol 2021; Naemi FMA, Al-Adwani S, Al-Khatabi H,

- Al-Nazawi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830530>
110. **Red Cell Distribution Width is Associated with Mortality in Non-Anemic Patients with COVID-19.** J Med Virol 2021; Rapp JL, Tremblay D, Alpert N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837966>
 111. **SARS-CoV-2 show no infectivity at later stages in a prolonged COVID-19 patient despite positivity in RNA testing.** J Med Virol 2021; Wan XF, Tang CY, Ritter D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830520>
 112. **Evaluation of six anti-SARS-CoV-2 antibody test kits and practical approaches to optimize the diagnostic performance.** J Microbiol Immunol Infect 2021; Ko JH, Joo EJ, Baek JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836943>
 113. **Hyponatremia is associated with poor outcome in COVID-19.** J Nephrol 2021; De Carvalho H, Letellier T, Karakachoff M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826113>
 114. **Salivary glands are a target for SARS-CoV-2: A source for saliva contamination.** J. Pathol. 2021; Matuck BF, Dolhnikoff M, Nunes Duarte-Neto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834497>
 115. **An efficient primary screening of COVID-19 by serum Raman spectroscopy.** J. Raman Spectrosc. 2021; Yin G, Li L, Lu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821082>
 116. **Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality.** J Thromb Haemost 2021; Smadja DM, Philippe A, Bory O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830623>
 117. **COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography.** J. Thromb. Thrombolysis 2021; Maier CL, Sarker T, Szlam F, Sniecinski RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829396>
 118. **Enhanced Throughput of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Real-Time RT-PCR Panel by Assay Multiplexing and Specimen Pooling.** J. Virol. Methods 2021;114:149Lu X, Sakthivel SK, Wang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839185>
 119. **Development and validation of a multiplex reverse transcriptase-PCR assay for simultaneous testing of influenza A, influenza B and SARS-CoV-2.** J. Virol. Methods 2021;114:151Pabbaraju K, Wong AA, Ma R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839186>
 120. **Intraventricular Conundrum in a SARS-CoV-2-Positive Patient With Elevated Biomarkers of Myocardial Injury.** JACC Case Rep 2021; Servato ML, Valente FX, García-Moreno LG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821246>
 121. **Incorporation of Urinary Neutrophil Gelatinase-Associated Lipocalin and Computed Tomography Quantification to Predict Acute Kidney Injury and In-Hospital Death in COVID-19 Patients.** Kidney Dis (Basel) 2021; 7:120-130He L, Zhang Q, Li Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824868>
 122. **Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19.** Med Clin (Engl Ed) 2021; 156:324-331Deng F, Zhang L, Lyu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824908>
 123. **Comparison of D-dimer Level Measured on the Third Day of Hospitalization with Admission D-dimer Level in Predicting In-hospital Mortality in COVID-19**

- Patients.** Medeni Med J 2021; 36:1-6Selcuk M, Cinar T, Gunay N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828883>
124. **CRISPR-Cas systems for diagnosing infectious diseases.** Methods 2021;
 Kostyusheva A, Brezgin S, Babin Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839288>
 125. **Investigating the ACE2 polymorphisms in COVID-19 susceptibility: An in silico analysis.** Mol Genet Genomic Med 2021:e1672Pouladi N, Abdolahi S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33818000>
 126. **Suspected sepsis in a 10-week-old infant and SARS-CoV-2 detection in cerebrospinal fluid and pharynx.** Monatsschr. Kinderheilkd. 2021; 169:312-316Färber K, Stäbler P, Getzinger T, Uhlig T.
 127. **SARS-CoV-2 Not Detectable in Ocular Specimens of a Patient with a Past Infection.** Ocul Immunol Inflamm 2021:1-3Felfeli T, Mazzulli T, Clark ST *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33826479>
 128. **[Complex oncologic therapy for loco-regionally advanced breast cancer associated with long-lasting SARS-CoV-2 PCR-positivity].** Orv. Hetil. 2021; 162:611-614Drozgyik A, Kollár D, Knausz M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33830935>
 129. **SARS-CoV-2 viral load dynamics and real-time RT-PCR cycle threshold interpretation in symptomatic non-hospitalised individuals in New Zealand: a multicentre cross sectional observational study.** Pathology 2021; Fox-Lewis A, Fox-Lewis S, Beaumont J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838922>
 130. **Focused Role of Nanoparticles Against COVID-19: Diagnosis and Treatment.** Photodiagnosis Photodyn. Ther. 2021:102287Dheyab MA, Khaniabadi PM, Aziz AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836276>
 131. **SARS-CoV-2 IgG Seropositivity and Acute Asymptomatic Infection Rate Among Firefighter First Responders in an Early Outbreak County in California.** Prehosp. Emerg. Care 2021:1-10Newberry JA, Gautreau M, Staats K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33819128>
 132. **Differences in COVID-19 Testing and Test Positivity Among Veterans, United States, 2020.** Public Health Rep. 2021:333549211009498Ferguson JM, Abdel Magid HS, Purnell AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826875>
 133. **Dyslipidaemia and mortality in COVID-19 patients - a meta-analysis.** QJM 2021; Zuin M, Rigatelli G, Bilato C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822215>
 134. **Letter to the editor: Vitamin D levels in acute illness and clinical severity in COVID-19 patients.** Respir Res 2021; 22:102Lohia P, Kapur S, Patel P, Seyoum B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33832495>
 135. **[Reflections on the position of the Covid-19 antigenic test based on a discrepancy of result].** Rev Francoph Lab 2021; 2021:67-69Friedberga B, Royoa J, Villieza V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815587>
 136. **Cycle Threshold Values in the Context of Multiple RT-PCR Testing for SARS-CoV-2.** Risk Manag. Healthc. Policy 2021; 14:1311-1317Romero-Alvarez D, Garzon-Chavez D, Espinosa F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824608>

137. **Fine-Scale Temporal Dynamics of SARS-CoV-2 RNA Abundance in Wastewater during A COVID-19 Lockdown.** Water Res 2021; 197:117093Li B, Di DYW, Saingam P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826985>

Children (28 articles)

1. **Short report on research trends during the COVID-19 pandemic and use of telehealth interventions and remote brain research in children with autism spectrum disorder.** Autism 2021:13623613211004795Su WC, Srinivasan S, Cleffi C, Bhat A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836625>
2. **Leucocytoclastic vasculitis secondary to COVID-19 infection in a young child.** BMJ Case Rep. 2021; 14Kumar G, Pillai S, Norwick P, Bukulmez H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827885>
3. **Covid-19 pandemic implications in pediatric and congenital heart surgery in Brazil.** Cardiol. Young 2021:1-19Augusto Miana L, Manuel V, Antoniali F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820594>
4. **Impact of SARS-CoV-2 pandemic on emergency department activity at the pediatric surgery unit of a third-level hospital.** Cir. Pediatr. 2021; 34:85-89Moratilla Lapeña L, Delgado-Miguel C, Sarmiento Caldas MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826261>
5. **Pediatric radiologic manifestations of COVID-19.** Clin Imaging 2021; 75:165-170Romberg EK, Menashe SJ, Kronman MP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831747>
6. **Atypical Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children: A Review.** Curr. Pediatr. Rev. 2021; Benou S, Ladhani S, Dimitriou G, Gkentzi D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823780>
7. **Mothers' and fathers' parenting attitudes during COVID-19.** Curr. Psychol. 2021:1-10Forbes LK, Lamar MR, Speciale M, Donovan C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821115>
8. **Characteristics and risk factors for SARS-CoV-2 in children tested in the early phase of the pandemic: a cross-sectional study, Italy, 23 February to 24 May 2020.** Euro Surveill 2021; 26Lazzerini M, Sforzi I, Trapani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834960>
9. **Characteristics of Children With Kawasaki Disease-Like Signs in COVID-19 Pandemic: A Systematic Review.** Front Pediatr 2021; 9:625377Mardi P, Esmaeili M, Iravani P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816398>
10. **Coping Behaviors and Psychological Disturbances in Youth Affected by the COVID-19 Health Crisis.** Front. Psychol. 2021; 12:565657Orgilés M, Morales A, Delvecchio E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828499>
11. **Adapting and adopting highly specialized pediatric eating disorder treatment to virtual care: a protocol for an implementation study in the COVID-19 context.** Implement Sci Commun 2021; 2:38Couturier J, Pellegrini D, Miller C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832543>
12. **COVID-19-Related Weight Gain in School-Aged Children.** Int J Endocrinol Metab 2021; 19:e110634Rezaeipour M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815521>

13. **Telemedicine usage via WeChat for Children with Congenital Heart Disease Preoperatively During COVID-19 Pandemic: A Retrospective Analysis.** Int. J. Qual. Health Care 2021; Zhang QL, Xie WP, Lei YQ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33835158>
14. **Evaluation of the effects of the COVID-19 pandemic on children with cerebral palsy, caregivers' quality of life, and caregivers' fear of COVID-19 with telemedicine.** Ir. J. Med. Sci. 2021;1-8Cankurtaran D, Tezel N, Yildiz SY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33834363>
15. **Mucocutaneous Manifestations in Hospitalized Children with COVID-19.** J Am Acad Dermatol 2021; Andina-Martinez D, Nieto-Moro M, Alonso-Cadenas JA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33819537>
16. **The Trilogy of SARS-CoV-2 in Pediatrics (Part 1): Acute COVID-19 in Special Populations.** J Pediatr Pharmacol Ther 2021; 26:220-239Parsons S, Tran VL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33833623>
17. **Could SARS-CoV-2 blocking of ACE2 in endothelial cells result in upregulation of CX3CL1, promoting thrombosis in COVID-19 patients?** Med. Hypotheses 2021; 151:110570Rivas-Fuentes S, Valdés VJ, Espinosa B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33836338>
18. **Suspected sepsis in a 10-week-old infant and SARS-CoV-2 detection in cerebrospinal fluid and pharynx.** Monatsschr. Kinderheilkd. 2021; 169:312-316Färber K, Stäbler P, Getzinger T, Uhlig T.
19. **[How COVID-19 pandemic influences paediatric acute appendicitis cases?].** Orv. Hetil. 2021; 162:608-610Fadgyas B, Garai GI, Ringwald Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33830938>
20. **Anesthesia and surgery for positive COVID-19 asymptomatic pediatric patients: how long should we wait?** Paediatr Anaesth 2021; Geng-Ramos G, Cronin J, Challa C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834573>
21. **Learning loss due to school closures during the COVID-19 pandemic.** Proc Natl Acad Sci U S A 2021; 118Engzell P, Frey A, Verhagen MD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33827987>
22. **COVID-19 as a Rare Cause of Facial Nerve Neuritis in a Pediatric Patient.** Radiol Case Rep 2021; Zain S, Petropollou K, Mirchia K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824691>
23. **COVID-19 as a rare cause of facial nerve neuritis in a pediatric patient.** Radiol Case Rep 2021; 16:1400-1404Zain S, Petropoulou K, Mirchia K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824691>
24. **Pain management in COVID-19 pediatric patients-An evidence- based review.** Saudi J. Anaesth. 2021; 15:33-39Mishra P, Tomar A, Kumar A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824640>
25. **Citizen science initiative points at childhood BCG vaccination as a risk factor for COVID-19.** Transbound Emerg Dis 2021; de la Fuente J, Armas O, Sánchez-Rodríguez L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825348>
26. **Therapeutic plasma exchange: A potential management strategy for critically ill MIS-C patients in the pediatric intensive care unit.** Transfus. Apher. Sci. 2021:103119Emeksiz S, Özcan S, Perk O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33836934>

27. **Supporting Parents & Kids Through Lockdown Experiences (SPARKLE): A digital parenting support app implemented in an ongoing general population cohort study during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial.** Trials 2021; 22:267Kostyrka-Allchorne K, Creswell C, Byford S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838678>
28. **[New coronavirus infection (COVID-19) associated with kidney infarction in a seventeen-year-old child].** Urologija 2021:84-88Kagantsov IM, Sizonov VV, Shelegin RV, Svarich VG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818941>

Clinical Features (37 articles)

1. **Rised sudden sensorineural hearing loss during COVID-19 widespread.** Am. J. Otolaryngol. 2021; 42:102996Fidan V, Akin O, Koyuncu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831819>
2. **Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study.** Am. J. Otolaryngol. 2021; 42:103033Rashid RA, Zgair A, Al-Ani RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839489>
3. **COVID-19-Induced Anosmia and Ageusia Are Associated With Younger Age and Lower Blood Eosinophil Counts.** Am J Rhinol Allergy 2021:19458924211004800Sehanobish E, Barbi M, Fong V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813917>
4. **Comparison and clinical characteristics of COVID-19 between January and February 2020 in Wuhan, China.** Ann Palliat Med 2021; Yang R, Wei J, Hu W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832296>
5. **Characteristics of a COVID-19 confirmed case series in primary care (COVID-19-PC project): a cross-sectional study.** BMC Fam. Pract. 2021; 22:66Rogero-Blanco E, González-García V, García RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832436>
6. **Clinical and CT features of mild-to-moderate COVID-19 cases after two sequential negative nucleic acid testing results: a retrospective analysis.** BMC Infect. Dis. 2021; 21:333Rong Y, Wang F, Tian J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832444>
7. **A Rare Case Report of Persistent Hiccups as an Atypical Presentation of COVID-19.** Cureus 2021; 13:e13625Atiyat R, Veeraballi S, Al-Atiyat N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816024>
8. **Development and Validation of a Clinical Symptom-based Scoring System for Diagnostic Evaluation of COVID-19 Patients Presenting to Outpatient Department in a Pandemic Situation.** Cureus 2021; 13:e13681Bhattacharya A, Ranjan P, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833907>
9. **Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19.** Cureus 2021; 13:e13687Salvador P, Oliveira P, Costa T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833912>
10. **Leukemoid Reaction in a Patient With Severe COVID-19 Infection.** Cureus 2021; 13:e13598Tarekegn K, Colon Ramos A, Sequeira Gross HG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815998>

11. **Coronavirus Disease Clinical and Laboratory Parameters: Dismembering the Values Reveals Outcomes.** Cureus 2021; 13:e13720Zehra T, Siddique SK, Aamir R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833931>
12. **Atypical Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children: A Review.** Curr. Pediatr. Rev. 2021; Benou S, Ladhani S, Dimitriou G, Gkentzi D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823780>
13. **The course of subjective and objective chemosensory dysfunction in hospitalized patients with COVID-19: a 6-month follow-up.** Eur Arch Otorhinolaryngol 2021; Bertlich M, Stihl C, Lüsebrink E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837835>
14. **Characteristics and risk factors for SARS-CoV-2 in children tested in the early phase of the pandemic: a cross-sectional study, Italy, 23 February to 24 May 2020.** Euro Surveill 2021; 26Lazzerini M, Sforzi I, Trapani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834960>
15. **Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis.** F1000Res 2021; 10:40Mutiawati E, Fahriani M, Mamada SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824716>
16. **Clinical and Radiological Characteristics of Acute Cerebrovascular Diseases Among Egyptian Patients With COVID-19 in Upper Egypt.** Front. Neurol. 2021; 12:635856Khedr EM, Soliman RK, Abo-Elfetof N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828521>
17. **Comparison of Clinical Features and Outcomes of Medically Attended COVID-19 and Influenza Patients in a Defined Population in the 2020 Respiratory Virus Season.** Front Public Health 2021; 9:587425Liu L, Zeng F, Rao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834012>
18. **SARS-CoV-2 molecular identification and clinical data analysis of associated risk factors from a COVID-19 testing laboratory of a coastal region in Bangladesh.** Heliyon 2021; 7:e06650Ali MR, Chowdhury MR, Mas-Ud MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817359>
19. **The Socio-impact of COVID-19 positive patients in Bangladesh: A study on clinical data from a COVID-19 testing laboratory: SARS-CoV-2 molecular identification and clinical data analysis of associated risk factors from a COVID-19 testing laboratory of a coastal region in Bangladesh.** Heliyon 2021; 7:e06650Ali R, Chowdhury R, Mas-Ud A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817359>
20. **Demographic & clinical profile of patients with COVID-19 at a tertiary care hospital in north India.** Indian J Med Res 2021; 153:115-125Soni SL, Kajal K, Yaddanapudi LN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818468>
21. **Incubation period of coronavirus disease 2019: new implications for intervention and control.** Int. J. Environ. Health Res. 2021:1-9Huang S, Li J, Dai C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818217>
22. **Simultaneously Complete but Not Partial Taste and Smell Losses were Associated with SAR-CoV-2 Infection.** Int J Infect Dis 2021; Trachootham D, Thongyen S, Lam-Ubol A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819604>

23. **Mucocutaneous Manifestations in Hospitalized Children with COVID-19.** J Am Acad Dermatol 2021; Andina-Martinez D, Nieto-Moro M, Alonso-Cadenas JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819537>
24. **Nail changes as manifestation of systemic disease in COVID-19 infection.** J Eur Acad Dermatol Venereol 2021; Ocampo-Garza SS, Ocampo-Candiani J, Camela E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830556>
25. **Estimation of Incubation Period and Serial Interval for SARS-CoV-2 in Jiangxi, China, and an Updated Meta-Analysis.** J Infect Dev Ctries 2021; 15:326-332 Zhang T, Ding S, Zeng Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839705>
26. **Psychophysical evaluations are important, usefulness and usability approaches to study the smell disorder related to COVID-19.** J Intern Med 2021; Saussez S, Hans S, Chiesa-Estomba CM, Lechien JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817882>
27. **Asymptomatic SARS-CoV-2 infection- Incidental findings on FDG PET/CT.** J Med Imaging Radiat Sci 2021; Bello Martinez R, Ghesani M, Ghesani N, Gavane S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820742>
28. **The Trilogy of SARS-CoV-2 in Pediatrics (Part 1): Acute COVID-19 in Special Populations.** J Pediatr Pharmacol Ther 2021; 26:220-239 Parsons S, Tran VL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833623>
29. **Structural and physiological changes of the human body upon SARS-CoV-2 infection.** J Zhejiang Univ Sci B 2021; 22:310-317 Wu Z, Zhang Q, Ye G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835765>
30. **Development and validation of an individualized nomogram for early prediction of the duration of SARS-CoV-2 shedding in COVID-19 patients with non-severe disease.** J Zhejiang Univ Sci B 2021; 22:318-329 Yuan S, Pan Y, Xia Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835766>
31. **Short-term chemosensory distortions and phantoms in COVID-19.** Laryngoscope Investig Otolaryngol 2021; Gurrola JG, 2nd, Chang JL, Roland LT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821217>
32. **Testicles, adipose organ and heart: A new axis in the management of SARS-CoV-2?** Med. Hypotheses 2021; 150:110587 Bertuccioli A, Cardinali M, Pierro FD, Balducci D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831722>
33. **An Update on COVID-19 Related Ophthalmic Manifestations.** Ocul Immunol Inflamm 2021; 1-6 Jevnikar K, Jaki Mekjavic P, Vidovic Valentincic N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826465>
34. **[Complex oncologic therapy for loco-regionally advanced breast cancer associated with long-lasting SARS-CoV-2 PCR-positivity].** Orv. Hetil. 2021; 162:611-614 Drozgyik A, Kollár D, Knausz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830935>
35. **SARS-CoV-2 viral load dynamics and real-time RT-PCR cycle threshold interpretation in symptomatic non-hospitalised individuals in New Zealand: a multicentre cross sectional observational study.** Pathology 2021; Fox-Lewis A, Fox-Lewis S, Beaumont J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838922>

36. **Pathophysiology of light phenotype SARS-CoV-2 interstitial pneumonia: from histopathological features to clinical presentations.** Pulmonology 2021; Oldani S, Ravaglia C, Bensai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832850>
37. **Atypical respiratory distress in eastern Democratic Republic of the Congo prior to the COVID-19 pandemic. A case report.** Trop Dis Travel Med Vaccines 2021; 7:9Mateso GQ, Baguma M, Mwene-Batu P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823942>

CNS (32 articles)

1. **The 'Great Imitator': A Case of COVID-19 Presenting with Encephalitis and Acute Coronary Syndrome.** Acta Med Indones 2021; 53:82-85Darmawan G, Makmud ST. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818410>
2. **Bilateral peripheral facial palsy following asymptomatic COVID-19 infection: a case report.** Acta Neurol. Belg. 2021; Kerstens J, Deschuytere L, Schotsmans K, Maréchal E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818743>
3. **COVID-19 in adults with dementia: clinical features and risk factors of mortality-a clinical cohort study on 125 patients.** Alzheimers Res. Ther. 2021; 13:77Vrillon A, Mhanna E, Aveneau C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838684>
4. **Cranial nerve involvement in COVID-19.** Am. J. Otolaryngol. 2021; 42:102999Doblan A, Kaplama ME, Ak S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838359>
5. **Encephalopathy responsive to thiamine in severe COVID-19 patients.** Brain Behav Immun Health 2021; 14:100252Branco de Oliveira MV, Irikura S, Lourenço FHB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817670>
6. **Encephalopathy responsive to thiamine in severe COVID-19 patients.** Brain Behav Immun Health 2021:100252de Oliveira MVB, Irikura S, Lourenço FHB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817670>
7. **Current opinion in neurological manifestations of SARS-CoV-2 infection.** Curr Opin Toxicol 2021; Engin AB, Engin ED, Engin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817451>
8. **Treatment of Women with Multiple Sclerosis Planning Pregnancy.** Curr. Treat. Options Neurol. 2021; 23:11Krysko KM, Bove R, Dobson R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814892>
9. **Severe Neurologic Complications of SARS-CoV-2.** Curr. Treat. Options Neurol. 2021; 23:14Sisniega DC, Reynolds AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814894>
10. **A case report of delayed manifestation of new-onset focal seizures presenting after COVID infection.** Epilepsy Behav Rep 2021:100447Park S, Majoka H, Sheikh A, Ali I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817617>
11. **Risk estimation of SUDEP during COVID-19 pandemic era in a tertiary referral center.** Epilepsy Res. 2021; 173:106625Magdy R, Kishk NA, Fouad AM, Alsayyad E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819756>
12. **Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis.**

- Eur. J. Neurol. 2021; Palaiodimou L, Stefanou MI, Katsanos AH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33837630>
13. **Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis.** F1000Res 2021; 10:40 Mutiawati E, Fahriani M, Mamada SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824716>
 14. **Neurologic and Neuroscientific Evidence in Aged COVID-19 Patients.** Front. Aging Neurosci. 2021; 13:648662 Mainali S, Darsie ME.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33833676>
 15. **Neuropsychiatric Symptoms of COVID-19 Explained by SARS-CoV-2 Proteins' Mimicry of Human Protein Interactions.** Front. Hum. Neurosci. 2021; 15:656313 Yapici-Eser H, Koroglu YE, Oztog-Cakmak O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33833673>
 16. **The Impact of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorder Beyond Infection Risk.** Front. Neurol. 2021; 12:657037 Yin H, Zhang Y, Xu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828524>
 17. **Association of COVID-19 Pandemic and Rate of Cognitive Decline in Patients with Dementia and Mild Cognitive Impairment: A Cross-sectional Study.** Gerontol Geriatr Med 2021; 7:23337214211005223 Ismail, II, Kamel WA, Al-Hashel JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816709>
 18. **Neuropathophysiology of coronavirus disease 2019: neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection.** Inflammopharmacology 2021:1-25 Welcome MO, Mastorakis NE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33822324>
 19. **Evaluation of the effects of the COVID-19 pandemic on children with cerebral palsy, caregivers' quality of life, and caregivers' fear of COVID-19 with telemedicine.** Ir. J. Med. Sci. 2021:1-8 Cankurtaran D, Tezel N, Yildiz SY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33834363>
 20. **Impact of Social Isolation on People with Dementia and Their Family Caregivers.** J. Alzheimers Dis. 2021; Dos Santos Azevedo LV, Calandri IL, Slachevsky A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814446>
 21. **Limbic encephalitis in a COVID-19 patient?** J. Neurovirol. 2021; Chiveri L, Verrengia E, Muscia F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825173>
 22. **Short-term chemosensory distortions and phantoms in COVID-19.** Laryngoscope Investig Otolaryngol 2021; Gurrola JG, 2nd, Chang JL, Roland LT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821217>
 23. **Clinical and Pathophysiologic Spectrum of Neuro-COVID.** Mol. Neurobiol. 2021; Finsterer J, Scorza FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829393>
 24. **Behind the mask: recognizing facial features of Parkinson's disease during the COVID-19 pandemic.** Mov Disord 2021; Soares C, Carneiro DR, Dias R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33834516>
 25. **Consequences of the COVID-19 pandemic for people with schizophrenia, dementia and substance use disorders.** Nervenarzt 2021; Adorjan K, Haussmann R, Rauen K, Pogarell O.

26. **Neuromuscular complications of SARS-CoV-2 infection—Part 2: muscle disorders.** Nervenarzt 2021; Lehmann HC, Schoser B, Wunderlich G *et al.*
27. **People with Parkinson's report increased impulse control behaviours during the COVID-19 UK lockdown.** Parkinsonism Relat. Disord. 2021; 86:38-39 Yule E, Pickering JS, McBride J, Poliakoff E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827015>
28. **Use of Remdesivir in Myasthenia Gravis and COVID-19.** Pharmacotherapy 2021; Peters BJ, Rabinstein AA, DuBrock HM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835512>
29. **COVID-19 as a Rare Cause of Facial Nerve Neuritis in a Pediatric Patient.** Radiol Case Rep 2021; Zain S, Petropollou K, Mirchia K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824691>
30. **COVID-19 as a rare cause of facial nerve neuritis in a pediatric patient.** Radiol Case Rep 2021; 16:1400-1404 Zain S, Petropoulou K, Mirchia K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824691>
31. **COVID-19 and the perioperative neuroscience - A narrative review.** Saudi J. Anaesth. 2021; 15:19-26 Kapoor I, Mahajan C, Prabhakar H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824638>
32. **Correlation of Seizure Increase and COVID-19 Outbreak in Adult Patients with Epilepsy: Findings and Suggestions from a Nationwide Multi-centre Survey in China.** Seizure 2021; 88:102-108 Zeng C, Meng H, Zhu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=3383956>

Coagulation (21 articles)

1. **Symptomatic arterial thrombosis associated with novel coronavirus disease 2019 (COVID-19): report of two cases.** Acta Chir. Belg. 2021;1-14 De Hous N, Hollering P, Van Looveren R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820491>
2. **Clinical Outcomes of Pulmonary Embolism in Mexican Patients With COVID-19.** Clin. Appl. Thromb. Hemost. 2021; 27:10760296211008988 Bobadilla-Rosado LO, Mier YT-ES, Lopez-Pena G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813911>
3. **Inflammatory and Prothrombotic Biomarkers Associated With the Severity of COVID-19 Infection.** Clin. Appl. Thromb. Hemost. 2021; 27:1076029621999099 Lopez-Castaneda S, García-Larragoiti N, Cano-Mendez A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835872>
4. **ABO Blood Group, SARS-CoV-2 Infection, and Risk of Venous Thromboembolism: Population-Based Cohort Study.** Clin. Appl. Thromb. Hemost. 2021; 27:10760296211008986 Ray JG, Vermeulen MJ, Schull MJ, Park AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827287>
5. **Pulmonary embolism in pregnancy with COVID-19 infection: A case report.** Clin Case Rep 2021; Goudarzi S, Firouzabadi FD, Mahmoudzadeh F, Aminimoghaddam S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821188>
6. **Severe hemolysis and vaso-occlusive crisis due to COVID-19 infection in a sickle cell disease patient improved after red blood cell exchange.** Clin Case

[Rep 2021](http://www.ncbi.nlm.nih.gov/pubmed/?term=33821186); Okar L, Rezek M, Gameil A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821186>

7. **Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19?** [Clin Rheumatol](#) 2021; Castillo-Martínez D, Torres Z, Amezcua-Guerra LM, Pineda C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826045>
8. **Branch Retinal Vein Occlusion in a COVID-19 Positive Patient.** [Cureus](#) 2021; 13:e13586Duff SM, Wilde M, Khurshid G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815989>
9. **Immune Thrombocytopenic Purpura in a Patient With SARS-CoV-2 and Epstein-Barr Virus.** [Cureus](#) 2021; 13:e13615Galestani A, Suthar KH, Karnath B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816014>
10. **Acute Coronary Syndrome and COVID-19: A Case Report of Refractory Hypercoagulability.** [Cureus](#) 2021; 13:e13675Inam F, Singh PR, Khalid F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824826>
11. **Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.** [Expert Rev. Anti Infect. Ther.](#) 2021; Savla SR, Prabhavalkar KS, Bhatt LK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832398>
12. **Acute portal vein thrombosis with COVID-19 and cirrhosis.** [IDCases](#) 2021; 24:e01094Miyazato Y, Ishikane M, Inada M, Ohmagari N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816118>
13. **Acute pulmonary embolism in patients presenting pulmonary deterioration after hospitalization for non-critical COVID-19.** [Intern. Med. J.](#) 2021; Polo Friz H, Gelfi E, Orenti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834578>
14. **Coagulopathy: Another side effect of coronavirus infection.** [J Cardiovasc Thorac Res](#) 2021; 13:15-22Sadoughi F, Maleki Dana P, Hallajzadeh J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815697>
15. **Myoclonus-Ataxia Syndrome Associated with COVID-19.** [J Mov Disord](#) 2021; Shetty K, Jadhav AM, Jayanthakumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819422>
16. **COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography.** [J. Thromb. Thrombolysis](#) 2021; Maier CL, Sarker T, Szlam F, Sniecinski RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829396>
17. **Comparison of D-dimer Level Measured on the Third Day of Hospitalization with Admission D-dimer Level in Predicting In-hospital Mortality in COVID-19 Patients.** [Medeni Med J](#) 2021; 36:1-6Selcuk M, Cinar T, Gunay N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828883>
18. **Hypercoagulability in COVID-19: A review of the potential mechanisms underlying clotting disorders.** [SAGE Open Med](#) 2021; 9:20503121211002996Alam W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815798>
19. **Portal vein thrombosis in COVID-19 infection.** [Surg Case Rep](#) 2021; 7:87Sinz S, Glaser-Gallion F, Steffen T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830380>
20. **Pulmonary Embolism Response Team utilization during the COVID-19 pandemic.** [Vasc. Med.](#) 2021:1358863x21995896Finn MT, Gogia S, Ingrassia JJ *et*

al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818200>

21. **COVID-19 and venous thromboembolism: Known and unknown for imaging decisions.** *World J Radiol* 2021; 13:64-74 Patel L, Gandhi D, Westergard E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815684>

Complications (63 articles)

1. **Hospital-acquired Skin and Skin-structure Infection in COVID-19 Infected Patient with Prolonged Hospitalization.** *Acta Med Indones* 2021; 53:105-107 Nelwan EJ, Tunjungputri RN, Tunjung N, Widodo D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818413>
2. **Bilateral peripheral facial palsy following asymptomatic COVID-19 infection: a case report.** *Acta Neurol. Belg.* 2021; Kerstens J, Deschuytere L, Schotsmans K, Maréchal E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818743>
3. **ECMO for COVID-19-Associated Severe ARDS in Chile: A Nationwide Incidence and Cohort Study.** *Am J Respir Crit Care Med* 2021; Diaz RA, Graf J, Zambrano JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823118>
4. **The role of extracorporeal membrane oxygenation in critically ill patients with COVID-19: a narrative review.** *BMC Pulm. Med.* 2021; 21:116 Huang S, Zhao S, Luo H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832474>
5. **Leucocytoclastic vasculitis secondary to COVID-19 infection in a young child.** *BMJ Case Rep.* 2021; 14 Kumar G, Pillai S, Norwick P, Bukulmez H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827885>
6. **COVID-19 severe pneumonia: Prospective multicentre study on demands on intensive care capacities.** *Cent. Eur. J. Public Health* 2021; 29:3-8 Džupová O, Moravec M, Bartoš H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831279>
7. **Clinical Outcomes of Pulmonary Embolism in Mexican Patients With COVID-19.** *Clin. Appl. Thromb. Hemost.* 2021; 27:10760296211008988 Bobadilla-Rosado LO, Mier YT-ES, Lopez-Pena G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813911>
8. **ABO Blood Group, SARS-CoV-2 Infection, and Risk of Venous Thromboembolism: Population-Based Cohort Study.** *Clin. Appl. Thromb. Hemost.* 2021; 27:10760296211008986 Ray JG, Vermeulen MJ, Schull MJ, Park AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827287>
9. **Severe hemolysis and vaso-occlusive crisis due to COVID-19 infection in a sickle cell disease patient improved after red blood cell exchange.** *Clin Case Rep* 2021; Okar L, Rezek M, Gameil A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821186>
10. **Covid-19 laryngectomized patients care, on field experience, and considerations.** *Clin Case Rep* 2021; Ricciardiello F, Caraglia M, Romano GM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821187>
11. **Interstitial lung abnormalities and pulmonary fibrosis in COVID-19 patients: a short-term follow-up case series.** *Clin Imaging* 2021; 77:180-186 Gulati A, Lakhani P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836413>
12. **Clinical and etiological analysis of co-infections and secondary infections in COVID-19 patients: an observational study.** *Clin. Respir. J.* 2021; Chen S, Zhu Q,

Xiao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818909>

13. **Prone position in intubated, mechanically ventilated patients with COVID-19: a multi-centric study of more than 1000 patients.** *Crit Care* 2021; 25:128 Langer T, Brioni M, Guzzardella A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823862>
14. **Branch Retinal Vein Occlusion in a COVID-19 Positive Patient.** *Cureus* 2021; 13:e13586 Duff SM, Wilde M, Khurshid G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815989>
15. **Immune Thrombocytopenic Purpura in a Patient With SARS-CoV-2 and Epstein-Barr Virus.** *Cureus* 2021; 13:e13615 Galestani A, Suthar KH, Karnath B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816014>
16. **Frequency of Comorbidities in Admitting COVID-19 Pneumonia Patients in a Tertiary Care Setup: An Observational Study.** *Cureus* 2021; 13:e13546 Hussain M, Iltaf S, Sr., Salman S, Sr. *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815969>
17. **A Case of Suspected Radiation Recall Pneumonitis After a COVID-19 Infection.** *Cureus* 2021; 13:e13688 Kurosaki H, Utsumi N, Miura K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824832>
18. **Tracheal Tube Obstruction Due to Hemoptysis Associated With Pulmonary Infarction in a Patient With Severe COVID-19 Pneumonia.** *Cureus* 2021; 13:e13599 Maruhashi T, Wada T, Masuda T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815999>
19. **COVID-19 and ARDS: Update On Preventive And Therapeutic Venues.** *Curr. Mol. Med.* 2021; Narota A, Puri G, Singh VP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829971>
20. **Invasive fungal infections in ICU patients - What's New?** *Deutsche Medizinische Wochenschrift* 2021; 146:455-460 Kochanek M, Köhler P.
21. **Predictors of new-onset diabetic ketoacidosis in patients with moderate to severe COVID-19 receiving parenteral glucocorticoids: A prospective single-centre study among Indian type 2 diabetes patients.** *Diabetes Metab Syndr* 2021; 15:795-801 Mondal S, DasGupta R, Lodh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839639>
22. **Presentation, management, and outcomes of COVID-19 in patients with sickle cell disease.** *EJHaem* 2021; 2:124-127 Anusim N, Gupta R, Ahaneku H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821259>
23. **Multisystem Inflammatory Syndrome in Adults after Mild SARS-CoV-2 Infection, Japan.** *Emerg Infect Dis* 2021; 27 Yamada Y, Fujinami K, Eguchi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821784>
24. **COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?** *ESMO Open* 2021; 6:100100 Silvestris N, Di Maio M, Russo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819751>
25. **Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis.** *Eur. J. Neurol.* 2021; Palaiodimou L, Stefanou MI, Katsanos AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837630>

26. **Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.** Expert Rev. Anti Infect. Ther. 2021; Savla SR, Prabhavalkar KS, Bhatt LK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832398>
27. **Mortality in mechanically ventilated patients with COVID-19: a systematic review.** Expert Rev. Med. Devices 2021; Tsikala Vafea M, Zhang R, Kalligeros M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836621>
28. **Persistent Bacterial Coinfection of a COVID-19 Patient Caused by a Genetically Adapted *Pseudomonas aeruginosa* Chronic Colonizer.** Front Cell Infect Microbiol 2021; 11:641920Qu J, Cai Z, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816347>
29. **Virus-Induced Changes of the Respiratory Tract Environment Promote Secondary Infections With *Streptococcus pneumoniae*.** Front Cell Infect Microbiol 2021; 11:643326Sender V, Hentrich K, Henriques-Normark B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828999>
30. **SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack.** HIV AIDS (Auckl.) 2021; 13:361-375Evans N, Martinez E, Petrosillo N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833585>
31. **Emergency cricothyroidotomy and conversion tracheostomy in a patient with COVID-19: a case report.** Hong Kong Med. J. 2021; Lau YF, Wong FKC, Kwan PKC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824216>
32. **Acute portal vein thrombosis with COVID-19 and cirrhosis.** IDCases 2021; 24:e01094Miyazato Y, Ishikane M, Inada M, Ohmagari N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816118>
33. **High-flow oxygen therapy in elderly patients infected with SARS-CoV2 with a contraindication for transfer to an intensive care unit: a preliminary report.** Int J Infect Dis 2021; Lagier JC, Amrane S, Mailhe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823281>
34. **Mechanical circulatory support in coronavirus disease-2019-positive patients with severe respiratory failure.** Interact. Cardiovasc. Thorac. Surg. 2021; Natanov R, Wiesner O, Haverich A, Kühn C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822952>
35. **Acute pulmonary embolism in patients presenting pulmonary deterioration after hospitalization for non-critical COVID-19.** Intern. Med. J. 2021; Polo Friz H, Gelfi E, Orenti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834578>
36. **Classification and analysis of outcome predictors in non-critically ill COVID-19 patients.** Intern. Med. J. 2021; Venturini S, Orso D, Cugini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835685>
37. **Effectiveness of dexmedetomidine combined with high flow nasal oxygen and long periods of awake prone positioning in moderate or severe COVID-19 pneumonia.** J. Clin. Anesth. 2021; 72:110261Taboada M, Baluja A, Santos LD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839432>
38. **Multisystem Inflammatory Syndrome in an Adult.** J. Emerg. Med. 2021; Amato MK, Hennessy C, Shah K, Mayer J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838966>
39. **Cervical abscess caused by methicillin-susceptible *Staphylococcus aureus* in an infant infected with SARS-CoV-2: Diagnostic dilemma.** J Infect Chemother

- 2021; Yildirim Arslan S, Sahbudak Bal Z, Guner Ozenen G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814352>
40. **Extracorporeal Membrane Oxygenation in Patients With COVID-19: An International Multicenter Cohort Study.** J. Intensive Care Med. 2021;8850666211007063Raasveld SJ, Delnoij TSR, Broman LM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33823709>
41. **Article title: Risk factors for bacterial infections in patients with moderate to severe COVID-19: A case control study.** J Med Virol 2021; Nasir N, Rehman F, Omair SF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822390>
42. **Myoclonus-Ataxia Syndrome Associated with COVID-19.** J Mov Disord 2021; Shetty K, Jadhav AM, Jayanthakumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819422>
43. **Spontaneous hemopneumothorax in an adolescent with COVID-19.** J Pediatr Surg Case Rep 2021; 69:101852Montgomery AB, Finck C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828949>
44. **Community-Acquired Neonatal SARS-CoV-2 Infection Associated with Neurological Symptoms in Colombia.** J. Trop. Pediatr. 2021; 67Alvarado-Socarras JL, Theurel-Martin D, Cruz-Hernandez M, Rodriguez-Morales AJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33823049>
45. **Could SARS-CoV-2 blocking of ACE2 in endothelial cells result in upregulation of CX3CL1, promoting thrombosis in COVID-19 patients?** Med. Hypotheses 2021; 151:110570Rivas-Fuentes S, Valdés VJ, Espinosa B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33836338>
46. **[Can the SARS-CoV-2 virus damage human hearing and balance?].** Med. Pr. 2021; Narożny W, Tretiakow D, Andrzej S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835112>
47. **COVID-19 infection in patients with connective tissue disease: A multicity study in Hubei province, China.** MedComm (Beijing) 2021; 2:82-90Ye C, Zhong J, Cai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821253>
48. **Suspected sepsis in a 10-week-old infant and SARS-CoV-2 detection in cerebrospinal fluid and pharynx.** Monatsschr. Kinderheilkd. 2021; 169:312-316Färber K, Stäbler P, Getzinger T, Uhlig T.
49. **Neuromuscular complications of SARS-CoV-2 infection—Part 2: muscle disorders.** Nervenarzt 2021; Lehmann HC, Schoser B, Wunderlich G *et al.*
50. **Infection control in the respiratory care of coronavirus disease-19 patients with neuromuscular diseases.** Neurol Clin Neurosci 2021; 9:159-165Matsumura T, Saito T, Mori M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821184>
51. **Early awake proning in critical and severe COVID-19 patients undergoing noninvasive respiratory support: A retrospective multicenter cohort study.** Pulmonology 2021; Tonelli R, Pisani L, Tabbì L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824084>
52. **Bilateral adrenal hemorrhage in a man with severe COVID-19 pneumonia.** Radiol Case Rep 2021; 16:1438-1442Elkhouly MMN, Elazzab AA, Moghul SS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33815638>
53. **COVID-19 as a Rare Cause of Facial Nerve Neuritis in a Pediatric Patient.** Radiol Case Rep 2021; Zain S, Petropollou K, Mirchia K *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824691>

54. **COVID-19 as a rare cause of facial nerve neuritis in a pediatric patient.** Radiol Case Rep 2021; 16:1400-1404 Zain S, Petropoulou K, Mirchia K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824691>
55. **Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients.** Res Pract Thromb Haemost 2021; Stals M, Grootenboers M, van Guldener C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821230>
56. **[Prevention measures to avoid COVID-19 spreading by: from the everyday to the technical-scientific actions.].** Rev. Esp. Salud Publica 2021; 95 Romero-Saritamá JM, Simaluiza J, Fernández H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833213>
57. **Delayed Parosmia Following SARS-CoV-2 Infection: a Rare Late Complication of COVID-19.** SN Compr Clin Med 2021;1-3 Duyan M, Ozturan IU, Altas M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817555>
58. **COVID-19 and Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis: a Case Report.** SN Compr Clin Med 2021;1-4 Ramos-Ruperto L, Busca-Arenzana C, Valdivieso J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824942>
59. **Portal vein thrombosis in COVID-19 infection.** Surg Case Rep 2021; 7:87 Sinz S, Glaser-Gallion F, Steffen T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830380>
60. **Dengue and leptospirosis infection during the coronavirus 2019 outbreak in Sri Lanka.** Trans. R. Soc. Trop. Med. Hyg. 2021; Niriella MA, Ediriweera DS, De Silva AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823550>
61. **Pulmonary Embolism Response Team utilization during the COVID-19 pandemic.** Vasc. Med. 2021;1358863x21995896 Finn MT, Gogia S, Ingrassia JJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818200>
62. **Siblings with coronavirus disease 2019 infection and opposite outcome-the hemodialysis's better outcome paradox: Two case reports.** World J Nephrol 2021; 10:21-28 Bacharaki D, Chrysanthopoulou E, Grigoropoulou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816154>
63. **COVID-19 and venous thromboembolism: Known and unknown for imaging decisions.** World J Radiol 2021; 13:64-74 Patel L, Gandhi D, Westergard E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815684>

Cured – Recovered (8 articles)

1. **Symptomatic, biochemical and radiographic recovery in patients with COVID-19.** BMJ Open Respir Res 2021; 8 Mallia P, Meghji J, Wong B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827856>
2. **Recurrent coronavirus diseases 19 (COVID-19): A different presentation from the first episode.** Clin Case Rep 2021; Shoar S, Khavandi S, Tabibzadeh E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821190>
3. **A High Percentage of Patients Recovered From COVID-19 but Discharged With Abnormal Liver Function Tests.** Front. Physiol. 2021; 12:642922 Gan Q, Gong B, Sun M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815147>

4. **A scoping review of international policy responses to mental health recovery during the COVID-19 pandemic.** Health Res. Policy Syst. 2021; 19:58 McCartan C, Adell T, Cameron J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823855>
5. **Lung Fibrosis Sequelae After Recovery from COVID-19 Infection.** J Infect Dev Ctries 2021; 15:360-365 Susanto AD, Triyoga PA, Isbaniah F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839710>
6. **Hypoalbuminemia in Patients Following Their Recovery from Severe Coronavirus Disease 2019.** J Med Virol 2021; Ali KM, Ali AM, Tawfeeq HM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830538>
7. **Incidence and Severity of Depression Among Recovered African Americans with COVID-19-Associated Respiratory Failure.** J Racial Ethn Health Disparities 2021; Olanipekun T, Abe T, Effoe V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825114>
8. **Lung ultrasonography for long-term follow-up of COVID-19 survivors compared to chest CT scan.** Respir. Med. 2021; 181:106384 Giovannetti G, De Michele L, De Ceglie M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839587>

Cardiovascular disease (42 articles)

1. **Comprehensive Review of Cardiovascular Involvement in COVID-19.** AACN Adv. Crit. Care 2021:e1-e19 Macale Cajanding RJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836538>
2. **Assessment of COVID-19 deaths from cardiological perspective.** Acta Cardiol. 2021:1-8 Omar T, Karakayalı M, Perincek G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823754>
3. **Symptomatic arterial thrombosis associated with novel coronavirus disease 2019 (COVID-19): report of two cases.** Acta Chir. Belg. 2021:1-14 De Hous N, Hollering P, Van Looveren R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820491>
4. **The 'Great Imitator': A Case of COVID-19 Presenting with Encephalitis and Acute Coronary Syndrome.** Acta Med Indones 2021; 53:82-85 Darmawan G, Makmud ST. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818410>
5. **COVID-19 and cardiovascular problems in elderly patients: Food for thought.** Aging Med (Milton) 2021; Costa R, Castagna A, Ruotolo G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821229>
6. **COVID-19 quarantine and depression in patients with congenital heart disease.** Am. J. Cardiovasc. Dis. 2021; 11:80-86 Martínez-Quintana E, Santana-Herrera D, Vega-Acedo LDC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815923>
7. **Covid-19, hypokalaemia and the renin-angiotensin-aldosterone system.** Ann Med Surg (Lond) 2021:102261 Mandal AKJ, Wenban C, Heer RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815782>
8. **Histopathologic Evaluation of COVID-19 Patients with Peripheral Arterial Thromboembolism: Does clot composition make any sense?** Ann. Vasc. Surg.

- 2021; Yesilkaya N, Tellioglu TM, Unay FC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33819598>
9. **Covid-19 pandemic implications in pediatric and congenital heart surgery in Brazil.** Cardiol. Young 2021;1-19Augusto Miana L, Manuel V, Antoniali F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33820594>
 10. **Impaired Right Ventricular Longitudinal Strain Without Pulmonary Hypertension in Patients Who Have Recovered From COVID-19.** Circ. Cardiovasc. Imaging 2021;Circimaging120012166Nuzzi V, Castrichini M, Collini V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827250>
 11. **Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support.** Circ Heart Fail 2021;Circheartfailure120007957Birati EY, Najjar SS, Tedford RJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813838>
 12. **Clinical Outcomes of Pulmonary Embolism in Mexican Patients With COVID-19.** Clin. Appl. Thromb. Hemost. 2021; 27:10760296211008988Bobadilla-Rosado LO, Mier YT-ES, Lopez-Pena G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813911>
 13. **Pulmonary embolism in pregnancy with COVID-19 infection: A case report.** Clin Case Rep 2021; Goudarzi S, Firouzabadi FD, Mahmoudzadeh F, Aminimoghaddam S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821188>
 14. **Cardiac magnetic resonance findings in coronavirus disease 2019.** Clin Case Rep 2021; Rezaeian N, Hosseini L, Asadian S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821185>
 15. **Paroxysmal atrial fibrillation associated with a moderate form of COVID-19 in a middle-aged man with low cardiovascular risk factor: More still needs to be done in this topic.** Clin Case Rep 2021; Temgoua MN, Chanseume S, Hilic E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821191>
 16. **Fast recovery of cardiac function in PIMS-TS patients early using intravenous anti-IL-1 treatment.** Crit Care 2021; 25:131Mastrolia MV, Marrani E, Calabri GB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827651>
 17. **Acute Coronary Syndrome and COVID-19: A Case Report of Refractory Hypercoagulability.** Cureus 2021; 13:e13675Inam F, Singh PR, Khalid F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824826>
 18. **Heart failure outcomes and Covid-19.** Diabetes Res Clin Pract 2021;108794Standl E, Schnell O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831494>
 19. **Assessment of pulmonary arterial circulation 3 months after hospitalization for SARS-CoV-2 pneumonia: Dual-energy CT (DECT) angiographic study in 55 patients.** EClinicalMedicine 2021; 34:100778Remy-Jardin M, Duthoit L, Perez T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817609>
 20. **Incidence of emergency calls and out-of-hospital cardiac arrest deaths during the COVID-19 pandemic: findings from a cross-sectional study in a UK ambulance service.** Emerg Med J 2021; Charlton K, Limmer M, Moore H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832923>
 21. **How Does SARS-CoV-2 Infection Affect Survival of Emergency Cardiovascular Patients? A Cohort Study From a German Insurance Claims Database.** Eur. J.

- Vasc. Endovasc. Surg. 2021; Behrendt CA, Seiffert M, Gerloff C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824066>
22. **The European TeleCheck-AF project on remote app-based management of atrial fibrillation during the COVID-19 pandemic: centre and patient experiences.** Europace 2021; Gawalko M, Duncker D, Manning M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33822029>
 23. **Characteristics of Children With Kawasaki Disease-Like Signs in COVID-19 Pandemic: A Systematic Review.** Front Pediatr 2021; 9:625377Mardi P, Esmaeili M, Iravani P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816398>
 24. **Latin-American Registry of Cardiovascular Disease and COVID-19: Rationale and Design of the CARDIO COVID 19-20 Registry.** Glob Heart 2021; 16:14Gómez-Mesa JE, Galindo-Coral S, Montes MC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33833938>
 25. **SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.** Glob Heart 2021; 16:18Ogah OS, Umuerrri EM, Adebisi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833942>
 26. **Managing acute myocardial infarction in patients with COVID-19 at a cardiac catheterisation laboratory.** Hong Kong Med. J. 2021; Chan AKC, Tsang CF, Chui SF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824214>
 27. **Evaluation the relationship of left ventricular global longitudinal strain and laboratory parameters in discharged patients with COVID-19: a follow-up study.** Int. J. Cardiovasc. Imaging 2021; Baykiz D, Govdeli EA, Ozer PK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33826019>
 28. **Impairment of right ventricular longitudinal strain associated with severity of pneumonia in patients recovered from COVID-19.** Int. J. Cardiovasc. Imaging 2021; Ozer PK, Govdeli EA, Baykiz D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839981>
 29. **Telemedicine usage via WeChat for Children with Congenital Heart Disease Preoperatively During COVID-19 Pandemic: A Retrospective Analysis.** Int. J. Qual. Health Care 2021; Zhang QL, Xie WP, Lei YQ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33835158>
 30. **Acute pulmonary embolism in patients presenting pulmonary deterioration after hospitalization for non-critical COVID-19.** Intern. Med. J. 2021; Polo Friz H, Gelfi E, Orenti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834578>
 31. **ECG markers of malignant arrhythmias and in-hospital outcome of COVID-19 pneumonia.** J Arrhythm 2021; Shaghee F, Nafakhi H, Alareedh M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821177>
 32. **Pathomechanism and Management of Stroke in COVID-19: Review of Immunopathogenesis, Coagulopathy, Endothelial Dysfunction, and Downregulation of ACE2.** J. Clin. Neurol. 2021; 17:155-163Rahmawati PL, Tini K, Susilawathi NM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835735>
 33. **Characterisation of cardiac pathology in 23 autopsies of lethal COVID-19.** J Pathol Clin Res 2021; Haslbauer JD, Tzankov A, Mertz KD *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33837673>
 34. **Information regarding acute stroke associated with COVID-19 in online news.** J Prev Interv Community 2021;1-9Park E, Kollia B.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33831333>

35. **Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension.** *J Zhejiang Univ Sci B* 2021; 22:330-340 Feng B, Zhang D, Wang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835767>
36. **Intraventricular Conundrum in a SARS-CoV-2-Positive Patient With Elevated Biomarkers of Myocardial Injury.** *JACC Case Rep* 2021; Servato ML, Valente FX, García-Moreno LG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821246>
37. **A Rare Cause of ST-Segment Elevation Myocardial Infarction in COVID-19: MINOCA Syndrome.** *Medeni Med J* 2021; 36:63-68 Eroglu SE, Ademoglu E, Bayram S, Aksel G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828892>
38. **Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials.** *Medwave* 2021; 21:e8105 Meza N, Pérez-Bracchiglione J, Pérez I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830976>
39. **Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease.** *Open Heart* 2021; 8 Tessitore E, Carballo D, Poncet A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833064>
40. **Portal vein thrombosis in COVID-19 infection.** *Surg Case Rep* 2021; 7:87 Sinz S, Glaser-Gallion F, Steffen T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830380>
41. **Pulmonary Embolism Response Team utilization during the COVID-19 pandemic.** *Vasc. Med.* 2021:1358863x21995896 Finn MT, Gogia S, Ingrassia JJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818200>
42. **COVID-19 and venous thromboembolism: Known and unknown for imaging decisions.** *World J Radiol* 2021; 13:64-74 Patel L, Gandhi D, Westergard E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815684>

Diagnosis (8 articles)

1. **COVID-19 -awareness of diagnostic pitfalls.** *Acta Clin. Belg.* 2021:1-2 Dos Santos VM, Modesto LC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825661>
2. **The 'Great Imitator': A Case of COVID-19 Presenting with Encephalitis and Acute Coronary Syndrome.** *Acta Med Indones* 2021; 53:82-85 Darmawan G, Makmud ST. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818410>
3. **Diagnostic accuracy estimates for COVID-19 RT-PCR and Lateral flow immunoassay tests with Bayesian latent class models.** *Am. J. Epidemiol.* 2021; Kostoulas P, Eusebi P, Hartnack S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823529>
4. **Diagnosing Covid-19 chest x-rays with a lightweight truncated DenseNet with partial layer freezing and feature fusion.** *Biomed. Signal Process. Control* 2021; 68:102583 Montalbo FJP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828610>
5. **Classification of COVID-19 individuals using adaptive neuro-fuzzy inference system.** *Multimed Syst* 2021:1-15 Iwendi C, Mahboob K, Khalid Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814730>
6. **FUSI-CAD: Coronavirus (COVID-19) diagnosis based on the fusion of CNNs and handcrafted features.** *PeerJ Comput Sci* 2020; 6:e306 Ragab DA, Attallah O.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816957>

7. **Focused Role of Nanoparticles Against COVID-19: Diagnosis and Treatment.** Photodiagnosis Photodyn. Ther. 2021;102287Dheyab MA, Khaniabadi PM, Aziz AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836276>
8. **A Call for the World Health Organization to Create International Classification of Disease Diagnostic Codes for Post-Intensive Care Syndrome in the Age of COVID-19.** World Med Health Policy 2021; Peach BC, Valenti M, Sole ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821196>

DM-MS-Obesity (15 articles)

1. **Syndemics at play: chronic kidney disease, diabetes and COVID-19 in Pakistan.** Ann. Med. 2021; 53:581-586Ali I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825598>
2. **Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19.** Brain 2021; Hosp JA, Dressing A, Blazhenets G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822001>
3. **COVID-19 and diabetes: Analysis of the scientific production indexed in Scopus.** Diabetes Metab Syndr 2021; 15:765-770Corrales-Reyes IE, Hernández-García F, Mejía CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831772>
4. **Predictors of new-onset diabetic ketoacidosis in patients with moderate to severe COVID-19 receiving parenteral glucocorticoids: A prospective single-centre study among Indian type 2 diabetes patients.** Diabetes Metab Syndr 2021; 15:795-801Mondal S, DasGupta R, Lodh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839639>
5. **Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.** Diabetes Metab Syndr 2021; 15:777-782Rakhmat, II, Kusmala YY, Handayani DR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838614>
6. **Pre-infection glycaemic control and disease severity among patients with type 2 diabetes and COVID-19: A retrospective, cohort study.** Diabetes Obes. Metab. 2021; Hayek S, Ben-Shlomo Y, Balicer R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822446>
7. **Abdominal obesity phenotype is associated with COVID-19 chest X-ray severity score better than BMI-based obesity.** Eat Weight Disord 2021;1-15Malavazos AE, Secchi F, Basilico S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821453>
8. **The Weight of Obesity in Immunity from Influenza to COVID-19.** Front Cell Infect Microbiol 2021; 11:638852Andrade FB, Gualberto A, Rezende C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816341>
9. **The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review.** Front. Endocrinol. (Lausanne) 2021; 12:645194Zangiabadian M, Nejadghaderi SA, Zahmatkesh MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815295>
10. **Ambulatory Patients with Cardiometabolic Disease and Without Evidence of COVID-19 During the Pandemic. The CorCOVID LATAM Study.** Glob Heart 2021;

- 16:15Santi RL, Márquez MF, Piskorz D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833939>
11. **COVID-19-Related Weight Gain in School-Aged Children.** Int J Endocrinol Metab 2021; 19:e110634Rezaeipour M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815521>
 12. **Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression.** J Diabetes Metab Disord 2021;1-8Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816358>
 13. **Obesity and its impact on COVID-19.** J. Mol. Med. (Berl.) 2021; de Leeuw AJM, Oude Luttikhuis MAM, Wellen AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824998>
 14. **Influence of the stage of emergency declaration due to the coronavirus disease 2019 outbreak on plasma glucose control of patients with diabetes mellitus in the Saku region of Japan.** J Rural Med 2021; 16:98-101Watanabe T, Temma Y, Okada J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833835>
 15. **Diabetes and COVID-19.** Open Life Sci 2021; 16:297-302Gazzaz ZJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817321>

Education and training and science (50 articles)

1. **Knowledge and Attitudes Towards COVID-19: A Cross-sectional Study in Portugal.** Acta Med Port 2021; Pires O, Oliveira AA, Moreira P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826493>
2. **Knowledge, attitude and practices of COVID-19 among medical laboratory professionals in Zambia.** Afr J Lab Med 2021; 10:1403Chawe A, Mfuno RL, Syapiila PM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821204>
3. **Two leading international congresses in Iran in the era of COVID-19: 21st royan international twin congress, 4th international and 16th Iranian genetics congress.** Bioessays 2021:e2100078Montazeri L, Mohajeri M, Baharvand H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825205>
4. **Knowledge, attitude and practices related to COVID-19 among young Lebanese population.** BMC Public Health 2021; 21:653Sakr S, Ghaddar A, Sheet I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823826>
5. **Longitudinal analyses of gender differences in first authorship publications related to COVID-19.** BMJ Open 2021; 11:e045176Lerchenmüller C, Schmallenbach L, Jena AB, Lerchenmueller MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820790>
6. **A bibliometric analysis of the dental scientific literature on COVID-19.** Clin Oral Investig 2021;1-13Jacimovic J, Jakovljevic A, Nagendrababu V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822288>
7. **The impact of social problem skills on academic motivation by means of Covid-19 fear: A SEM Model: Social Problem Solving, Covid-19, Academic Motivation.** Curr. Psychol. 2021;1-10Günaydın HD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821113>

8. **COVID-19 and diabetes: Analysis of the scientific production indexed in Scopus.** Diabetes Metab Syndr 2021; 15:765-770Corrales-Reyes IE, Hernández-García F, Mejía CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831772>
9. **Teaching an experiential field course via online participatory science projects: A COVID-19 case study of a UC California Naturalist course.** Ecol. Evol. 2021; Gerhart LM, Jadallah CC, Angulo SS, Ira GC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821180>
10. **Analytical study on the impact of technology in higher education during the age of COVID-19: Systematic literature review.** Educ Inf Technol (Dordr) 2021:1-28Abu Talib M, Bettayeb AM, Omer RI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814958>
11. **Emergency remote teaching during the COVID-19 pandemic: Parents experiences and perspectives.** Educ Inf Technol (Dordr) 2021:1-20Misirli O, Ergulec F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814956>
12. **Toward a sociocultural approach to computerized dynamic assessment of the TOEFL iBT listening comprehension test.** Educ Inf Technol (Dordr) 2021:1-26Pileh Roud LF, Hidri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814957>
13. **Beyond Bricks and Mortar: The efficacy of online learning and community-building at College Park Academy during the COVID-19 pandemic.** Educ Inf Technol (Dordr) 2021:1-22Williams KM, Corwith A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814960>
14. **COVID-19 research priorities for non-pharmaceutical public health and social measures.** Epidemiol Infect 2021; 149:e87Semenza JC, Adlhoch C, Baka A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818348>
15. **SARS-CoV-2 Human Challenge Trials: Rethinking the Recruitment of Healthy Young Adults First.** Ethics Hum Res 2021; Matsui K, Inoue Y, Yamamoto K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821569>
16. **Perception on Online Teaching and Learning Among Health Sciences Students in Higher Education Institutions during the COVID-19 Lockdown - Ways to Improve Teaching and Learning in Saudi Colleges and Universities.** F1000Res 2021; 10:177Aziz Ansari K, Farooqi F, Qadir Khan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824717>
17. **Online Virtual Supervised Visitation During the COVID-19 Pandemic: One State's Experience.** Fam Court Rev 2021; 59:131-143Oehme K, O'Rourke KS, Bradley L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821152>
18. **Riding the rapids: COVID-19, the three rivers curriculum, and the experiences of the university of pittsburgh school of medicine.** FASEB Bioadv 2021; Elnicki DM, Drain P, Null G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821236>
19. **Modification of teaching during the COVID-19 pandemic at the Department of Medical Education of Jagiellonian University Medical College.** Folia Med. Cracov. 2020; 60:113-121Skrzypek A, Perera I, Szeliga M, Cebula G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821856>
20. **The Impact of Telehealth on Clinical Education in Adolescent Medicine During the COVID-19 Pandemic: Positive Preliminary Findings.** Front Pediatr 2021; 9:642279Pham DQ, Golub SA, Breuner CC, Evans YN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816404>

21. **The Status of Occupational Protection During COVID-19 Pandemic: Knowledge, Attitudes, and Practice of Healthcare Workers in Endoscopy Units, China.** Front Public Health 2021; 9:632608 Tian Y, Nian B, Ma Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829007>
22. **Public Knowledge, Attitudes, and Practices Behaviors Towards Coronavirus Disease 2019 (COVID-19) During a National Epidemic-China.** Front Public Health 2021; 9:638430 Xu Y, Lin G, Spada C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816423>
23. **Researching gender inequalities in academic labor during the COVID-19 pandemic: Avoiding common problems and asking different questions.** Gend Work Organ 2021; Pereira MDM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821108>
24. **Revisiting sustainable development Goal 4 in the context of COVID-19 Pandemic: A case study of online teaching in Algerian higher education institutions.** Hum Behav Emerg Technol 2021; 3:160-168 Hadjeris F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821243>
25. **Burnout and depression among psychiatry residents during COVID-19 pandemic.** Hum Resour Health 2021; 19:46 Alkhamees AA, Assiri H, Alharbi HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823857>
26. **Emerging trends from COVID-19 research registered in the Clinical Trials Registry - India.** Indian J Med Res 2021; 153:26-63 Rao MVV, Juneja A, Maulik M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818466>
27. **Impact of COVID-19 on paramedicine students: A mixed methods study.** Int. Emerg. Nurs. 2021; 56:100996 Brett W, King C, Shannon B, Gosling C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819846>
28. **Quality of life of nursing internship students in Saudi Arabia during the COVID-19 pandemic: A cross-sectional study.** Int J Afr Nurs Sci 2021; 14:100301 Grande RAN, Butcon VER, Indonto MCL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824852>
29. **The General Public Knowledge, Attitude, and Practices Regarding COVID-19 During the Lockdown in Asian Developing Countries.** Int. Q. Community Health Educ. 2021:272684x211004945 Qalati SA, Ostic D, Fan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832371>
30. **Prevalence and risk factors for anxiety symptoms during the outbreak of COVID-19: A large survey among 373216 junior and senior high school students in China.** J. Affect. Disord. 2021; 288:17-22 Xu Q, Mao Z, Wei D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839554>
31. **Harnessing the Web: How Chiropractic Education Survives and Thrives During the COVID-19 Pandemic: Chiropractic Educators Research Forum (CERF), December 5, 2020.** J Chiropr Educ 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825871>
32. **Investigating the mediating role of online learning motivation in the COVID-19 pandemic situation in Bangladesh.** J Comput Assist Learn 2021; Rahman MHA, Uddin MS, Dey A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821076>
33. **The impact of risk and protective factors on online teaching experience in high school Italian teachers during the COVID-19 pandemic.** J Comput Assist

Learn 2021; Truzoli R, Pirola V, Conte S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821075>

34. **At your 'online' service! A continuous service-learning program for college students during the COVID-19 pandemic.** J Public Health (Oxf) 2021; Vicente NE, Moredó PJA, Cordero DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823020>
35. **Reporting and Availability of COVID-19 Demographic Data by US Health Departments (April to October 2020): Observational Study.** JMIR Public Health Surveill 2021; 7:e24288Ossom-Williamson P, Williams IM, Kim K, Kindratt TB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821804>
36. **University presses and the impact of COVID-19.** Learn Publ 2021; 34:17-24Watkinson C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821102>
37. **Did anthropause generate a research pause during the pandemic? The experiences of a non-medical journal.** Learn Publ 2021; Zhang J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821100>
38. **Report of National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from COVID-19 Experience.** Neuro Oncol 2021; Lee EQ, Selig W, Meehan C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822177>
39. **How did Tunisian university students cope with fear of COVID-19? A comparison across schizotypy features.** Pers. Individ. Dif. 2021; 178:110872Fekih-Romdhane F, Dissem N, Cheour M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814659>
40. **Learning loss due to school closures during the COVID-19 pandemic.** Proc Natl Acad Sci U S A 2021; 118Engzell P, Frey A, Verhagen MD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827987>
41. **Online-Based Survey on College Students' Anxiety During COVID-19 Outbreak.** Psychol. Res. Behav. Manag. 2021; 14:385-392Han W, Xu L, Niu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824607>
42. **School opening during the SARS-CoV-2 pandemic: Public acceptance of wearing fabric masks in class.** Public Health Pract (Oxf) 2021; 2:100115Betsch C, Korn L, Felgendreiff L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817681>
43. **An evaluation of the experiences of radiography students working on the temporary HCPC register during the COVID-19 pandemic.** Radiography (Lond) 2021; Cushen-Brewster N, Strudwick RM, Doolan C, Driscoll-Evans P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814306>
44. **Mental health and well-being of university staff during the coronavirus disease 2019 levels 4 and 5 lockdown in an Eastern Cape university, South Africa.** S. Afr. J. Psychiatr. 2021; 27:1589van Niekerk RL, van Gent MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824757>
45. **COVID-19 and the perioperative neuroscience - A narrative review.** Saudi J. Anaesth. 2021; 15:19-26Kapoor I, Mahajan C, Prabhakar H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824638>
46. **COVID-19 enabled co-authoring networks: a country-case analysis.** Scientometrics 2021:1-20Sachini E, Sioumalas-Christodoulou K, Chrysomallidis C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814647>

47. **Ophthalmology Residency Match in the Covid-19 Era: Applicant and Program Director Perceptions of the 2020-2021 Application Cycle.** Semin. Ophthalmol. 2021;1-6 Venincasa MJ, Steren B, Young BK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33825672>
48. **Essential or not? Knowledge problems and COVID-19 stay-at-home orders.** South Econ J 2021; Storr VH, Haeffele S, Lofthouse JK, Grube LE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821051>
49. **Impact of COVID-19 Pandemic on Ophthalmology Medical Student Teaching: Educational Innovations, Challenges, and Future Directions.** Surv. Ophthalmol. 2021; Succar T, Beaver HA, Lee AG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838164>
50. **Costs of US Allopathic Medical Students Applying to Neurosurgery Residency: Geographic Considerations and Implications for the 2020-2021 Application Cycle.** World Neurosurg. 2021; Gordon AM, Malik AT.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33831614>

Elderly (11 articles)

1. **COVID-19 Vaccine for Elderly: Should We Be Reactive or Proactive?** Acta Med Indones 2021; 53:1-4 Setiati S, Marsigit J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818400>
2. **COVID-19 and cardiovascular problems in elderly patients: Food for thought.** Aging Med (Milton) 2021; Costa R, Castagna A, Ruotolo G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821229>
3. **Nutritional determinants and COVID-19 outcomes of older patients with COVID-19: A systematic review.** Arch. Gerontol. Geriatr. 2021; 95:104411 Damayanthi H, Prabani KIP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836322>
4. **Associations Between Fear of COVID-19, Affective Symptoms and Risk Perception Among Community-Dwelling Older Adults During a COVID-19 Lockdown.** Front. Psychol. 2021; 12:638831 Han MFY, Mahendran R, Yu J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33833722>
5. **High-Minority Nursing Homes Disproportionately Affected by COVID-19 Deaths.** Front Public Health 2021; 9:606364 Weech-Maldonado R, Lord J, Davlyatov G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829006>
6. **Life in lockdown: Social isolation, loneliness and quality of life in the elderly during the COVID-19 pandemic: A scoping review.** Geriatr. Nurs. 2021; Sayin Kasar K, Karaman E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824008>
7. **SARS-CoV-2 detection in sewage samples: Standardization of method & preliminary observations.** Indian J Med Res 2021; 153:159-165 Sharma DK, Nalavade UP, Kalgutkar K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818473>
8. **Contact with older people, ageism, and containment behaviours during the COVID-19 pandemic.** J. Community Appl. Soc. Psychol. 2021; Visintin EP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821117>

9. **Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19.** J Inflamm Res 2021; 14:1207-1216Xie C, Li Q, Li L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33833543>
10. **Managing malnutrition in older adults in the community during the COVID-19 pandemic.** Nurs. Older People 2021; Baic S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825366>
11. **The impact of confinement on older Jordanian adults' mental distress during the COVID-19 pandemic: A web-based cross-sectional study.** Perspect. Psychiatr. Care 2021; Abu Kamel AK, Alnazly EK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33834502>

Epidemiology (108 articles)

1. **Obtaining Prevalence Estimates of COVID-19: A Model to Inform Decision-making.** Am. J. Epidemiol. 2021; Sahlu I, Whittaker AB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33831172>
2. **Epidemiology of COVID-19 Infection in Hospitalized End-Stage Kidney Disease Patients in a Predominantly African-American Population.** Am. J. Nephrol. 2021:1-9Navarrete JE, Tong DC, Cobb J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33827078>
3. **Framework for Real-Time Detection and Identification of possible patients of COVID-19 at public places.** Biomed. Signal Process. Control 2021; 68:102605Peddinti B, Shaikh A, K RB, K CN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824682>
4. **Determinants of health care use among homeless individuals: evidence from the Hamburg survey of homeless individuals.** BMC Health Serv. Res. 2021; 21:317Hajek A, Bertram F, Heinrich F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827570>
5. **Modeling the interplay between demography, social contact patterns, and SARS-CoV-2 transmission in the South West Shewa Zone of Oromia Region, Ethiopia.** BMC Med 2021; 19:89Trentini F, Guzzetta G, Galli M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33832497>
6. **Quantifying the association between ethnicity and COVID-19 mortality: a national cohort study protocol.** BMJ Open 2021; 11:e045286Dambha-Miller H, Tan PS, Saatci D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827839>
7. **Distribution of COVID-19 cases and deaths in Europe during the first 12 peak weeks of outbreak.** Cent. Eur. J. Public Health 2021; 29:9-13Zach H, Hanová M, Letkovičová M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831280>
8. **How epidemics end.** Centaurus 2021; 63:210-224Charters E, Heitman K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821019>
9. **Uncertainty Quantification of a Mathematical Model of COVID-19 Transmission Dynamics with Mass Vaccination Strategy.** Chaos Solitons Fractals 2021:110895Olivares A, Staffetti E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814733>
10. **Maximum Likelihood-based Extended Kalman Filter for COVID-19 Prediction.** Chaos Solitons Fractals 2021:110922Song J, Xie H, Gao B *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824550>

11. **Influence of COVID-19 lockdown overlapping Chinese Spring Festival on household PM_{2.5} in rural Chinese homes.** Chemosphere 2021; 278:130406Du W, Wang J, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819885>
12. **High infection secondary attack rates of SARS-CoV-2 in Dutch households revealed by dense sampling.** Clin Infect Dis 2021; Reukers DFM, van Boven M, Meijer A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822007>
13. **Seroprevalence of SARS-CoV-2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned.** Clin Microbiol Infect 2021; Poljak M, Valenčak AO, Štrumbelj E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838303>
14. **Computational simulation of the COVID-19 epidemic with the SEIR stochastic model.** Comput Math Organ Theory 2021:1-19Balsa C, Lopes I, Guarda T, Rufino J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814968>
15. **The relationship between in-person voting and COVID-19: Evidence from the Wisconsin primary.** Contemp Econ Policy 2021; Cotti C, Engelhardt B, Foster J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821123>
16. **Re-opening Sudan: the Balance Between Maintaining Daily Living and Avoiding the Next Peak of COVID-19.** Curr Trop Med Rep 2021:1-7Fadul N, Hussein ME, Fadul AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816059>
17. **An Aspect of Kumbh Mela Massive Gathering and COVID-19.** Curr Trop Med Rep 2021:1-6Quadri SA, Padala PR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816058>
18. Deutsche Apotheker Zeitung 2020; 160.
19. **Pandemic concepts: Unchecked course.** Deutsches Arzteblatt International 2020; 117:A2356Helbig M.
20. **Review of the role of big data and digital technologies in controlling COVID-19 in Asia: Public health interest vs. privacy.** Digit Health 2021; 7:20552076211002953Nageshwaran G, Harris RC, Guerche-Seblain CE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815815>
21. **Paradox of Protective Behaviours among Muslim Men during the Early Stage of the COVID-19 Pandemic in Aceh, Indonesia.** Disaster Med Public Health Prep 2021:1-20Nurrahmi F, Masykar T, Harapan H, Masykar T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820583>
22. **The impact of the lockdown and the re-opening of schools and day cares on the epidemiology of SARS-CoV-2 and other respiratory infections in children - A nationwide register study in Finland.** EClinicalMedicine 2021; 34:100807Haapanen M, Renko M, Artama M, Kuitunen I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817612>
23. **Numerical analysis of factors, pace and intensity of the corona virus (COVID-19) epidemic in Poland.** Ecol. Inform. 2021:101284Kowalski PA, Szwagrzyk M, Kiełpńska J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815029>
24. **Home alone? Effect of weather-induced behaviour on spread of SARS-CoV-2 in Germany.** Econ. Hum. Biol. 2021; 42:100998Yakubenko S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838616>

25. **Epidemiologic Evidence for Airborne Transmission of SARS-CoV-2 during Church Singing, Australia, 2020.** Emerg Infect Dis 2021; 27:Katelaris AL, Wells J, Clark P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818372>
26. **Novel coronavirus disease 2019 (COVID-19) pandemic: From transmission to control with an interdisciplinary vision.** Environ. Res. 2021:111126Anand U, Cabrereros C, Mal J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831411>
27. **Selected restrictions in specific places are better policy responses than full lockdown.** Environ. Res. 2021:111099Coccia M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819476>
28. **The COVID-19 pandemic: prediction study based on machine learning models.** Environ. Sci. Pollut. Res. Int. 2021; Malki Z, Atlam ES, Ewis A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33840016>
29. **Exploration of spatial-temporal varying impacts on COVID-19 cumulative case in Texas using geographically weighted regression (GWR).** Environ. Sci. Pollut. Res. Int. 2021; Wu X, Zhang J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837938>
30. **Estimating the effects of reopening of schools on the course of the epidemic of COVID-19.** Epidemiol Infect 2021; 149:e86Massad E, Amaku M, Tadeu Covas D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814022>
31. **Selective perimeter lockdowns in Madrid: a way to bend the COVID-19 curve?** Eur. J. Public Health 2021; Fontán-Vela M, Gullón P, Padilla-Bernáldez J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831211>
32. **Determining the communicable period of SARS-CoV-2: A rapid review of the literature, March to September 2020.** Euro Surveill 2021; 26Park M, Pawliuk C, Nguyen T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834961>
33. **SARS-CoV-2 tracking in Tunisia through next-generation sequencing: lessons for the future.** EuroMediterr J Environ Integr 2021; 6:40Rebai A, Souissi A, Abid N, Masmoudi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824883>
34. **Gradient-Based Grey Wolf Optimizer with Gaussian Walk: Application in Modelling and Prediction of the COVID-19 Pandemic.** Expert Syst Appl 2021:114920Khalilpourazari S, Hashemi Doulabi H, Özyüksel Çiftçioğlu A, Weber GW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814731>
35. **Initial Insights Into the Genetic Epidemiology of SARS-CoV-2 Isolates From Kerala Suggest Local Spread From Limited Introductions.** Front Genet 2021; 12:630542Radhakrishnan C, Divakar MK, Jain A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815467>
36. **Message Framing Effects on Individuals' Social Distancing and Helping Behavior During the COVID-19 Pandemic.** Front. Psychol. 2021; 12:579164Ceylan M, Hayran C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828501>
37. **COVID-19 Pandemic on Fire: Evolved Propensities for Nocturnal Activities as a Liability Against Epidemiological Control.** Front. Psychol. 2021; 12:646711Varella MAC, Luoto S, Soares R, Valentova JV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828510>
38. **High-Minority Nursing Homes Disproportionately Affected by COVID-19 Deaths.** Front Public Health 2021; 9:606364Weech-Maldonado R, Lord J, Davlyatov

G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829006>

39. **Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study.** Future Sci OA 2021; 7:Fso673Cerino P, Coppola A, Volzone P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33815819>
40. **Latin-American Registry of Cardiovascular Disease and COVID-19: Rationale and Design of the CARDIO COVID 19-20 Registry.** Glob Heart 2021; 16:14Gómez-Mesa JE, Galindo-Coral S, Montes MC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33833938>
41. **SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.** Glob Heart 2021; 16:18Ogah OS, Umuerrri EM, Adebisi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833942>
42. **Ambulatory Patients with Cardiometabolic Disease and Without Evidence of COVID-19 During the Pandemic. The CorCOVID LATAM Study.** Glob Heart 2021; 16:15Santi RL, Márquez MF, Piskorz D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833939>
43. **A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa.** Global Health 2021; 17:42Amimo F, Lambert B, Magit A, Hashizume M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33832487>
44. **Responding to pandemics and other disease outbreaks in homeless populations: A review of the literature and content analysis.** Health Soc Care Community 2021; Babando J, Quesnel DA, Woodmass K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33825271>
45. **Environmental correlation and epidemiologic analysis of COVID-19 pandemic in ten regions in five continents.** Heliyon 2021; 7:e06576Sharif N, Sarkar MK, Ahmed SN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817387>
46. **Aiding decision makers to reopening of places of worship.** Hum Factors Ergon Manuf 2021; Rothrock L, Abraham A, Graf A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821128>
47. **SARS-CoV-2 detection in sewage samples: Standardization of method & preliminary observations.** Indian J Med Res 2021; 153:159-165Sharma DK, Nalavade UP, Kalgutkar K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818473>
48. **Disease momentum: Estimating the reproduction number in the presence of superspreading.** Infect Dis Model 2021; Johnson KD, Beiglböck M, Eder M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824936>
49. **The first familial cluster of the B.1.1.7 variant of SARS-CoV-2 in the northeast of Italy.** Infection 2021; Lo Menzo S, Marinello S, Biasin M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33840038>
50. **HOSTED-England's Household Transmission Evaluation Dataset: preliminary findings from a novel passive surveillance system of COVID-19.** Int J Epidemiol 2021; Hall JA, Harris RJ, Zaidi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837417>

51. **Modelling intensive care unit capacity under different epidemiological scenarios of the COVID-19 pandemic in three Western European countries.** Int J Epidemiol 2021; McCabe R, Kont MD, Schmit N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33837401>
52. **Gender-based disparities on health indices during COVID-19 crisis: a nationwide cross-sectional study in Jordan.** Int J Equity Health 2021; 20:91Abufaraj M, Eyadat Z, Al-Sabbagh MQ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33823852>
53. **A deep learning model for mass screening of COVID-19.** Int J Imaging Syst Technol 2021; Dhaka VS, Rani G, Oza MG *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821094>
54. **Are we ready to deal with a global COVID-19 pandemic? Rethinking countries' capacity based on the Global Health Security Index.** Int J Infect Dis 2021; Ji Y, Shao J, Tao B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823282>
55. **Evaluating the impact of the travel ban within mainland China on the epidemic of the COVID-19.** Int J Infect Dis 2021; Xue L, Jing S, Sun W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33838344>
56. **Monitoring of Three-Phase Variations in the Mortality of Covid-19 Pandemic Using Control Charts: Where Does Pakistan Stand?** Int. J. Qual. Health Care 2021; Mahmood Y, Ishtiaq S, Khoo MBC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33822932>
57. **COVID-19 is not over and age is not enough: Using frailty for prognostication in hospitalized patients.** J Am Geriatr Soc 2021; Aliberti MJR, Szlejf C, Avelino-Silva VI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818759>
58. **Mobility Change and COVID-19 in Japan: Mobile Data Analysis of Locations of Infection.** J. Epidemiol. 2021; Nagata S, Nakaya T, Adachi Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814508>
59. **Sex Disparities in COVID-19 Mortality Vary Across US Racial Groups.** J Gen Intern Med 2021; Rushovich T, Boulicault M, Chen JT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33818679>
60. **Genomic surveillance of Nevada patients revealed prevalence of unique SARS-CoV-2 variants bearing mutations in the RdRp gene.** J Genet Genomics 2021; Hartley PD, Tillett RL, AuCoin DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820739>
61. **Time Series Modelling and Simulating the Lockdown Scenarios of COVID-19 in Kurdistan Region of Iraq.** J Infect Dev Ctries 2021; 15:370-381Abdullah M, Kolo K, Aspoukeh P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839712>
62. **A comparative analysis of COVID-19 outbreak on age groups and both the sexes of population from India and other countries.** J Infect Dev Ctries 2021; 15:333-341Jakhmola S, Baral B, Jha HC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839706>
63. **Coronavirus Pandemic: a major public health crisis for the developed and developing world.** J Infect Dev Ctries 2021; 15:366-369Ullah R, Suleman Rana M, Qadir M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839711>
64. **COVID-19 in the MENA Region: Facts and Findings.** J Infect Dev Ctries 2021; 15:342-349Younis NK, Rahm M, Bitar F, Arabi M.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33839707>

65. **A Silver Lining? Fewer non-SARS-CoV-2 Respiratory Viruses during the COVID-19 Pandemic.** J Infect Dis 2021; Most ZM, Holcomb M, Jamieson AR, Perl TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830238>
66. **Interaction Effects between COVID-19 Outbreak and Community Income Levels on Excess Mortality among Patients Visiting Emergency Departments.** J Korean Med Sci 2021; 36:e100Jung E, Ro YS, Ryu HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821595>
67. **Correcting notification delay and forecasting of COVID-19 data.** J Math Anal Appl 2021:125202Sarnaglia AJQ, Zamprogno B, Fajardo Molinares FA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814611>
68. **Low circulation of Influenza A and coinfection with SARS-CoV-2 among other respiratory viruses during the COVID-19 pandemic in a region of southern Brazil.** J Med Virol 2021; Eisen AKA, Gularte JS, Demoliner M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829531>
69. **SARS-CoV-2 show no infectivity at later stages in a prolonged COVID-19 patient despite positivity in RNA testing.** J Med Virol 2021; Wan XF, Tang CY, Ritter D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830520>
70. **Actual versus perceived infection rates of COVID-19: Impact on distress, behavior and disability.** J. Psychiatr. Res. 2021; 137:525-533Schmidt NB, Martin AD, Allan NP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831818>
71. **Epidemic zone of COVID-19 from social media using hypergraph with weighting factor (HWF).** J Supercomput 2021:1-18Pradeepa S, Manjula KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814722>
72. **Reporting and Availability of COVID-19 Demographic Data by US Health Departments (April to October 2020): Observational Study.** JMIR Public Health Surveill 2021; 7:e24288Ossom-Williamson P, Williams IM, Kim K, Kindratt TB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821804>
73. **A simple mathematical model to predict and validate the spread of Covid-19 in India.** Mater Today Proc 2021; Kumar H, Arora PK, Pant M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821202>
74. **How statistics of World Health Index react against COVID-19.** Mater Today Proc 2021; Tomer V, Gupta S, Manwal M, Singh DP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816130>
75. **Fractional order mathematical modeling of novel corona virus (COVID-19).** Math Methods Appl Sci 2021; Ahmad W, Sarwar M, Shah K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821069>
76. **Modeling and simulation of fractional order COVID-19 model with quarantined-isolated people.** Math Methods Appl Sci 2021; Aslam M, Farman M, Akgül A, Su M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821071>
77. **A case study of Covid-19 epidemic in India via new generalised Caputo type fractional derivatives.** Math Methods Appl Sci 2021; Kumar P, Suat Erturk V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821068>
78. **A dynamic model for the COVID-19 with direct and indirect transmission pathways.** Math Methods Appl Sci 2021; Memarbashi R, Mahmoudi SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821067>

79. **COVID-19 Real-time Information System for Preparedness and Epidemic Response (CRISPER).** Med. J. Aust. 2021; Field E, Dyda A, Lau CL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33837527>
80. **Segmentation of COVID-19 pneumonia lesions: A deep learning approach.** Med. J. Islam. Repub. Iran 2020; 34:174 Ghomi Z, Mirshahi R, Khameneh Bagheri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816373>
81. **Eliciting Beliefs about COVID-19 Prevalence and Mortality: Epidemiological Models Compared with The Street.** Methods 2021; Harrison GW, Hofmeyr A, Kincaid H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838269>
82. **Prevention schemes for future pandemic cases: mathematical model and experience of interurban multi-agent COVID-19 epidemic prevention.** Nonlinear Dyn 2021:1-36 Yin S, Zhang N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814725>
83. **Network-based Virus-Host Interaction Prediction with Application to SARS-CoV-2.** Patterns (N Y) 2021:100242 Du H, Chen F, Liu H, Hong P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817672>
84. **Using demographic data to understand the distribution of H1N1 and COVID-19 pandemics cases among federal entities and municipalities of Mexico.** PeerJ 2021; 9:e11144 Sarria-Guzmán Y, Bernal J, De Biase M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828926>
85. **Early survey with bibliometric analysis on machine learning approaches in controlling COVID-19 outbreaks.** PeerJ Comput Sci 2020; 6:e313 Chiroma H, Ezugwu AE, Jauro F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816964>
86. **Digital herd immunity and COVID-19.** Phys. Biol. 2021; Bulchandani VB, Shivam S, Moudgalya S, Sondhi SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827059>
87. **Epidemics, the Ising-model and percolation theory: A comprehensive review focussed on Covid-19.** Physica A 2021:125963 Mello IF, Squillante L, Gomes GO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814681>
88. **Epidemics, the Ising-model and percolation theory: A comprehensive review focused on Covid-19.** Physica A 2021; 573:125963 Mello IF, Squillante L, Gomes GO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814681>
89. **Explicit formulae for the peak time of an epidemic from the SIR model.** Physica D 2021; 422:132902 Turkyilmazoglu M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814655>
90. **Social distancing attitudes, national context, and health outcomes during the COVID-19 pandemic: Findings from a global survey.** Prev. Med. 2021:106544 Kim HH, Ryu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819518>
91. **Time-dependent heterogeneity leads to transient suppression of the COVID-19 epidemic, not herd immunity.** Proc Natl Acad Sci U S A 2021; 118 Tkachenko AV, Maslov S, Elbanna A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833080>
92. **The significance of sense in the time of plagues: Curricular responsiveness to the Covid-19 crisis.** Prospects (Paris) 2021:1-17 Spector H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814637>
93. **Reduction in Hospitalizations for Respiratory Diseases during the First COVID-19 Wave in Greece.** Respiration 2021:1-6 Kyriakopoulos C, Gogali A, Exarchos K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827103>

94. **Modeling the dynamics of novel coronavirus (COVID-19) via stochastic epidemic model.** Results Phys 2021; 24:104004Khan T, Zaman G, El-Khatib Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816091>
95. **Modeling the dynamics of novel coronavirus (COVID-19) via stochastic epidemic model.** Results Phys 2021:104004Khan T, Zaman G, Khatib YE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816091>
96. **Analysis, modeling and optimal control of COVID-19 outbreak with three forms of infection in Democratic Republic of the Congo.** Results Phys 2021:104096Ndondo AM, Kasereka SK, Bisuta SF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816092>
97. **[Corrections to daily excess mortality estimates in Spain during the COVID-19 pandemic.].** Rev. Esp. Salud Publica 2021; 95Equiza-Goñi J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824266>
98. **What determines city's resilience against epidemic outbreak: evidence from China's COVID-19 experience.** Sustain Cities Soc 2021:102892Yang T, Pan H, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816083>
99. **The incubation period during the pandemic of COVID-19: a systematic review and meta-analysis.** Syst Rev 2021; 10:101Dhouib W, Maatoug J, Ayouni I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832511>
100. **Prediction of COVID-19 cases using the weather integrated deep learning approach for India.** Transbound Emerg Dis 2021; Bhimala KR, Patra GK, Mopuri R, Mutheneneni SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837675>
101. **SARS-CoV-2 outbreak in Iran; the dynamics of the epidemic and evidence on two independent introductions.** Transbound Emerg Dis 2021; Fattahi Z, Mohseni M, Jalalvand K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835709>
102. **Slowing the spread of COVID-19: Review of "Social distancing" interventions deployed by public transit in the United States and Canada.** Transp Policy (Oxf) 2021; 106:25-36Kamga C, Eickemeyer P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814735>
103. **Coronavirus disease 2019 pandemic in Greece, February 26 - May 3, 2020: the first wave.** Travel Med Infect Dis 2021:102051Maltezou HC, Papadima K, Gkolfinopoulou K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819570>
104. **Using Urban Landscape Pattern to Understand and Evaluate Infectious Disease Risk: A Case Study of COVID-19 in Wuhan.** Urban For Urban Green 2021:127126Ye Y, Qiu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824634>
105. **Fine-Scale Temporal Dynamics of SARS-CoV-2 RNA Abundance in Wastewater during A COVID-19 Lockdown.** Water Res 2021; 197:117093Li B, Di DYW, Saingam P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826985>
106. **Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey.** World J. Gastroenterol. 2021; 27:1226-1239Queiroz NSF, Teixeira FV, Motta MP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828396>
107. **Predictive Analyses of COVID-19 Case Data to Estimate the Effectiveness of Nationwide Face Cover.** World Med Health Policy 2021; Kim H, Simpson J, Park B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821197>

108. **Agent-based simulation of pedestrian dynamics for exposure time estimation in epidemic risk assessment.** Z Gesundh Wiss 2021;1-8Harweg T, Bachmann D, Weichert F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824850>

Gastro-enterology (13 articles)

1. **Considerations and perspectives on digestive diseases during the COVID-19 pandemic: a narrative review.** Ann Palliat Med 2021; Li J, Li C, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832321>
2. **COVID-19 outbreak and acute cholecystitis in a Hub Hospital in Milan: wider indications for percutaneous cholecystostomy.** BMC Surg 2021; 21:180Barabino M, Piccolo G, Trizzino A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823831>
3. **Successful hemostasis of bleeding gastric inflammatory fibroid polyp by endoscopic treatment in a patient with severe COVID-19.** Clin. J. Gastroenterol. 2021; Murota A, Yoshi S, Okuda R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33840076>
4. **Functional Exams in the gastroenterology - New developments and tips for the common practice.** Deutsche Medizinische Wochenschrift 2021; 146:441-445Barbone G, Jochum C.
5. **A High Percentage of Patients Recovered From COVID-19 but Discharged With Abnormal Liver Function Tests.** Front. Physiol. 2021; 12:642922Gan Q, Gong B, Sun M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815147>
6. **Assessing efficacy of hepatocellular carcinoma prediction scores to prioritise hepatitis B surveillance in the COVID-19 era.** GastroHep 2021; 3:80-87Sinharay R, Grant AJ, Rivett L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821150>
7. **Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study.** Hepatol Int 2021; Satapathy SK, Roth NC, Kvasnovsky C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826042>
8. **Care of inflammatory bowel disease patients during coronavirus disease-19 pandemic using digital health-care technology.** JGH Open 2021; Ghoshal UC, Sahu S, Biswas SN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821221>
9. **Gastrointestinal endoscopic practice during COVID-19 pandemic: a multi-institutional survey.** Rom. J. Intern. Med. 2020; Maruyama H, Hosomi S, Nebiki H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826812>
10. **Anesthesia for GI endoscopy in the era of COVID-19.** Saudi J. Anaesth. 2021; 15:27-32Goudra B, Singh PM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824639>
11. **COVID-19 and comorbidities of hepatic diseases in a global perspective.** World J. Gastroenterol. 2021; 27:1296-1310Ahmad A, Ishtiaq SM, Khan JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833483>
12. **Coronavirus disease-2019 and the intestinal tract: An overview.** World J. Gastroenterol. 2021; 27:1255-1266Alberca GGF, Solis-Castro RL, Solis-Castro ME, Alberca RW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833480>
13. **Risk perception and knowledge of COVID-19 in patients with celiac disease.** World J. Gastroenterol. 2021; 27:1213-1225Zhen J, Stefanolo JP, Temprano MP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828395>

Guidelines (3 articles)

1. **Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.** Indian J Med Res 2021; 153:64-85Khaire NS, Jindal N, Yaddanapudi LN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818467>
2. **Getting trustworthy guidelines into the hands of global decision-makers and supporting their consideration of contextual factors for implementation: recommendation mapping of COVID-19 guidelines.** J. Clin. Epidemiol. 2021; Lotfi T, Stevens A, Akl EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836255>
3. **Discharge Practices for COVID-19 Patients: Rapid Review of Published Guidance and Synthesis of Documents and Practices at 22 US Academic Medical Centers.** J Gen Intern Med 2021:1-7Greysen SR, Auerbach AD, Mitchell MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835314>

Imaging (52 articles)

1. **Evaluation of COVID-19 chest computed tomography: a texture analysis based on three-dimensional entropy.** Biomed. Signal Process. Control 2021:102582Gaudêncio AS, Vaz PG, Hilal M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824680>
2. **Automatic Diagnosis of Coronavirus (COVID-19) Using Shape and Texture Characteristics Extracted From X-Ray and CT-Scan Images.** Biomed. Signal Process. Control 2021; 68:102602Imani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824681>
3. **Diagnosing Covid-19 chest x-rays with a lightweight truncated DenseNet with partial layer freezing and feature fusion.** Biomed. Signal Process. Control 2021; 68:102583Montalbo FJP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828610>
4. **A Fully Automated Deep Learning-based Network For Detecting COVID-19 from a New And Large Lung CT Scan Dataset.** Biomed. Signal Process. Control 2021:102588Rahimzadeh M, Attar A, Sakhaei SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821166>
5. **Clinical and CT features of mild-to-moderate COVID-19 cases after two sequential negative nucleic acid testing results: a retrospective analysis.** BMC Infect. Dis. 2021; 21:333Rong Y, Wang F, Tian J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832444>
6. **Cardiac magnetic resonance findings in coronavirus disease 2019.** Clin Case Rep 2021; Rezaeian N, Hosseini L, Asadian S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821185>
7. **Pediatric radiologic manifestations of COVID-19.** Clin Imaging 2021; 75:165-170Romberg EK, Menashe SJ, Kronman MP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831747>
8. **Abdominal obesity phenotype is associated with COVID-19 chest X-ray severity score better than BMI-based obesity.** Eat Weight Disord 2021:1-15Malavazos AE, Secchi F, Basilico S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821453>

9. **Clinical and Radiological Characteristics of Acute Cerebrovascular Diseases Among Egyptian Patients With COVID-19 in Upper Egypt.** Front. Neurol. 2021; 12:635856Khedr EM, Soliman RK, Abo-Elfetof N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828521>
10. **Robotic Ultrasound Scanning With Real-Time Image-Based Force Adjustment: Quick Response for Enabling Physical Distancing During the COVID-19 Pandemic.** Front Robot AI 2021; 8:645424Akbari M, Carriere J, Meyer T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33829043>
11. **COVID-19 infection map generation and detection from chest X-ray images.** Health Inf Sci Syst 2021; 9:15Degerli A, Ahishali M, Yamac M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824721>
12. **Back to the basics: Study of portable chest radiographic findings in 116 COVID-19 positive patients in an Indian tertiary care hospital.** Indian J. Radiol. Imaging 2021; 31:S148-s153Dutta P, Ahmad Z, Sagar M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814775>
13. **Are radiological diagnostic centres ready to tackle COVID-19 pandemic? An Indian perspective.** Indian J. Radiol. Imaging 2021; 31:S15-s20Gala KB, Gala BM, Gala FB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814757>
14. **The utility of HRCT in the initial diagnosis of COVID-19 pneumonia-An Indian perspective.** Indian J. Radiol. Imaging 2021; 31:S178-s181Kashyape R, Jain R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814779>
15. **Where have the others gone? Impact of lockdown during COVID-19 pandemic on patient populations undergoing Computed Tomography imaging in a public tertiary care hospital in India.** Indian J. Radiol. Imaging 2021; 31:S134-s138Kawthalkar AS, Somani SD, Bhalde RP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814773>
16. **Role of chest radiography in the management of COVID-19 pneumonia: An overview and correlation with pathophysiologic changes.** Indian J. Radiol. Imaging 2021; 31:S70-s79Kohli A, Hande PC, Chugh S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814764>
17. **The value of AI based CT severity scoring system in triage of patients with Covid-19 pneumonia as regards oxygen requirement and place of admission.** Indian J. Radiol. Imaging 2021; 31:S61-s69Kohli A, Jha T, Pazhayattil AB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814763>
18. **Where have all the diseases gone during the COVID-19 pandemic?** Indian J. Radiol. Imaging 2021; 31:S119-s121Kohli A, Shetty A, Joshi A, Bansal A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814770>
19. **Comparing a deep learning model's diagnostic performance to that of radiologists to detect Covid -19 features on chest radiographs.** Indian J. Radiol. Imaging 2021; 31:S53-s60Krishnamoorthy S, Ramakrishnan S, Colaco LB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814762>
20. **Pneumomediastinum and subcutaneous emphysema as complication in COVID-19 patient with high CT severity score: Two case reports.** Indian J. Radiol. Imaging 2021; 31:S187-s191Kumar RR, Singhai AK, Lokare SV, Pandya SP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814781>

21. **CT chest analysis of 2019 novel coronavirus pneumonia: An Indian perspective.** Indian J. Radiol. Imaging_2021; 31:S154-s160Kumar S, Pujari VS, Kotak SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814776>
22. **Psychological impact of COVID-19 on radiology: Emotional wellbeing versus psychological burnout.** Indian J. Radiol. Imaging_2021; 31:S11-s14Mahajan A, Sharma P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814756>
23. **Artificial intelligence and radiology: Combating the COVID-19 conundrum.** Indian J. Radiol. Imaging_2021; 31:S4-s10Pankhania M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814755>
24. **Spectrum of chest CT manifestations of coronavirus disease (COVID-19): A pictorial essay.** Indian J. Radiol. Imaging_2021; 31:S170-s177Parry AH, Wani HA, Choh NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814778>
25. **Management of a diagnostic radiology department amid Coronavirus disease-19 (COVID-19) pandemic.** Indian J. Radiol. Imaging_2021; 31:S192-s195Parry AH, Wani HA, Yaseen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814782>
26. **Pattern recognition of high-resolution computer tomography (HRCT) chest to guide clinical management in patients with mild to moderate COVID-19.** Indian J. Radiol. Imaging_2021; 31:S110-s118Rajalingam B, Narayanan E, Nirmalan P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814769>
27. **Incidental chest computed tomography findings in asymptomatic Covid-19 patients. A multicentre Indian perspective.** Indian J. Radiol. Imaging_2021; 31:S45-s52Ramanan RV, Joshi AR, Venkataramanan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814761>
28. **Diagnostic accuracy and false-positive rate of chest CT as compared to RT-PCR in coronavirus disease 2019 (COVID-19) pneumonia: A prospective cohort of 612 cases from India and review of literature.** Indian J. Radiol. Imaging_2021; 31:S161-s169Ravikanth R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814777>
29. **Radiographic features of COVID-19 infection at presentation and significance of chest X-ray: Early experience from a super-specialty hospital in India.** Indian J. Radiol. Imaging_2021; 31:S128-s133Sahu AK, Dhar A, Aggarwal B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814772>
30. **HRCT chest in COVID-19 patients: An initial experience from a private imaging center in western India.** Indian J. Radiol. Imaging_2021; 31:S182-s186Shah JV, Shah C, Shah S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814780>
31. **Retrospective analysis of chest HRCT findings in coronavirus disease pandemic (COVID-19)- An early experience.** Indian J. Radiol. Imaging_2021; 31:S101-s109Shah SA, Gajbhiye MI, Saibannawar AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814768>
32. **Demographic and clinico-radiological profile on High-Resolution Computerized Tomography (HRCT) thorax in mild or asymptomatic clinically suspected COVID-19 patients in high-endemicity area of India-Can HRCT be the first screening tool? -The DECRYPTION study.** Indian J. Radiol. Imaging_2021; 31:S122-s127Sharma K, Gupta A, Vadgama K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814771>

33. **Perception and practice regarding infection control measures in Radiology department during pre-COVID and COVID times-A survey among radiologists and a review of current concepts and literature.** Indian J. Radiol. Imaging 2021; 31:S139-s147Srivastava S, Rai PS, Jain A, Shenoy S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814774>
34. **An automated and fast system to identify COVID-19 from X-ray radiograph of the chest using image processing and machine learning.** Int J Imaging Syst Technol 2021; Khan MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821097>
35. **Automatic detection and localization of COVID-19 pneumonia using axial computed tomography images and deep convolutional neural networks.** Int J Imaging Syst Technol 2021; Polat H, Özerdem MS, Ekici F, Akpolat V.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821092>
36. **Convolutional capsule network for COVID-19 detection using radiography images.** Int J Imaging Syst Technol 2021; Tiwari S, Jain A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821095>
37. **Helping Roles of Artificial Intelligence (AI) in the Screening and Evaluation of COVID-19 Based on the CT Images.** J Inflamm Res 2021; 14:1165-1172Xie H, Li Q, Hu PF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814922>
38. **Asymptomatic SARS-CoV-2 infection- Incidental findings on FDG PET/CT.** J Med Imaging Radiat Sci 2021; Bello Martinez R, Ghesani M, Ghesani N, Gavane S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33820742>
39. **Quantification of the $\alpha\beta6$ Integrin by PET/CT Imaging in the Lungs of Patients after SARS-CoV2 Infection and Comparison to Fibrotic Lungs.** J Nucl Med 2021; Lukey PT, Wilson FJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837070>
40. **Segmentation of COVID-19 pneumonia lesions: A deep learning approach.** Med. J. Islam. Repub. Iran 2020; 34:174Ghomi Z, Mirshahi R, Khameneh Bagheri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816373>
41. **A multi-task pipeline with specialized streams for classification and segmentation of infection manifestations in COVID-19 scans.** PeerJ Comput Sci 2020; 6:e303El-Bana S, Al-Kabbany A, Sharkas M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816954>
42. **COVID-19: a new deep learning computer-aided model for classification.** PeerJ Comput Sci 2021; 7:e358Elzeki OM, Shams M, Sarhan S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817008>
43. **Performance analysis of lightweight CNN models to segment infectious lung tissues of COVID-19 cases from tomographic images.** PeerJ Comput Sci 2021; 7:e368Iyer TJ, Joseph Raj AN, Ghildiyal S, Nersisson R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817018>
44. **ADID-UNET-a segmentation model for COVID-19 infection from lung CT scans.** PeerJ Comput Sci 2021; 7:e349Joseph Raj AN, Zhu H, Khan A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816999>
45. **A deep learning algorithm to detect coronavirus (COVID-19) disease using CT images.** PeerJ Comput Sci 2021; 7:e345Mohammadpoor M, Sheikhi Karizaki M, Sheikhi Karizaki M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834092>
46. **FUSI-CAD: Coronavirus (COVID-19) diagnosis based on the fusion of CNNs and handcrafted features.** PeerJ Comput Sci 2020; 6:e306Ragab DA, Attallah O.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816957>

47. **COVID-19: high-resolution computed tomography findings in the first 64 patients admitted to the Hospital of Cremona, the epicentre of the pandemic in Europe.** Pol J Radiol 2021; 86:e172-e176 Sabatino V, Sergio P, Muri M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828629>
48. **Computed tomography imaging findings in hospitalized patients with coronavirus disease 2019 (COVID-19): a descriptive study of 81 cases.** Pol J Radiol 2021; 86:e165-e171 Zarrintan A, Javadrashid R, Jalili J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828628>
49. **Chest CT severity score and radiological patterns as predictors of disease severity, ICU admission, and viral positivity in COVID-19 patients.** Respir Investig 2021; Bellos I, Tavernaraki K, Stefanidis K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33820751>
50. **Lung ultrasonography for long-term follow-up of COVID-19 survivors compared to chest CT scan.** Respir. Med. 2021; 181:106384 Giovannetti G, De Michele L, De Ceglie M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839587>
51. **One-month outcomes of patients with SARS-CoV-2 infection and their relationships with lung ultrasound signs.** Ultrasound J 2021; 13:19 Mafort TT, Rufino R, da Costa CH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835273>
52. **Radiological and clinical spectrum of COVID-19: A major concern for public health.** World J Radiol 2021; 13:53-63 Verma HK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=3381568>

Immune response (29 articles)

1. **Diagnostic accuracy estimates for COVID-19 RT-PCR and Lateral flow immunoassay tests with Bayesian latent class models.** Am. J. Epidemiol. 2021; Kostoulas P, Eusebi P, Hartnack S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823529>
2. **Joint testing of IgM and IgG has high value for ruling in SARS-CoV-2 infection.** Ann Intern Med 2021; Loeb M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819063>
3. **Expectations of citizens from the government in response to COVID-19 pandemic: a cross-sectional study in Iran.** BMC Public Health 2021; 21:686 Zarei L, Shahabi S, Sadati AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832471>
4. **COVID-19 and immunomodulation treatment for women with reproductive failures.** Cas. Lek. Cesk. 2021; 160:33-36 Sedláčková L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33823602>
5. **Inflammatory and Prothrombotic Biomarkers Associated With the Severity of COVID-19 Infection.** Clin. Appl. Thromb. Hemost. 2021; 27:1076029621999099 Lopez-Castaneda S, García-Larragoiti N, Cano-Mendez A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835872>
6. **Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.** Clin Chem Lab Med 2021; Danese E, Montagnana M, Salvagno GL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33838087>

7. **Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.** Clin Chem Lab Med 2021; Irsara C, Egger AE, Prokop W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837679>
8. **Ultra-sensitive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection for the Diagnosis of Coronavirus Disease 2019 (COVID-19) in Upper Respiratory Samples.** Clin Infect Dis 2021; Wang H, Hogan CA, Verghese M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830203>
9. **Multisystem Inflammatory Syndrome in Adults after Mild SARS-CoV-2 Infection, Japan.** Emerg Infect Dis 2021; 27Yamada Y, Fujinami K, Eguchi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821784>
10. **Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.** Emerg Microbes Infect 2021:1-23Rockstroh A, Wolf J, Fertey J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830901>
11. **Endothelial cell, myeloid, and adaptive immune responses in SARS-CoV-2 infection.** Faseb j 2021; 35:e21577Degauque N, Haziot A, Brouard S, Mooney N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831263>
12. **The Weight of Obesity in Immunity from Influenza to COVID-19.** Front Cell Infect Microbiol 2021; 11:638852Andrade FB, Gualberto A, Rezende C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816341>
13. **Immunity to SARS-CoV-2: Lessons Learned.** Front. Immunol. 2021; 12:654165Fergie J, Srivastava A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815415>
14. **COVID-19-A Theory of Autoimmunity Against ACE-2 Explained.** Front. Immunol. 2021; 12:582166McMillan P, Dexhiemer T, Neubig RR, Uhal BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833750>
15. **Rapid chromatographic immunoassay-based evaluation of COVID-19: A cross-sectional, diagnostic test accuracy study & its implications for COVID-19 management in India.** Indian J Med Res 2021; 153:126-131Gupta A, Khurana S, Das R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818469>
16. **CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity.** Infection 2021; Doehn JM, Tabelaing C, Biesen R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825125>
17. **Identification of COVID-19 subtypes based on immunogenomic profiling.** Int Immunopharmacol 2021; 96:107615Chen Z, Feng Q, Zhang T, Wang X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836368>
18. **A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm.** Intern Emerg Med 2021; Pouladzadeh M, Safdarian M, Eshghi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837906>
19. **Serology testing demonstrates that antibodies to SARS-CoV-2 S1-RBD correlate with neutralization of virus infection of Vero E6 cells.** J Appl Lab Med 2021; Freeman J, Conklin J, Oramus D, Cycon K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822063>

20. **Multisystem Inflammatory Syndrome in an Adult.** *J. Emerg. Med.* 2021; Amato MK, Hennessy C, Shah K, Mayer J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838966>
21. **Differential T cell reactivity to endemic coronaviruses and SARS-CoV-2 in community and health care workers.** *J Infect Dis* 2021; da Silva Antunes R, Pallikkuth S, Williams E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822097>
22. **IgG immune complexes may contribute to neutrophil activation in the course of severe COVID-19.** *J Infect Dis* 2021; Mazzitelli I, Bleichmar L, Ludueña MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822045>
23. **Broad SARS-CoV-2 cell tropism and immunopathology in lung tissues from fatal COVID-19.** *J Infect Dis* 2021; Ramos da Silva S, Ju E, Meng W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837392>
24. **Inflammatory profiles and clinical features of COVID-19 survivors three months after discharge in Wuhan, China.** *J Infect Dis* 2021; Zhou M, Yin Z, Xu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822106>
25. **Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19.** *J Inflamm Res* 2021; 14:1207-1216 Xie C, Li Q, Li L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833543>
26. **SARS-CoV-2 IgG Seropositivity and Acute Asymptomatic Infection Rate Among Firefighter First Responders in an Early Outbreak County in California.** *Prehosp. Emerg. Care* 2021:1-10 Newberry JA, Gautreau M, Staats K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819128>
27. **[Reflections on the position of the Covid-19 antigenic test based on a discrepancy of result].** *Rev Francoph Lab* 2021; 2021:67-69 Friedberga B, Royoa J, Villieza V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815587>
28. **Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients.** *Vaccine* 2021; Azzi L, Focosi D, Dentali F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824042>
29. **SARS-CoV-2 presented moderately during two episodes of the infection with lack of antibody responses.** *Virus Res.* 2021:198421 Salehi-Vaziri M, Omrani MD, Pouriayevali MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836204>

Management miscellaneous diseases (73 articles)

1. **Screening Colonoscopy for Colon Cancer in Women during COVID-19 Pandemic.** *Acta Med Indones* 2021; 53:132-139 Bestari MB, Joewono IR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818416>
2. **COVID-19 Pandemic: Evaluation of Socio-Economic Impact on Aesthetic Plastic Surgery Providers.** *Aesthetic Plast. Surg.* 2021; Paprottka FJ, Rolfes SB, Richter DF, Kaye KO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830307>
3. **COVID-19 impact on bladder cancer-orientations for diagnosing, decision making, and treatment.** *Am J Clin Exp Urol* 2021; 9:132-139 Travassos TC, De Oliveira JMI, Selegatto IB, Reis LO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816701>
4. **The impact of Covid-19 on patients with suspected cancer: An analysis of ED presentation and referrals to a quick diagnosis unit.** *Am J Emerg Med* 2021;

- 48:1-11 Bosch X, Capdevila A, Grafia I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836386>
5. **Impacts and challenges of the COVID-19 pandemic on emergency medicine physicians in the United States.** *Am J Emerg Med* 2021; 48:38-47 Nguyen J, Liu A, McKenney M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836387>
 6. **Adrenal insufficiency in the COVID-19 era.** *Am J Physiol Endocrinol Metab* 2021; 320:E784-e785 Siejka A, Barabutis N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825496>
 7. **Perioperative management.** *Anesthesiologie Intensivmedizin Notfallmedizin Schmerztherapie* 2021; 56:157-158 Zacharowski K.
 8. **Correspondence on 'Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study'.** *Ann. Rheum. Dis.* 2021; Wee LE, Conceicao EP, Tan JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837047>
 9. **Differential trends of admissions in accident and emergency departments during the COVID-19 pandemic in Germany.** *BMC Emerg. Med.* 2021; 21:42 Jaehn P, Holmberg C, Uhlenbrock G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823795>
 10. **Restarting cataract surgery during the COVID-19 pandemic; a prospective study analysing 30 day outcomes after elective cataract surgery in the United Kingdom.** *BMC Ophthalmol.* 2021; 21:167 Carr F, Agarwal P, Narula H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836704>
 11. **A risk assessment strategy to re-introduce elective neurosurgery patients during COVID-19.** *Br. J. Neurosurg.* 2021:1-5 Youshani AS, Whittle C, Ghosh K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829937>
 12. **Adapting a 2-week-wait colorectal service in the pandemic using the quantitative faecal immunochemical test.** *Br J Nurs* 2021; 30:404-408 Cock K, Bromley R, Faux W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830800>
 13. **The Impact of Non-Compliance to a Standardized Risk-Adjusted Protocol on Recurrence, Progression, and Mortality in Non-Muscle Invasive Bladder Cancer.** *Cancer Manag. Res.* 2021; 13:2937-2945 Abushamma F, Khayat Z, Soroghle A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833577>
 14. **SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms.** *Cell* 2021; Clark SA, Clark LE, Pan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831372>
 15. **Impact of SARS-CoV-2 pandemic on emergency department activity at the pediatric surgery unit of a third-level hospital.** *Cir. Pediatr.* 2021; 34:85-89 Moratilla Lapeña L, Delgado-Miguel C, Sarmiento Caldas MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826261>
 16. **Travel Trouble With Legionella in the Era of COVID-19: A Case Report.** *Cureus* 2021; 13:e13632 Hussain KM, Alam MDU, Ahmad NT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816031>
 17. **The effect of COVID-19 emergency in the management of melanoma in Italy.** *Dermatol Reports* 2021; 13:8972 Intergruppo Melanoma I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824708>

18. **COVID-19 and tumor treatment: Mortality risk of cancer patients already increases after short treatment delays.** Deutsches Arzteblatt International 2020; 117:A2348Meyer R.
19. **How COVID-19 lockdown measures could impact patients with bulimia nervosa: Exploratory results from an ongoing experience sampling method study.** Eat Behav 2021; 41:101505Leenaerts N, Vaessen T, Ceccarini J, Vrieze E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831813>
20. **Changes in drug use in European cities during early COVID-19 lockdowns - A snapshot from wastewater analysis.** Environ Int 2021; 153:106540Been F, Emke E, Matias J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838618>
21. **Abscopal antitumor effect in a patient with melanoma and coronavirus disease 2019.** Eur. J. Cancer 2021; 149:91-93Herrscher H, Sauer B, Truntzer P, Robert C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839589>
22. **What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects.** Eur. J. Ophthalmol. 2020;1120672120958323Fambuena-Muedra I, Jiménez-García M, Hershko S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829895>
23. **Acute surgical abdomen during the COVID-19 pandemic: Clinical and therapeutic challenges.** Exp. Ther. Med. 2021; 21:519Serban D, Socea B, Badiu CD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815592>
24. **Public Oral Health Care During COVID-19: Time for Reflection and Action.** Front Med (Lausanne) 2021; 8:610450Singh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816519>
25. **Impact of the COVID-19 Pandemic on Patients and Staff in Radiation Oncology Departments in Belgium: A National Survey.** Front. Oncol. 2021; 11:654086Vaandering A, Ben Mustapha S, Lambrecht M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816310>
26. **Impact of COVID-19 on Gynaecological oncology; a global perspective.** Heliyon 2021; 7:e06658O'Neill D, El-Ghobashy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829116>
27. **Immunotherapy in psoriasis.** Immunotherapy 2021; Landeck L, Sabat R, Ghoreschi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820446>
28. **Covid-19 and Ear Surgery: Treatment Strategies and Triage during the Post-lockdown Period.** Indian J Otolaryngol Head Neck Surg 2021;1-6Bhardwaj R, Sharma A, Singhal B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816213>
29. **Interventional radiology and COVID-19: How to face the challenge?** Indian J. Radiol. Imaging 2021; 31:S38-s44Chaluvashetty SB, Kalra N, Bhujade H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814760>
30. **Interventional radiology preparedness during coronavirus disease (COVID-19) pandemic.** Indian J. Radiol. Imaging 2021; 31:S21-s30Garg T, Desai A, Gala K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814758>
31. **Suggestions for Shaping Tinnitus Service Provision in Western Europe: Lessons from the COVID-19 Pandemic.** Int J Clin Pract 2021:e14196Beukes EW, Lourenco M, Biot L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837639>
32. **Pharmacists' Experience, Competence, and Perception of Telepharmacy Technology in Response to COVID-19.** Int J Clin Pract 2021:e14209Muflih SM, Al-

Azzam S, Abuhammad S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819372>

33. **Health Systems and Services During COVID-19: Lessons and Evidence From Previous Crises: A Rapid Scoping Review to Inform the United Nations Research Roadmap for the COVID-19 Recovery.** Int J Health Serv 2021:20731421997088Baral P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827309>
34. **Social Cohesion and Community Resilience During COVID-19 and Pandemics: A Rapid Scoping Review to Inform the United Nations Research Roadmap for COVID-19 Recovery.** Int J Health Serv 2021:20731421997092Jewett RL, Mah SM, Howell N, Larsen MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827308>
35. **Impact of COVID-19 on the practice of orthopaedics and trauma-an epidemiological study of the full pandemic year of a tertiary care centre of New Delhi.** Int. Orthop. 2021:1-7Vaishya R, Vaish A, Kumar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835246>
36. **Evaluation of the effects of the COVID-19 pandemic on children with cerebral palsy, caregivers' quality of life, and caregivers' fear of COVID-19 with telemedicine.** Ir. J. Med. Sci. 2021:1-8Cankurtaran D, Tezel N, Yildiz SY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834363>
37. **Loss of Reproductive Ability due to Late Application of Young Refugee with Choriocarcinoma During the COVID-19 Pandemic.** J Adolesc Young Adult Oncol 2021; Bas S, Seyfettinoglu S, Narin MA, Ogur M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835857>
38. **Race, Ethnicity and Comorbidities are Critical Factors in the Diagnosis of Telogen Effluvium During the COVID- 19 Pandemic.** J Am Acad Dermatol 2021; Cline A, Jacobs AK, Fonseca M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839211>
39. **Adaptation of clinical pharmacy services to meet patient care needs during the COVID-19 pandemic.** J Am Coll Clin Pharm 2021; 4:364-371Danelich IM, Thomson L, Alberto J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821239>
40. **Availability of Services and Caregiver Burden: Supporting Individuals With Neurogenetic Conditions During the COVID-19 Pandemic.** J. Child Neurol. 2021:8830738211001209Kowanda M, Cartner L, Kentros C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829918>
41. **Global orthopaedic trauma surgeons highlight telenomics during the COVID-19 era: A case for advancing telemedicine in orthopaedics.** J Clin Orthop Trauma 2021; 17:182-185Cole PA, Jr., Lezak BA, Schroder LK, Cole PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814860>
42. **The impact of COVID-19 on hand therapy practice.** J. Hand Ther. 2021; Ivy CC, Doerrer S, Naughton N, Priganc V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820708>
43. **First, second and third wave of COVID-19. What have we changed in the ICU management of these patients?** J Infect 2021; Taboada M, González M, Alvarez A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826927>
44. **HIV/AIDS in the Era of COVID-19: A Juxtaposition of Two Pandemics.** J Infect Dis 2021; Eisinger RW, Lerner AM, Fauci AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826927>

term=33825905

45. **The impact of disruptions due to COVID-19 on HIV transmission and control among men who have sex with men in China.** J Int AIDS Soc 2021; 24:e25697 Booton RD, Fu G, MacGregor L *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821553>
46. **COVID-19 pandemic, the scarcity of medical resources, community-centred medicine and discrimination against persons with disabilities.** J. Med. Ethics 2021; Panocchia N, D'Ambrosio V, Corti S *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33827907>
47. **(68)Ga-DOTATATE PET/CT for Neuroblastoma staging. Utility for clinical use.** J. Nucl. Med. Technol. 2021; Maaz AUR, O'Doherty J, Djekidel M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33820858>
48. **Early mortality in hip fracture patients admitted during first wave of the COVID-19 pandemic in Northern Italy: a multicentre study.** J. Orthop. Traumatol. 2021; 22:15 Dallari D, Zagra L, Cimatti P *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818650>
49. **Invisible burden of COVID-19: enzyme replacement therapy disruptions.** J. Pediatr. Endocrinol. Metab. 2021; Kahraman AB, Yıldız Y, Çıkkı K *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33818036>
50. **A multicenter study of acute testicular torsion in the time of COVID-19.** J. Pediatr. Urol. 2021; Holzman SA, Ahn JJ, Baker Z *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33832873>
51. **Spinal surgery during the COVID-19 pandemic: the experience in a tertiary referral centre.** J Spine Surg 2021; 7:62-67 Riley J, Verma R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33834129>
52. **The impact of the SARS-CoV-2 epidemic outbreak on the vascular access team operations after conversion to COVID-19 dedicated hospital.** J Vasc Access 2021:11297298211005254 Deganello E, Gastaldo F, Masiero S *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33827318>
53. **Simulation of Adult Surgical Cricothyrotomy for Anesthesiology and Emergency Medicine Residents: Adapted for COVID-19.** MedEdPORTAL 2021; 17:11134 Asselin M, Lafleur A, Labrecque P *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816795>
54. **How the COVID-19 Pandemic has changed multiple sclerosis clinical practice: Results of a nationwide provider survey.** Mult Scler Relat Disord 2021; 51:102913 Morrison EH, Michtich K, Hersh CM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33839482>
55. **Report of National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from COVID-19 Experience.** Neuro Oncol 2021; Lee EQ, Selig W, Meehan C *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33822177>
56. **Neurosurgery resumption in Wuhan during the early post-epidemic period: what should we pay attention to?** Neurosurg. Rev. 2021; Qi Y, Liu X, Wan X *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33839945>
57. **[Complex oncologic therapy for loco-regionally advanced breast cancer associated with long-lasting SARS-CoV-2 PCR-positivity].** Orv. Hetil. 2021;

- 162:611-614Drozgyik A, Kollár D, Knausz M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33830935>
58. **[How COVID-19 pandemic influences paediatric acute appendicitis cases?].** Orv. Hetil. 2021; 162:608-610Fadgyas B, Garai GI, Ringwald Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33830938>
59. **Anesthesia and surgery for positive COVID-19 asymptomatic pediatric patients: how long should we wait?** Paediatr Anaesth 2021; Geng-Ramos G, Cronin J, Challa C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834573>
60. **Virtual Care in the Veterans Affairs Spinal Cord Injuries and Disorders System of Care During the COVID-19 National Public Health Emergency.** Phys. Med. Rehabil. Clin. N. Am. 2021; 32:207-221Barrows D, Goldstein B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814053>
61. **The perception of COVID-19 among Italian dental patients: an orthodontic point of view.** Prog. Orthod. 2021; 22:11Martina S, Amato A, Faccioni P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33825992>
62. **Mental Health and Quality & Safety of Care in Czech Residential Institutions during the COVID-19 Pandemic: A Mixed-Methods Study.** Psychiatr. Q. 2021;1-19Guerrero Z, Aliev AA, Kondrátová L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821407>
63. **Effect of the COVID-19 pandemic lockdown on non-COVID-19 emergency department visits in Eastern France: Reduced risk or avoidance behavior?** Public Health Pract (Oxf) 2021; 2:100109Wartelle A, Mourad-Chehade F, Yalaoui F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817678>
64. **Practical recommendations for the management of the patient with chronic pain during the pandemic of COVID-19.** Rev. Esp. Anesthesiol. Reanim. 2020; Asensio-Samper JM, Quesada-Carrascosa M, Fabregat-Cid G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33823985>
65. **[COVID-19, drugs and hospital pharmacy].** Rev. Infirm. 2021; 70:40-42Didelot N, Hofmann C, Larcher B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832730>
66. **Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1).** RMD Open 2021; 7Garrido-Cumbrera M, Marzo-Ortega H, Christen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827969>
67. **Pain management in COVID-19 pediatric patients-An evidence- based review.** Saudi J. Anaesth. 2021; 15:33-39Mishra P, Tomar A, Kumar A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824640>
68. **Correlation of Seizure Increase and COVID-19 Outbreak in Adult Patients with Epilepsy: Findings and Suggestions from a Nationwide Multi-centre Survey in China.** Seizure 2021; 88:102-108Zeng C, Meng H, Zhu Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33839561>
69. **Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study.** Semin. Oncol. 2021; Martín-Bravo C, Quirós R, Blancas I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832767>
70. **How to use laser safely in times of COVID-19: Systematic review.** Spec. Care Dentist. 2021; Lago ADN, Cordon R, Gonçalves LM *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33822391>

71. **Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products.** Transplant Cell Ther 2021; 27:133-141 Auletta JJ, Novakovich JL, Stritesky GL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33830022>
72. **COVID-19 and its effects upon orthopaedic surgery: The Trinidad and Tobago experience.** World J Orthop 2021; 12:94-101 Mencia MM, Goalan R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816137>
73. **Pain and function deteriorate in patients awaiting total joint arthroplasty that has been postponed due to the COVID-19 pandemic.** World J Orthop 2021; 12:152-168 Pietrzak JRT, Maharaj Z, Erasmus M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816142>

Management (50 articles)

1. **Scalable Model for Delivery of Inpatient Palliative Care During a Pandemic.** Am. J. Hosp. Palliat. Care 2021:10499091211005701 Kaya E, Lewin W, Frost D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823653>
2. **Timing of delivery with COVID-19 pneumonia requiring intensive care unit admission.** Am J Obstet Gynecol MFM 2021:100373 Rose CH, Wyatt MA, Narang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831584>
3. **ECMO for COVID-19-Associated Severe ARDS in Chile: A Nationwide Incidence and Cohort Study.** Am J Respir Crit Care Med 2021; Diaz RA, Graf J, Zambrano JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823118>
4. **Pulmonary rehabilitation focusing on the regulation of respiratory movement can improve prognosis of severe patients with COVID-19.** Ann Palliat Med 2021; Sun J, Liu J, Li H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832294>
5. **Coping with the burden of the COVID-19 pandemic: a cross-sectional study of community pharmacists from Serbia.** BMC Health Serv. Res. 2021; 21:304 Jovičić-Bata J, Pavlović N, Milošević N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33823866>
6. **The role of extracorporeal membrane oxygenation in critically ill patients with COVID-19: a narrative review.** BMC Pulm. Med. 2021; 21:116 Huang S, Zhao S, Luo H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832474>
7. **Encephalopathy responsive to thiamine in severe COVID-19 patients.** Brain Behav Immun Health 2021:100252 de Oliveira MVB, Irikura S, Lourenço FHB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817670>
8. **SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms.** Cell 2021; Clark SA, Clark LE, Pan J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33831372>
9. **Covid-19 laryngectomized patients care, on field experience, and considerations.** Clin Case Rep 2021; Ricciardiello F, Caraglia M, Romano GM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821187>
10. **Rising to the Occasion of This COVID-19-Impacted Nation: Development, Implementation, and Feasibility of the Brief Assessment-Informed Skills**

- Intervention for COVID-19 (BASIC).** Cogn. Behav. Pract. 2021; Hsu KJ, Carl E, DiVita A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814877>
11. **Traditional Chinese exercise potential role as prevention and adjuvant therapy in patients with COVID-19.** Complement. Ther. Clin. Pract. 2021; 43:101379Yang S, Liu T, Xiong J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839522>
 12. **Working short and working long: can primary healthcare be protected as a public good in Lebanon today?** Confl Health 2021; 15:23Hamadeh RS, Kdouh O, Hammoud R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827637>
 13. **Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test.** Contact Dermatitis 2021; Stingeni L, Francisci D, Bianchi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834491>
 14. **Prone position in intubated, mechanically ventilated patients with COVID-19: a multi-centric study of more than 1000 patients.** Crit Care 2021; 25:128Langer T, Brioni M, Guzzardella A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823862>
 15. **Tracheal Tube Obstruction Due to Hemoptysis Associated With Pulmonary Infarction in a Patient With Severe COVID-19 Pneumonia.** Cureus 2021; 13:e13599Maruhashi T, Wada T, Masuda T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815999>
 16. **COVID-19 and ARDS: Update On Preventive And Therapeutic Venues.** Curr. Mol. Med. 2021; Narota A, Puri G, Singh VP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829971>
 17. **COVID-19 intensive care patients: Intra-German transfers.** Deutsches Arzteblatt International 2020; 117:A2321-A2323Gräsner JT, Hannappel L, Zill M *et al.*
 18. **COVID-19 emphasis: Simple prophylaxis.** Deutsches Arzteblatt International 2020; 117:A2353Wenderlein JM.
 19. **The Covid-19 infection: An opportunity to develop systematic vitamin D supplementation in psychiatry.** Encephale 2021; Fond G, Masson M, Richieri R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820650>
 20. **Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.** Expert Rev. Anti Infect. Ther. 2021; Savla SR, Prabhavalkar KS, Bhatt LK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832398>
 21. **Mortality in mechanically ventilated patients with COVID-19: a systematic review.** Expert Rev. Med. Devices 2021; Tsikala Vafea M, Zhang R, Kalligeros M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836621>
 22. **The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review.** Front. Endocrinol. (Lausanne) 2021; 12:645194Zangiabadian M, Nejadghaderi SA, Zahmatkesh MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815295>
 23. **Whom Should Be Saved? A Proposed Ethical Framework for Allocating Scarce Medical Resources to COVID-19 Patients Using Fuzzy Logic.** Front Med (Lausanne) 2021; 8:600415Saadeh H, Saadeh M, Almobaideen W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829020>
 24. **Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg-a report from the AGMT COVID-19 Registry.** Geroscience 2021;

Huemer F, Rinnerthaler G, Jörg B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837912>

25. **Balancing scarce hospital resources during the COVID-19 pandemic using discrete-event simulation.** Health Care Manag Sci 2021;1-19Melman GJ, Parlikad AK, Cameron EAB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835338>
26. **Approaches, Successes, and Challenges in Recruiting Closed Points of Dispensing Sites: A Qualitative Study.** Health Secur 2021; Rebmann T, Foerst K, Charney RL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826857>
27. **Emergency cricothyroidotomy and conversion tracheostomy in a patient with COVID-19: a case report.** Hong Kong Med. J. 2021; Lau YF, Wong FKC, Kwan PKC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824216>
28. **Differentiating impacts of non-pharmaceutical interventions on non-coronavirus disease-2019 respiratory viral infections: Hospital-based retrospective observational study in Taiwan.** Influenza Other Respir Viruses 2021; Chen AP, Chu IY, Yeh ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825310>
29. **Nurses' Preparedness And Response To COVID-19.** Int J Afr Nurs Sci 2021;100302Mubarak Al Baalharith I, Mary Pappiya E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816114>
30. **Effects of non-pharmaceutical interventions against COVID-19: A cross-country analysis.** Int. J. Health Plann. Manage. 2021; Gokmen Y, Baskici C, Ercil Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819370>
31. **High-flow oxygen therapy in elderly patients infected with SARS-CoV2 with a contraindication for transfer to an intensive care unit: a preliminary report.** Int J Infect Dis 2021; Lagier JC, Amrane S, Mailhe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823281>
32. **Mechanical circulatory support in coronavirus disease-2019-positive patients with severe respiratory failure.** Interact. Cardiovasc. Thorac. Surg. 2021; Natanov R, Wiesner O, Haverich A, Kühn C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822952>
33. **Effectiveness of dexmedetomidine combined with high flow nasal oxygen and long periods of awake prone positioning in moderate or severe COVID-19 pneumonia.** J. Clin. Anesth. 2021; 72:110261Taboada M, Baluja A, Santos LD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839432>
34. **Vitamin D and COVID-19: is there a role?** J Diabetes Metab Disord 2021;1-8Khan AH, Nasir N, Nasir N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816359>
35. **Discharge Practices for COVID-19 Patients: Rapid Review of Published Guidance and Synthesis of Documents and Practices at 22 US Academic Medical Centers.** J Gen Intern Med 2021;1-7Greysen SR, Auerbach AD, Mitchell MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835314>
36. **Appropriate use of essential oils and their components in the management of upper respiratory tract symptoms in patients with COVID-19.** J Herb Med 2021;100451Valussi M, Antonelli M, Donelli D, Firenzuoli F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816085>
37. **The Current separating / screening process for suspected patients with COVID-19 at Hue University Hospital, Vietnam.** J Infect Dev Ctries 2021; 15:350-

- 352Binh TD, Loan TT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839708>
38. **Extracorporeal Membrane Oxygenation in Patients With COVID-19: An International Multicenter Cohort Study.** J. Intensive Care Med. 2021;8850666211007063Raasveld SJ, Delnoij TSR, Broman LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823709>
 39. **COVID-19 pandemic, the scarcity of medical resources, community-centred medicine and discrimination against persons with disabilities.** J. Med. Ethics 2021; Panocchia N, D'Ambrosio V, Corti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827907>
 40. **The importance of patient-centered care during the COVID-19 pandemic: lessons from a rural ward in Japan.** J Rural Med 2021; 16:128-129Ohta R, Ikeda H, Sawa J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833842>
 41. **Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension.** J Zhejiang Univ Sci B 2021; 22:330-340Feng B, Zhang D, Wang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835767>
 42. **Testicles, adipose organ and heart: A new axis in the management of SARS-CoV-2?** Med. Hypotheses 2021; 150:110587Bertuccioli A, Cardinali M, Pierro FD, Balducci D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831722>
 43. **Infection control in the respiratory care of coronavirus disease-19 patients with neuromuscular diseases.** Neurol Clin Neurosci 2021; 9:159-165Matsumura T, Saito T, Mori M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821184>
 44. **Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression.** Nutr. Metab. Cardiovasc. Dis. 2021; Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838992>
 45. **Home palliative care professionals perception of challenges during the Covid-19 outbreak: A qualitative study.** Palliat. Med. 2021:2692163211008732Franchini L, Varani S, Ostan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829909>
 46. **Early awake proning in critical and severe COVID-19 patients undergoing noninvasive respiratory support: A retrospective multicenter cohort study.** Pulmonology 2021; Tonelli R, Pisani L, Tabbi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824084>
 47. **Complementary and alternative medicine therapies and COVID-19: a systematic review.** Rev. Environ. Health 2021; Badakhsh M, Dastras M, Sarchahi Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838089>
 48. **[COVID-19, drugs and hospital pharmacy].** Rev. Infirm. 2021; 70:40-42Didelot N, Hofmann C, Larcher B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832730>
 49. **Assessment and management of asymptomatic COVID-19 infection: A Systematic Review.** Travel Med Infect Dis 2021; 41:102058Barboza JJ, Chambergo-Michilot D, Velasquez-Sotomayor M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838319>
 50. **Jugular central line inserted into the hepatic vein of a COVID-19 patient.** Vis J Emerg Med 2021; 23:101027Eid MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817350>

Mental – public health (150 articles)

1. **From the Operating Room to the Front Lines: Shared Experiences of Nurse Anesthetists During the Coronavirus Pandemic.** AANA J. 2021; 89:109-116 Everson M, Wilbanks BA, Hranchook AM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33832570>
2. **The Men's Mental Health Perspective on Adolescent Suicide in the COVID-19 Era.** Acta Neuropsychiatr. 2021:1-11 Rice T, Sher L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33818340>
3. **COVID-19 in adults with dementia: clinical features and risk factors of mortality-a clinical cohort study on 125 patients.** Alzheimers Res. Ther. 2021; 13:77 Vrillon A, Mhanna E, Aveneau C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838684>
4. **COVID-19 quarantine and depression in patients with congenital heart disease.** Am. J. Cardiovasc. Dis. 2021; 11:80-86 Martínez-Quintana E, Santana-Herrera D, Vega-Acedo LDC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815923>
5. **Effects of the COVID-19 pandemic in a psychiatric emergency service: Utilization patterns and patient perceptions.** Am J Emerg Med 2021; Shobassy A, Nordsletten AE, Ali A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836932>
6. **Mood Disorders and Outcomes of COVID-19 Hospitalizations.** Am. J. Psychiatry 2021:appiajp202020060842 Castro VM, Gunning FM, McCoy TH, Perlis RH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33820425>
7. **Adherence to Social Distancing Guidelines Throughout the COVID-19 Pandemic: The Roles of Pseudoscientific Beliefs, Trust, Political Party Affiliation, and Risk Perceptions.** Ann. Behav. Med. 2021; Gratz KL, Richmond JR, Woods SE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830215>
8. **Perceived stress among university students in south-east Serbia during the COVID-19 outbreak.** Ann Gen Psychiatry 2021; 20:25 Kostić J, Žikić O, Đorđević V, Krivokapić Ž. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827625>
9. **When we are worried, what are we thinking? Anxiety, lack of control, and conspiracy beliefs amidst the COVID-19 pandemic.** Appl. Cogn. Psychol. 2021; Šrol J, Ballová Mikušková E, Čavojová V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821088>
10. **The COVID-19 outbreak increases maternal stress during pregnancy, but not the risk for postpartum depression.** Arch Womens Ment Health 2021; Boekhorst M, Muskens L, Hulsbosch LP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830373>
11. **Challenges and opportunities of the COVID-19 pandemic for perinatal mental health care: a mixed-methods study of mental health care staff.** Arch Womens Ment Health 2021; Wilson CA, Dalton-Locke C, Johnson S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33830374>
12. **Association Between Adherence to Healthy Lifestyles and Depressive Symptoms Among Japanese Hospital Workers During the COVID-19 Pandemic.** Asia Pac. J. Public Health 2021:10105395211007604 Fukunaga A, Inoue Y, Yamamoto S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829896>
13. **COVID: Using the DAN Model with Couples to Increase Family Resilience.** Aust N Z J Fam Ther 2021; Mariotti M, Muratori G, Langella A, Scaltriti N.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821087>

14. **Impact of Covid-19 on the mental health needs of asylum seekers in Australia.** *Australas Psychiatry* 2021;10398562211005445Mares S, Jenkins K, Lutton S, Newman Am L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818174>
15. **Short report on research trends during the COVID-19 pandemic and use of telehealth interventions and remote brain research in children with autism spectrum disorder.** *Autism* 2021;13623613211004795Su WC, Srinivasan S, Cleffi C, Bhat A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836625>
16. **Stress and psychological impact of the COVID-19 outbreak on the healthcare staff at the fever clinic of a tertiary general hospital in Beijing: a cross-sectional study.** *BJPsych Open* 2021; 7:e76Hong X, Cao J, Wei J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814026>
17. **Determinants of health care use among homeless individuals: evidence from the Hamburg survey of homeless individuals.** *BMC Health Serv. Res.* 2021; 21:317Hajek A, Bertram F, Heinrich F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827570>
18. **Health anxiety, perceived stress, and coping styles in the shadow of the COVID-19.** *BMC Psychol* 2021; 9:53Garbóczy S, Szemán-Nagy A, Ahmad MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823945>
19. **History for some or lesson for all? A systematic review and meta-analysis on the immediate and long-term mental health impact of the 2002-2003 Severe Acute Respiratory Syndrome (SARS) outbreak.** *BMC Public Health* 2021; 21:670Chau SWH, Wong OWH, Ramakrishnan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827499>
20. **Barriers and coping mechanisms to accessing healthcare during the COVID-19 lockdown: a cross-sectional survey among patients with chronic diseases in rural Rwanda.** *BMC Public Health* 2021; 21:704Nshimiyiryo A, Barnhart DA, Cubaka VK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838676>
21. **Health, psychosocial, and economic impacts of the COVID-19 pandemic on people with chronic conditions in India: a mixed methods study.** *BMC Public Health* 2021; 21:685Singh K, Kondal D, Mohan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832478>
22. **Unwillingness to engage in behaviors that protect against COVID-19: the role of conspiracy beliefs, trust, and endorsement of complementary and alternative medicine.** *BMC Public Health* 2021; 21:684Soveri A, Karlsson LC, Antfolk J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832446>
23. **Impact of COVID-19 pandemic on mental health among general Bangladeshi population: a cross-sectional study.** *BMJ Open* 2021; 11:e045727Das R, Hasan MR, Daria S, Islam MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837107>
24. **Emerging responses implemented to prevent and respond to violence against women and children in WHO European member states during the COVID-19 pandemic: a scoping review of online media reports.** *BMJ Open* 2021; 11:e045872Pearson I, Butler N, Yelgezekova Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827844>
25. **The impact of COVID-19 restrictions in the United Kingdom on the positive behavioural support of people with an intellectual disability.** *Br J Learn Disabil*

- 2021; Murray GC, McKenzie K, Martin R, Murray A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821134>
26. **Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19.** Brain 2021; Hosp JA, Dressing A, Blazhenets G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822001>
 27. **A scoping review of COVID-19 experiences of people living with dementia.** Can. J. Public Health. 2021; Bacsu JR, O'Connell ME, Webster C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825134>
 28. **COVID-19 phobia across the world: Impact of resilience on COVID-19 phobia in different nations.** Couns Psychother Res 2021; Lindinger-Sternart S, Kaur V, Widyaningsih Y, Patel AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821149>
 29. **Mothers' and fathers' parenting attitudes during COVID-19.** Curr. Psychol. 2021:1-10Forbes LK, Lamar MR, Speciale M, Donovan C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821115>
 30. **Individual and community psychological experiences of the COVID-19 pandemic: The state of emergency in Portugal.** Curr. Psychol. 2021:1-11Morgado AM, Cruz J, Peixoto MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821114>
 31. **Latent profile analysis of COVID-19 fear, depression, anxiety, stress, mindfulness, and resilience.** Curr. Psychol. 2021:1-11Yalçın İ, Can N, Mançe Çalışır Ö *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821112>
 32. **Corona-Pandemie: Das ändert sich im sozialen Bereich.** Deutsche Apotheker Zeitung 2020; 160.
 33. **COVID-19 emphasis: Ashamed of being a doctor.** Deutsches Arzteblatt International 2020; 117:A-2353Mascher D.
 34. **For the church community after COVID-19.** Dialog 2021; Cho A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821023>
 35. **The Role of Emotionally Focused Therapy (EFT) in Coronavirus (COVID-19) Prevention.** Disaster Med Public Health Prep 2021:1-3Javidi N, Fatahian Tehran HM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820596>
 36. **Framing a Theological Response to COVID-19 in the Presence of the Religious Other.** Ecum Rev 2020; 72:849-860Pearson C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821024>
 37. **The Covid-19 infection: An opportunity to develop systematic vitamin D supplementation in psychiatry.** Encephale 2021; Fond G, Masson M, Richieri R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820650>
 38. **COVID-19 research priorities for non-pharmaceutical public health and social measures.** Epidemiol Infect 2021; 149:e87Semenza JC, Adlhoch C, Baka A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818348>
 39. **Factors associated with changes in consumption among smokers and alcohol drinkers during the COVID-19 'lockdown' period.** Eur. J. Public Health 2021; Reynolds CME, Purdy J, Rodriguez L, McAvoy H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839763>
 40. **Partner Support and Goal Outcomes during COVID-19: A Mixed Methods Study.** Eur. J. Soc. Psychol. 2021; Vowels LM, Carnelley KB, Francois-Walcott RRR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821056>

41. **Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables.** Eur. Neuropsychopharmacol. 2021; 46:39-48 Miskowiak KW, Johnsen S, Sattler SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823427>
42. **Geographic variability in homicide rates following the COVID-19 pandemic.** Forensic Sci. Med. Pathol. 2021; Byard RW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830452>
43. **Neurologic and Neuroscientific Evidence in Aged COVID-19 Patients.** Front. Aging Neurosci. 2021; 13:648662 Mainali S, Darsie ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833676>
44. **Neuropsychiatric Symptoms of COVID-19 Explained by SARS-CoV-2 Proteins' Mimicry of Human Protein Interactions.** Front. Hum. Neurosci. 2021; 15:656313 Yapici-Eser H, Koroglu YE, Oztup-Cakmak O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833673>
45. **Coping With COVID-19: Mindfulness-Based Approaches for Mitigating Mental Health Crisis.** Front Psychiatry 2021; 12:563417 Antonova E, Schlosser K, Pandey R, Kumari V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833695>
46. **Death and Mourning Process in Frontline Health Care Professionals and Their Families During COVID-19.** Front Psychiatry 2021; 12:624428 Das S, Singh T, Varma R, Arya YK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828492>
47. **Symptoms of Anxiety and Depression in Students With Developmental Disabilities During COVID-19 Lockdown in Poland.** Front Psychiatry 2021; 12:576867 Gacek M, Krzywoszanski L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815160>
48. **Risk Perception, Unhealthy Behavior, and Anxiety Due to Viral Epidemic Among Healthcare Workers: The Relationships With Depressive and Insomnia Symptoms During COVID-19.** Front Psychiatry 2021; 12:615387 Lee J, Lee HJ, Hong Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815164>
49. **Mental Health Status of the General Public, Frontline, and Non-frontline Healthcare Providers in the Early Stage of COVID-19.** Front Psychiatry 2021; 12:553021 Luo D, Liu Q, Chen Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815157>
50. **COVID-19: Mental Health Prevention and Care for Healthcare Professionals.** Front Psychiatry 2021; 12:566740 Rolling J, Mengin AC, Palacio C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833696>
51. **A Fear of COVID-19 and PTSD Symptoms in Pathological Personality: The Mediating Effect of Dissociation and Emotion Dysregulation.** Front Psychiatry 2021; 12:590021 Velotti P, Civilla C, Rogier G, Beomonte Zobel S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833698>
52. **Health Care Workers' Mental Health During the First Weeks of the SARS-CoV-2 Pandemic in Switzerland-A Cross-Sectional Study.** Front Psychiatry 2021; 12:594340 Weilenmann S, Ernst J, Petry H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815162>
53. **The Importance of Well-Being on Resiliency of Filipino Adults During the COVID-19 Enhanced Community Quarantine: A Necessary Condition Analysis.**

- [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.558930) 2021; 12:558930Camitan DSt, Bajin LN.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=33828498](https://pubmed.ncbi.nlm.nih.gov/33828498/)
54. **Message Framing Effects on Individuals' Social Distancing and Helping Behavior During the COVID-19 Pandemic.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.579164) 2021; 12:579164Ceylan M, Hayran C. [http://www.ncbi.nlm.nih.gov/pubmed/?term=33828501](https://pubmed.ncbi.nlm.nih.gov/33828501/)
55. **Academic Stress and Emotional Well-Being in United States College Students Following Onset of the COVID-19 Pandemic.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.628787) 2021; 12:628787Clabaugh A, Duque JF, Fields LJ. [http://www.ncbi.nlm.nih.gov/pubmed/?term=33815214](https://pubmed.ncbi.nlm.nih.gov/33815214/)
56. **Italian Community Psychology in the COVID-19 Pandemic: Shared Feelings and Thoughts in the Storytelling of University Students.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.571257) 2021; 12:571257Di Napoli I, Guidi E, Arcidiacono C *et al.*
[http://www.ncbi.nlm.nih.gov/pubmed/?term=33815188](https://pubmed.ncbi.nlm.nih.gov/33815188/)
57. **Meaning-Centered Coping in the Era of COVID-19: Direct and Moderating Effects on Depression, Anxiety, and Stress.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.648383) 2021; 12:648383Eisenbeck N, Pérez-Escobar JA, Carreno DF.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=33815231](https://pubmed.ncbi.nlm.nih.gov/33815231/)
58. **Exploring the Effect of Collective Cultural Attributes on Covid-19-Related Public Health Outcomes.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.627669) 2021; 12:627669Ermann A, Medeiros M.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=33833717](https://pubmed.ncbi.nlm.nih.gov/33833717/)
59. **Music-Evoked Nostalgia and Wellbeing During the United Kingdom COVID-19 Pandemic: Content, Subjective Effects, and Function.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.647891) 2021; 12:647891Gibbs H, Eggermann H. [http://www.ncbi.nlm.nih.gov/pubmed/?term=33828512](https://pubmed.ncbi.nlm.nih.gov/33828512/)
60. **Positive Psychological Impacts of Cooking During the COVID-19 Lockdown Period: A Qualitative Study.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.635957) 2021; 12:635957Güler O, Haseki M.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=33815223](https://pubmed.ncbi.nlm.nih.gov/33815223/)
61. **Associations Between Fear of COVID-19, Affective Symptoms and Risk Perception Among Community-Dwelling Older Adults During a COVID-19 Lockdown.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.638831) 2021; 12:638831Han MFY, Mahendran R, Yu J.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=33833722](https://pubmed.ncbi.nlm.nih.gov/33833722/)
62. **Pandemic Leadership: Sex Differences and Their Evolutionary-Developmental Origins.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.633862) 2021; 12:633862Luoto S, Varella MAC.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=33815218](https://pubmed.ncbi.nlm.nih.gov/33815218/)
63. **Disgust Sensitivity Among Women During the COVID-19 Outbreak.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.622634) 2021; 12:622634Miłkowska K, Galbarczyk A, Mijas M, Jasienska G.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=33833715](https://pubmed.ncbi.nlm.nih.gov/33833715/)
64. **The Use of Online Training Tools in Competition Cyclists During COVID-19 Confinement in Spain.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.622905) 2021; 12:622905Moreno-Tenas A, León-Zarceño E, Serrano-Rosa MA. [http://www.ncbi.nlm.nih.gov/pubmed/?term=33815207](https://pubmed.ncbi.nlm.nih.gov/33815207/)
65. **"Like Pieces in a Puzzle": Online Sacred Harp Singing During the COVID-19 Pandemic.** [Front. Psychol.](https://doi.org/10.3389/fpsyg.2021.627038) 2021; 12:627038Morgan-Ellis EM.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=33815212](https://pubmed.ncbi.nlm.nih.gov/33815212/)

66. **Mood Disorder in Cancer Patients Undergoing Radiotherapy During the COVID-19 Outbreak.** Front. Psychol. 2021; 12:568839Nardone V, Reginelli A, Vinciguerra C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815186>
67. **Coping Behaviors and Psychological Disturbances in Youth Affected by the COVID-19 Health Crisis.** Front. Psychol. 2021; 12:565657Orgilés M, Morales A, Delvecchio E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828499>
68. **Musical Engagement and Parent-Child Attachment in Families With Young Children During the Covid-19 Pandemic.** Front. Psychol. 2021; 12:641733Steinberg S, Liu T, Lense MD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828508>
69. **Impact of Divergent Thinking Training on Teenagers' Emotion and Self-Efficacy During the COVID-19 Pandemic.** Front. Psychol. 2021; 12:600533Zuo B, Wang Q, Qiao LY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815199>
70. **COVID-19 as an "Infodemic" in Public Health: Critical Role of the Social Media.** Front Public Health 2021; 9:610623Banerjee D, Meena KS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816415>
71. **Psychological Stress Risk Factors, Concerns and Mental Health Support Among Health Care Workers in Vietnam During the Coronavirus Disease 2019 (COVID-19) Outbreak.** Front Public Health 2021; 9:628341Nguyen PTL, Nguyen TBL, Pham AG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816419>
72. **Qualitative Study on Dialogic Literary Gatherings as Co-creation Intervention and Its Impact on Psychological and Social Well-Being in Women During the COVID-19 Lockdown.** Front Public Health 2021; 9:602964Ruiz-Eugenio L, Toledo Del Cerro A, Gómez-Cuevas S, Villarejo-Carballido B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816414>
73. **Robotic Telemedicine for Mental Health: A Multimodal Approach to Improve Human-Robot Engagement.** Front Robot AI 2021; 8:618866Lima MR, Wairagkar M, Natarajan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816568>
74. **Life in lockdown: Social isolation, loneliness and quality of life in the elderly during the COVID-19 pandemic: A scoping review.** Geriatr. Nurs. 2021; Sayin Kasar K, Karaman E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824008>
75. **Association of COVID-19 Pandemic and Rate of Cognitive Decline in Patients with Dementia and Mild Cognitive Impairment: A Cross-sectional Study.** Gerontol Geriatr Med 2021; 7:23337214211005223Ismail, II, Kamel WA, Al-Hashel JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816709>
76. **Can psychological flexibility and prosociality mitigate illness perceptions toward COVID-19 on mental health? A cross-sectional study among Hong Kong adults.** Global Health 2021; 17:43Chong YY, Chien WT, Cheng HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832501>
77. **Impact of the COVID-19 pandemic on psychological well-being of students in an Italian university: a web-based cross-sectional survey.** Global Health 2021; 17:39Villani L, Pastorino R, Molinari E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823897>
78. **Study problems and depressive symptoms in adolescents during the COVID-19 outbreak: poor parent-child relationship as a vulnerability.** Global Health

2021; 17:40Wang J, Wang H, Lin H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823875>

79. **Prevalence of psychiatric diagnosis and related psychopathological symptoms among patients with COVID-19 during the second wave of the pandemic.** Global Health 2021; 17:44Zhang Z, Feng Y, Song R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832489>
80. **Antiracist Praxis in Public Health: A Call for Ethical Reflections.** Hastings Cent Rep 2021; 51:6-9Fletcher FE, Jiang W, Best AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33840102>
81. **A scoping review of international policy responses to mental health recovery during the COVID-19 pandemic.** Health Res. Policy Syst. 2021; 19:58McCartan C, Adell T, Cameron J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823855>
82. **Responding to pandemics and other disease outbreaks in homeless populations: A review of the literature and content analysis.** Health Soc Care Community 2021; Babando J, Quesnel DA, Woodmass K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825271>
83. **Fear and anxiety about COVID-19 among local and overseas Chinese university students.** Health Soc Care Community 2021; Feng S, Zhang Q, Ho SMY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825220>
84. **Specifics of chronic fatigue syndrome coping strategies identified in a French flash survey during the COVID-19 containment.** Health Soc Care Community 2021; Moncorps F, Jouet E, Bayen S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825299>
85. **The exacerbation of violence against women as a form of discrimination in the period of the COVID-19 pandemic.** Heliyon 2021; 7:e06491Valencia Londoño PA, Nateras González ME, Bruno Solera C, Paz PS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817371>
86. **Aiding decision makers to reopening of places of worship.** Hum Factors Ergon Manuf 2021; Rothrock L, Abraham A, Graf A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821128>
87. **Burnout and depression among psychiatry residents during COVID-19 pandemic.** Hum Resour Health 2021; 19:46Alkhamees AA, Assiri H, Alharbi HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823857>
88. **Adapting and adopting highly specialized pediatric eating disorder treatment to virtual care: a protocol for an implementation study in the COVID-19 context.** Implement Sci Commun 2021; 2:38Couturier J, Pellegrini D, Miller C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832543>
89. **Quality of life of nursing internship students in Saudi Arabia during the COVID-19 pandemic: A cross-sectional study.** Int J Afr Nurs Sci 2021; 14:100301Grande RAN, Butcon VER, Indonto MCL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824852>
90. **Quality of life of nursing internship students during the COVID-19 pandemic: A cross- sectional study.** Int J Afr Nurs Sci 2021; 14:100301Rizal Angelo Grande R, Edward RBV, Charito Laarni Indonto M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824852>

91. **The Role of Risk Perceptions and Affective Consequences in COVID-19 Protective Behaviors.** Int. J. Behav. Med. 2021:1-7Alegria KE, Fleszar-Pavlović SE, Ngo DD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834368>
92. **Pathways between COVID-19 public health responses and increasing overdose risks: A rapid review and conceptual framework.** Int. J. Drug Policy 2021:103236Nguyen T, Buxton JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838990>
93. **How prepared is Mozambique to treat COVID-19 patients? A new approach for estimating oxygen service availability, oxygen treatment capacity, and population access to oxygen-ready treatment facilities.** Int J Equity Health 2021; 20:90Denhard L, Kaviany P, Chicumbe S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823863>
94. **Healthcare workers during the COVID-19 pandemic: Experiences of doctors and nurses in Bangladesh.** Int. J. Health Plann. Manage. 2021; Hussain M, Begum T, Batul SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819348>
95. **Decentralizing COVID-19 care-Moving towards a COVID-19-capable healthcare system (CCHS).** Int. J. Health Plann. Manage. 2021; Keri VC, R LB, Jorwal P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826175>
96. **Social Cohesion and Community Resilience During COVID-19 and Pandemics: A Rapid Scoping Review to Inform the United Nations Research Roadmap for COVID-19 Recovery.** Int J Health Serv 2021:20731421997092Jewett RL, Mah SM, Howell N, Larsen MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827308>
97. **Yoga and music intervention to reduce depression, anxiety, and stress during COVID-19 outbreak on healthcare workers.** Int J Soc Psychiatry 2021:207640211006742Vajpeyee M, Tiwari S, Jain K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818166>
98. **A longitudinal evaluation of the impact of the COVID-19 pandemic on patients with pre-existing anxiety disorders.** Ir. J. Psychol. Med. 2021:1-21Hennigan K, McGovern M, Plunkett R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818322>
99. **No psychological vaccination: Vaccine hesitancy is associated with negative psychiatric outcomes among Israelis who received COVID-19 vaccination.** J. Affect. Disord. 2021; 287:352-353Palgi Y, Bergman YS, Ben-David B, Bodner E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819733>
100. **Prevalence and risk factors for anxiety symptoms during the outbreak of COVID-19: A large survey among 373216 junior and senior high school students in China.** J. Affect. Disord. 2021; 288:17-22Xu Q, Mao Z, Wei D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839554>
101. **Yoga-Based Breathing Techniques for Health Care Workers During COVID-19 Pandemic: Interests, Feasibility, and Acceptance.** J. Altern. Complement. Med. 2021; Narayanan S, Tennison J, Cohen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835830>
102. **Impact of Social Isolation on People with Dementia and Their Family Caregivers.** J. Alzheimers Dis. 2021; Azevedo L, Calandri IL, Slachevsky A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814446>

103. **Impact of Social Isolation on People with Dementia and Their Family Caregivers.** J. Alzheimers Dis. 2021; Dos Santos Azevedo LV, Calandri IL, Slachevsky A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814446>
104. **Dementia-Friendly "Design": Impact on COVID-19 Death Rates in Long-Term Care Facilities Around the World.** J. Alzheimers Dis. 2021; Olson NL, Albeni BC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814449>
105. **Disruptions and General Distress for Essential and Nonessential Employees During the COVID-19 Pandemic.** J. Bus. Psychol. 2021:1-16 van Zoonen W, Ter Hoeven CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824548>
106. **Postpartum during COVID-19 pandemic: Portuguese mothers' mental health, mindful parenting, and mother-infant bonding.** J. Clin. Psychol. 2021; Fernandes DV, Canavarro MC, Moreira H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822369>
107. **Domestic violence during COVID-19 pandemic: The case for Indian women.** J. Community Appl. Soc. Psychol. 2021; Maji S, Bansod S, Singh T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821118>
108. **Compassionate goals, prosocial emotions, and prosocial behaviours during the COVID-19 pandemic.** J. Community Appl. Soc. Psychol. 2021; Yue Z, Yang JZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821120>
109. **Facilitator lessons from online psychoeducational group for relational well-being in India during COVID-19 pandemic.** J. Fam. Ther. 2021; 43:314-328 Joshi A, Joshi A, Chatterjee I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821065>
110. **The psychological effects of the COVID-19 pandemic: an introduction to the special issue.** J. Gen. Psychol. 2021:1-7 Miller ED. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825617>
111. **Well-Being Reduces COVID-19 Anxiety: A Three-Wave Longitudinal Study in China.** J Happiness Stud 2021:1-17 Wang Z, Luo S, Xu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814971>
112. **Anxiety impact during COVID-19: a systematic review.** J Infect Dev Ctries 2021; 15:320-325 Batista P, Duque V, Luzio-Vaz A, Pereira A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839704>
113. **Coronavirus Pandemic: a major public health crisis for the developed and developing world.** J Infect Dev Ctries 2021; 15:366-369 Ullah R, Suleman Rana M, Qadir M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839711>
114. **Psychophysical evaluations are important, usefulness and usability approaches to study the smell disorder related to COVID-19.** J Intern Med 2021; Saussez S, Hans S, Chiesa-Estomba CM, Lechien JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817882>
115. **Anxiety Levels and Solution-Focused Thinking Skills of Nurses and Midwives Working in Primary Care during the COVID-19 Pandemic: A Descriptive Correlational Study.** J. Nurs. Manag. 2021; Selçuk Tosun A, Akgül Gündoğdu N, Taş F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838066>
116. **Determining Frailty in People With Intellectual Disabilities in the COVID-19 Pandemic.** J Policy Pract Intellect Disabil 2021; Festen DAM, Schoufour JD, Hilgenkamp TIM, Oppewal A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821163>

117. **Community mitigation of COVID-19: Health communications and varied community reactions.** J Prev Interv Community 2021;1-7 Meleo-Erwin ZC, Basch CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823744>
118. **Intolerance of uncertainty and mental health during the COVID-19 pandemic: The role of anger as a moderator.** J. Psychiatr. Res. 2021; 138:50-52 Hamama-Raz Y, Goodwin R, Leshem E, Ben-Ezra M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819877>
119. **Actual versus perceived infection rates of COVID-19: Impact on distress, behavior and disability.** J. Psychiatr. Res. 2021; 137:525-533 Schmidt NB, Martin AD, Allan NP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831818>
120. **Subjective wellbeing in parents during the COVID-19 pandemic in Australia.** J. Psychosom. Res. 2021;110482 Westrupp EM, Stokes MA, Fuller-Tyszkiewicz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820645>
121. **From grieving to healing: moving forward a year after COVID-19.** J Public Health (Oxf) 2021; Corpuz JCG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823030>
122. **COVID-19 and suicide: when crises collide.** J Public Health (Oxf) 2021; Corpuz JCG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825900>
123. **Incidence and Severity of Depression Among Recovered African Americans with COVID-19-Associated Respiratory Failure.** J Racial Ethn Health Disparities 2021; Olanipekun T, Abe T, Effoe V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825114>
124. **The effect of social fear on the establishment of fever standards in rural hospitals during the coronavirus disease (COVID-19) pandemic.** J Rural Med 2021; 16:126-127 Ohta R, Ikeda H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833841>
125. **Change in Health-Related Socioeconomic Risk Factors and Mental Health During the Early Phase of the COVID-19 Pandemic: A National Survey of U.S. Women.** J Womens Health (Larchmt) 2021; Lindau ST, Makelarski JA, Boyd K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818123>
126. **Factors Associated with Mental Health Outcomes: Results from a Tertiary Referral Hospital in Lebanon during the COVID-19 Pandemic.** Libyan J. Med. 2021; 16:1901438 Msheik El Khoury F, Tali H, Khatib MFE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820499>
127. **Nongovernmental organizations and social aspects of COVID-19 pandemic: A successful experience in health policy.** Med. J. Islam. Repub. Iran 2020; 34:170 Alizadeh M, Abbasi M, Bashirvand N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816369>
128. **Consequences of the COVID-19 pandemic for people with schizophrenia, dementia and substance use disorders.** Nervenarzt 2021; Adorjan K, Haussmann R, Rauen K, Pogarell O.
129. **[Coronavirus Pandemic - #STAYHOME: How Are You Holding Up? Questions And Tips For 11-18-Year-Olds To Make It Better].** Neuropsychopharmacol. Hung. 2021; 23:208-214 Szentiványi D, Horvath LO, Kjeldsen A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835042>

130. **Prevalence of corona-associated anxiety and mental health disorder among dentists during the COVID-19 pandemic.** Neuropsychopharmacol Rep 2021; Salehiniya H, Abbaszadeh H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825340>
131. **The relationship between resilience and intent to stay among Chinese nurses to support Wuhan in managing COVID-19: The serial mediation effect of post-traumatic growth and perceived professional benefits.** Nurs Open 2021; Liu X, Ju X, Liu X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829673>
132. **Psychological Consequences of the Delay in the Silent Mentor Programme During the COVID-19 Pandemic: Perspectives From Family Members of Silent Mentors.** Omega (Westport) 2021:302228211000952 Wong LP, Tan SL, Alias H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818157>
133. **Dying in times of the coronavirus: An online survey among healthcare professionals about end-of-life care for patients dying with and without COVID-19 (the CO-LIVE study).** Palliat. Med. 2021:2692163211003778 Onwuteaka-Philipsen BD, Pasman HRW, Korfage IJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825567>
134. **People with Parkinson's report increased impulse control behaviours during the COVID-19 UK lockdown.** Parkinsonism Relat. Disord. 2021; 86:38-39 Yule E, Pickering JS, McBride J, Poliakoff E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827015>
135. **How did Tunisian university students cope with fear of COVID-19? A comparison across schizotypy features.** Pers. Individ. Dif. 2021; 178:110872 Fekih-Romdhane F, Dissem N, Cheour M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814659>
136. **The impact of confinement on older Jordanian adults' mental distress during the COVID-19 pandemic: A web-based cross-sectional study.** Perspect. Psychiatr. Care 2021; Abu Kamel AK, Alnazly EK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834502>
137. **Telehealth in Rehabilitation Psychology and Neuropsychology.** Phys. Med. Rehabil. Clin. N. Am. 2021; 32:405-418 Wells MJ, Dukarm P, Mills A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814065>
138. **"Everybody Needs to Do Their Part, So We Can Get This Under Control." Reactions to the Norwegian Government Meta-Narratives on COVID-19 Measures.** Polit. Psychol. 2021; Moss SM, Sandbakken EM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821063>
139. **Harnessing Shared Identities to Mobilize Resilient Responses to the COVID-19 Pandemic.** Polit. Psychol. 2021; Vignoles VL, Jaser Z, Taylor F, Ntontis E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821062>
140. **Social distancing attitudes, national context, and health outcomes during the COVID-19 pandemic: Findings from a global survey.** Prev. Med. 2021:106544 Kim HH, Ryu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819518>
141. **Measuring voluntary and policy-induced social distancing behavior during the COVID-19 pandemic.** Proc Natl Acad Sci U S A 2021; 118 Yan Y, Malik AA, Bayham J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820846>
142. **Mental Health and Quality & Safety of Care in Czech Residential Institutions during the COVID-19 Pandemic: A Mixed-Methods Study.** Psychiatr. Q. 2021:1-

- 19Guerrero Z, Aliev AA, Kondrátová L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821407>
143. **Impact and consequences of COVID-19 pandemic on complicated grief and persistent complex bereavement disorder.** Psychiatry Res 2021; 300:113916Diolaiuti F, Marazziti D, Beatino MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836468>
144. **A longitudinal assessment of depression and anxiety in the Republic of Ireland before and during the COVID-19 pandemic.** Psychiatry Res 2021; 300:113905Hyland P, Shevlin M, Murphy J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827013>
145. **Depression and anxiety in pregnancy during COVID-19: A rapid review and meta-analysis.** Psychiatry Res 2021; 300:113912Tomfohr-Madsen LM, Racine N, Giesbrecht GF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836471>
146. **Autistic traits and negative emotions in the general population during COVID-19: Mediating roles of the behavioural immune system and COVID-19 risk perception.** Psychiatry Res 2021; 300:113918Zhao X, Shi W, Li X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831811>
147. **Online-Based Survey on College Students' Anxiety During COVID-19 Outbreak.** Psychol. Res. Behav. Manag. 2021; 14:385-392Han W, Xu L, Niu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824607>
148. **How Well Do They Manage a Crisis? The Government's Effectiveness during the Covid-19 Pandemic.** Public Adm. Rev. 2021; Mizrahi S, Vigoda-Gadot E, Cohen N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821042>
149. **The European Union, economies and public health: not one without the other.** Public Health 2021; 194:1-3Vervoort D, van Daalen KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836317>
150. **Healthcare resource allocation in the COVID-19 pandemic: Ethical considerations from the perspective of distributive justice within public health.** Public Health Pract (Oxf) 2021; 2:100111Yuk-Chiu Yip J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817679>
151. **Reduction in Hospitalizations for Respiratory Diseases during the First COVID-19 Wave in Greece.** Respiration 2021; 1-6Kyriakopoulos C, Gogali A, Exarchos K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827103>
152. **Analysis, modeling and optimal control of COVID-19 outbreak with three forms of infection in Democratic Republic of the Congo.** Results Phys 2021; 104096Ndondo AM, Kasereka SK, Bisuta SF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816092>
153. **A Tale of Three Countries: What is the Relationship Between COVID-19, Lockdown and Happiness?** S Afr J Econ 2021; 89:25-43Greyling T, Rossouw S, Adhikari T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821044>
154. **Mental health and well-being of university staff during the coronavirus disease 2019 levels 4 and 5 lockdown in an Eastern Cape university, South Africa.** S. Afr. J. Psychiatr. 2021; 27:1589van Niekerk RL, van Gent MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824757>
155. **An online survey and review about the awareness, coping style, and exercise behavior during the "COVID-19 pandemic situation" by implementing the**

- cloud-based medical treatment technology system in China among the public.** *Sci. Prog.* 2021; 104:368504211000889Ma C, Ma L, Helwan A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33827338>
156. **Trauma Exposure and the PTSD symptoms of College Teachers During the Peak of the COVID-19 Outbreak.** *Stress Health* 2021; Fan C, Fu P, Li X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33837651>
157. **Trends in mental health symptoms, service use, and unmet need for services among U.S. adults through the first 9 months of the COVID-19 pandemic.** *Transl. Behav. Med.* 2021; Coley RL, Baum CF.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33823047>
158. **Future directions of the National Institutes of Health Science of Behavior Change Program.** *Transl. Behav. Med.* 2021; Keller C, Ferrer RA, King RB, Collier E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837790>
159. **Supporting Parents & Kids Through Lockdown Experiences (SPARKLE): A digital parenting support app implemented in an ongoing general population cohort study during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2021; 22:267Kostyrka-Allchorne K, Creswell C, Byford S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838678>
160. **[Mental health assessment of medical workers during the COVID-19 pandemic in Russia: results of an online survey].** *Zh. Nevrol. Psikiatr. Im. S. S. Korsakova* 2021; 121:104-109Bachilo EV, Novikov DE, Efremov AA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33834726>

Meta-analyses - systematic reviews (14 articles)

1. **A meta-analysis: Proton pump inhibitors current use and the risk of Coronavirus Infectious Disease 2019 development and its related mortality.** *Arch Med Res* 2021; Toubasi AA, AbuAnzeh RB, Khraisat BR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814207>
2. **History for some or lesson for all? A systematic review and meta-analysis on the immediate and long-term mental health impact of the 2002-2003 Severe Acute Respiratory Syndrome (SARS) outbreak.** *BMC Public Health* 2021; 21:670Chau SWH, Wong OWH, Ramakrishnan R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33827499>
3. **The Main Receptors Involved with COVID-19: a Systematic Review and Meta-analysis.** *Curr Med Chem* 2021; Câmara AB, Brandão IA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33820514>
4. **Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.** *Diabetes Metab Syndr* 2021; 15:777-782Rakhmat, II, Kusmala YY, Handayani DR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838614>
5. **Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis.** *Eur. J. Neurol.* 2021; Palaiodimou L, Stefanou MI, Katsanos AH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33837630>

6. **Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.** Expert Rev. Clin. Immunol. 2021;1-13Rezaei S, Fatemi B, Karimi Majd Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823733>
7. **Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis.** F1000Res 2021; 10:40Mutiawati E, Fahriani M, Mamada SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824716>
8. **Impact of the COVID-19 Pandemic on Parent, Child, and Family Functioning.** Fam. Process 2021; Feinberg ME, J AM, Lee JK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830510>
9. **Characteristics of Viral Shedding Time in SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis.** Front Public Health 2021; 9:652842Yan D, Zhang X, Chen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816427>
10. **Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression.** J Diabetes Metab Disord 2021;1-8Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816358>
11. **Estimation of Incubation Period and Serial Interval for SARS-CoV-2 in Jiangxi, China, and an Updated Meta-Analysis.** J Infect Dev Ctries 2021; 15:326-332Zhang T, Ding S, Zeng Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839705>
12. **Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression.** Nutr. Metab. Cardiovasc. Dis. 2021; Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838992>
13. **The incubation period during the pandemic of COVID-19: a systematic review and meta-analysis.** Syst Rev 2021; 10:101Dhouib W, Maatoug J, Ayouni I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832511>
14. **What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis.** Transfus. Clin. Biol. 2021; Zeng J, Yin S, Du X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839301>

Mortality (28 articles)

1. **Assessment of COVID-19 deaths from cardiological perspective.** Acta Cardiol. 2021;1-8Omar T, Karakayalı M, Perincek G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823754>
2. **COVID-19 in adults with dementia: clinical features and risk factors of mortality-a clinical cohort study on 125 patients.** Alzheimers Res. Ther. 2021; 13:77Vrillon A, Mhanna E, Aveneau C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838684>
3. **The role of the BUN/albumin ratio in predicting mortality in COVID-19 patients in the emergency department.** Am J Emerg Med 2021; 48:33-37Küçükceran K, Ayrancı MK, Girişgin AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838471>

4. **Quantifying the association between ethnicity and COVID-19 mortality: a national cohort study protocol.** BMJ Open 2021; 11:e045286Dambha-Miller H, Tan PS, Saatci D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827839>
5. **Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USA.** BMJ Open 2021; 11:e047121Incerti D, Rizzo S, Li X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827848>
6. **Distribution of COVID-19 cases and deaths in Europe during the first 12 peak weeks of outbreak.** Cent. Eur. J. Public Health 2021; 29:9-13Zach H, Hanová M, Letkovičová M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831280>
7. **COVID-19 and tumor treatment: Mortality risk of cancer patients already increases after short treatment delays.** Deutsches Arzteblatt International 2020; 117:A2348Meyer R.
8. **Impact of the vitamin D deficiency on COVID-19 infection and morality in Asian countries.** Diabetes Metab Syndr 2021; 15:757-764Jayawardena R, Jeyakumar DT, Francis TV, Misra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823331>
9. **Impact of the vitamin D deficiency on COVID-19 infection and mortality in Asian countries.** Diabetes Metab Syndr 2021; 15:757-764Jayawardena R, Jeyakumar DT, Francis TV, Misra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823331>
10. **Mortality in mechanically ventilated patients with COVID-19: a systematic review.** Expert Rev. Med. Devices 2021; Tsikala Vafea M, Zhang R, Kalligeros M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836621>
11. **Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis.** E1000Res 2021; 10:40Mutiawati E, Fahriani M, Mamada SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824716>
12. **Death and Mourning Process in Frontline Health Care Professionals and Their Families During COVID-19.** Front Psychiatry 2021; 12:624428Das S, Singh T, Varma R, Arya YK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828492>
13. **High-Minority Nursing Homes Disproportionately Affected by COVID-19 Deaths.** Front Public Health 2021; 9:606364Weech-Maldonado R, Lord J, Davlyatov G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829006>
14. **COVID-19 shifts mortality salience, activities, and values in the United States: Big data analysis of online adaptation.** Hum Behav Emerg Technol 2021; 3:107-126Evers NFG, Greenfield PM, Evers GW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821242>
15. **Monitoring of Three-Phase Variations in the Mortality of Covid-19 Pandemic Using Control Charts: Where Does Pakistan Stand?** Int. J. Qual. Health Care 2021; Mahmood Y, Ishtiaq S, Khoo MBC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822932>
16. **Fatal Underfunding? Explaining COVID-19 Mortality in Spanish Nursing Homes.** J. Aging Health 2021:8982643211003794Costa-Font J, Jiménez Martin S, Viola A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818164>
17. **Broad SARS-CoV-2 cell tropism and immunopathology in lung tissues from fatal COVID-19.** J Infect Dis 2021; Ramos da Silva S, Ju E, Meng W *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33837392>

18. **Interaction Effects between COVID-19 Outbreak and Community Income Levels on Excess Mortality among Patients Visiting Emergency Departments.** J Korean Med Sci 2021; 36:e100Jung E, Ro YS, Ryu HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821595>
19. **Red Cell Distribution Width is Associated with Mortality in Non-Anemic Patients with COVID-19.** J Med Virol 2021; Rapp JL, Tremblay D, Alpert N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837966>
20. **Characterisation of cardiac pathology in 23 autopsies of lethal COVID-19.** J Pathol Clin Res 2021; Haslbauer JD, Tzankov A, Mertz KD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837673>
21. **Analysis of Risk Factors in COVID-19 Adult Mortality in Russia.** J. Prim. Care Community Health 2021; 12:21501327211008050Kirillov Y, Timofeev S, Avdalyan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829916>
22. **Sex Differences in Coronavirus Disease 2019 (COVID-19) Hospitalization and Mortality.** J Womens Health (Larchmt) 2021; Gomez JMD, Du-Fay-de-Lavallaz JM, Fugar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826864>
23. **Eliciting Beliefs about COVID-19 Prevalence and Mortality: Epidemiological Models Compared with The Street.** Methods 2021; Harrison GW, Hofmeyr A, Kincaid H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838269>
24. **Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease.** Open Heart 2021; 8Tessitore E, Carballo D, Poncet A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833064>
25. **Dying in times of the coronavirus: An online survey among healthcare professionals about end-of-life care for patients dying with and without COVID-19 (the CO-LIVE study).** Palliat. Med. 2021:2692163211003778Onwuteaka-Philipsen BD, Pasman HRW, Korfage IJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825567>
26. **[Telemedicine, ethics, and law in times of COVID-19. A look towards the future].** Rev Clin Esp 2021; Gil Membrado C, Barrios V, Cosín-Sales J, Gámez JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814552>
27. **Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection.** Rev. Esp. Quimioter. 2021; Moreno-García E, Rico E, Albiach L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829722>
28. **[Corrections to daily excess mortality estimates in Spain during the COVID-19 pandemic.].** Rev. Esp. Salud Publica 2021; 95Equiza-Goñi J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824266>

Online – IT – Apps (65 articles)

1. **Teleneurology in Parkinson's disease: A step-by-step video guide.** Acta Neurol. Scand. 2021; Ferreira D, Azevedo E, Araújo R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835482>
2. **Short report on research trends during the COVID-19 pandemic and use of telehealth interventions and remote brain research in children with autism**

- spectrum disorder.** *Autism* 2021;13623613211004795Su WC, Srinivasan S, Cleffi C, Bhat A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836625>
3. **Framework for Real-Time Detection and Identification of possible patients of COVID-19 at public places.** *Biomed. Signal Process. Control* 2021; 68:102605Peddinti B, Shaikh A, K RB, K CN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824682>
 4. **The experience of Australian general practice patients at high risk of poor health outcomes with telehealth during the COVID-19 pandemic: a qualitative study.** *BMC Fam. Pract.* 2021; 22:69Javanparast S, Roeger L, Kwok Y, Reed RL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832422>
 5. **Physiotherapists' perceptions of and willingness to use telerehabilitation in Kuwait during the COVID-19 pandemic.** *BMC Med. Inform. Decis. Mak.* 2021; 21:122Albahrouh SI, Buabbas AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832473>
 6. **Bioinformatics and machine learning approach identifies potential drug targets and pathways in COVID-19.** *Brief. Bioinform.* 2021; Auwul MR, Rahman MR, Gov E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839760>
 7. **Content Analysis and Characterization of Medical Tweets During the Early Covid-19 Pandemic.** *Cureus* 2021; 13:e13594Prager R, Pratte MT, Unni RR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815994>
 8. **Review of the role of big data and digital technologies in controlling COVID-19 in Asia: Public health interest vs. privacy.** *Digit Health* 2021; 7:20552076211002953Nageshwaran G, Harris RC, Guerche-Seblain CE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815815>
 9. **Designing a multicenter registry of COVID-19 and other respiratory infections in Fars, Iran.** *Disaster Med Public Health Prep* 2021;1-12Emami A, Akbari A, Javanmardi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820582>
 10. **Teaching an experiential field course via online participatory science projects: A COVID-19 case study of a UC California Naturalist course.** *Ecol. Evol.* 2021; Gerhart LM, Jadallah CC, Angulo SS, Ira GC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821180>
 11. **Online learning satisfaction in higher education during the COVID-19 pandemic: A regional comparison between Eastern and Western Chinese universities.** *Educ Inf Technol (Dordr)* 2021;1-23Jiang H, Islam A, Gu X, Spector JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814959>
 12. **Emergency remote teaching during the COVID-19 pandemic: Parents experiences and perspectives.** *Educ Inf Technol (Dordr)* 2021;1-20Misirli O, Ergulec F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814956>
 13. **The COVID-19 pandemic: prediction study based on machine learning models.** *Environ. Sci. Pollut. Res. Int.* 2021; Malki Z, Atlam ES, Ewis A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33840016>
 14. **Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network.** *ESMO Open* 2021; 6:100104Morgan G, Tagliamento M, Lambertini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838532>

15. **Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.** Eur J Hosp Pharm 2021; Skalafouris C, Samer C, Stirnemann J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33832918>
16. **The European TeleCheck-AF project on remote app-based management of atrial fibrillation during the COVID-19 pandemic: centre and patient experiences.** Europace 2021; Gawalko M, Duncker D, Manninger M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33822029>
17. **Predicting the pandemic: sentiment evaluation and predictive analysis from large-scale tweets on Covid-19 by deep convolutional neural network.** Evol Intell 2021;1-22Das S, Kolya AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815622>
18. **Perception on Online Teaching and Learning Among Health Sciences Students in Higher Education Institutions during the COVID-19 Lockdown - Ways to Improve Teaching and Learning in Saudi Colleges and Universities.** F1000Res 2021; 10:177Aziz Ansari K, Farooqi F, Qadir Khan S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824717>
19. **Online Virtual Supervised Visitation During the COVID-19 Pandemic: One State's Experience.** Fam Court Rev 2021; 59:131-143Oehme K, O'Rourke KS, Bradley L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821152>
20. **Telehealth: from the abstract to necessity to competency.** FASEB Bioadv 2021; Adams JE, Ecker DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821234>
21. **Modification of teaching during the COVID-19 pandemic at the Department of Medical Education of Jagiellonian University Medical College.** Folia Med. Cracov. 2020; 60:113-121Skrzypek A, Perera I, Szeliga M, Cebula G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821856>
22. **The Impact of Telehealth on Clinical Education in Adolescent Medicine During the COVID-19 Pandemic: Positive Preliminary Findings.** Front Pediatr 2021; 9:642279Pham DQ, Golub SA, Breuner CC, Evans YN.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816404>
23. **The Use of Online Training Tools in Competition Cyclists During COVID-19 Confinement in Spain.** Front. Psychol. 2021; 12:622905Moreno-Tenas A, León-Zarceño E, Serrano-Rosa MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815207>
24. **COVID-19 as an "Infodemic" in Public Health: Critical Role of the Social Media.** Front Public Health 2021; 9:610623Banerjee D, Meena KS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816415>
25. **Benefits of Mobile Contact Tracing on COVID-19: Tracing Capacity Perspectives.** Front Public Health 2021; 9:586615Lee U, Kim A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816413>
26. **Robotic Telemedicine for Mental Health: A Multimodal Approach to Improve Human-Robot Engagement.** Front Robot AI 2021; 8:618866Lima MR, Wairagkar M, Natarajan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816568>
27. **COVID-19 shifts mortality salience, activities, and values in the United States: Big data analysis of online adaptation.** Hum Behav Emerg Technol 2021; 3:107-

126Evers NFG, Greenfield PM, Evers GW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821242>

28. **Revisiting sustainable development Goal 4 in the context of COVID-19 Pandemic: A case study of online teaching in Algerian higher education institutions.** Hum Behav Emerg Technol 2021; 3:160-168Hadjeris F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821243>
29. **COVID-19 and technology use by teenagers: A case study.** Hum Behav Emerg Technol 2021; 3:185-193Yan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821244>
30. **Pharmacists' Experience, Competence, and Perception of Telepharmacy Technology in Response to COVID-19.** Int J Clin Pract 2021:e14209Muflih SM, Al-Azzam S, Abuhammad S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819372>
31. **Classification of the social distance during the COVID-19 pandemic from electricity consumption using artificial intelligence.** Int J Energy Res 2021; Sausen A, de Campos M, Sausen PS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821081>
32. **Future IoT tools for COVID-19 contact tracing and prediction: A review of the state-of-the-science.** Int J Imaging Syst Technol 2021; Jahmunah V, Sudarshan VK, Oh SL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821093>
33. **Telemedicine usage via WeChat for Children with Congenital Heart Disease Preoperatively During COVID-19 Pandemic: A Retrospective Analysis.** Int. J. Qual. Health Care 2021; Zhang QL, Xie WP, Lei YQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835158>
34. **Shelter in Place, Connect Online: Trending TikTok Content During the Early Days of the U.S. COVID-19 Pandemic.** J. Adolesc. Health 2021; Unni Z, Weinstein E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824071>
35. **Bridging the digital divide: The use of text message enabled video in the public safety-net setting.** J Am Acad Dermatol 2021; Cline A, Kim C, Berk-Krauss J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823199>
36. **Appointment attendance and patient perception of drive-up INR testing in a rural anticoagulation clinic during the COVID-19 pandemic.** J Am Coll Clin Pharm 2021; Zobeck B, Carson E, MacDowell M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821238>
37. **Global orthopaedic trauma surgeons highlight telenomics during the COVID-19 era: A case for advancing telemedicine in orthopaedics.** J Clin Orthop Trauma 2021; 17:182-185Cole PA, Jr., Lezak BA, Schroder LK, Cole PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814860>
38. **Investigating the mediating role of online learning motivation in the COVID-19 pandemic situation in Bangladesh.** J Comput Assist Learn 2021; Rahman MHA, Uddin MS, Dey A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821076>
39. **The impact of risk and protective factors on online teaching experience in high school Italian teachers during the COVID-19 pandemic.** J Comput Assist Learn 2021; Truzoli R, Pirola V, Conte S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821075>

40. **'Living in a Zoom world': Survey mapping how COVID-19 is changing family therapy practice in the UK.** J. Fam. Ther. 2021; 43:272-294Mc Kenny R, Galloghly E, Porter CM, Burbach FR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821064>
41. **Experiences in Electronic Consultation (eConsult) Service in Gynecology from a Quaternary Academic Medical Center.** J Med Syst 2021; 45:58Corbetta-Rastelli CM, Morgan TK, Homaifar N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825075>
42. **Public perceptions and disparities in access to telehealth orthopaedic services in the COVID-19 era.** J. Natl. Med. Assoc. 2021; Puzzitiello RN, Moverman MA, Pagani NR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814179>
43. **United States internet searches for "infertility" following COVID-19 vaccine misinformation.** J Osteopath Med 2021; Sajjadi NB, Nowlin W, Nowlin R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838086>
44. **Faster than warp speed: early attention to COVID-19 by anti-vaccine groups on Facebook.** J Public Health (Oxf) 2021; Kalichman SC, Eaton LA, Earnshaw VA, Brousseau N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837428>
45. **At your 'online' service! A continuous service-learning program for college students during the COVID-19 pandemic.** J Public Health (Oxf) 2021; Vicente NE, Moredo PJA, Cordero DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823020>
46. **Epidemic zone of COVID-19 from social media using hypergraph with weighting factor (HWF).** J Supercomput 2021:1-18Pradeepa S, Manjula KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814722>
47. **Digital social entrepreneurship: the N-Helix response to stakeholders' COVID-19 needs.** J Technol Transf 2021:1-24Ibáñez MJ, Guerrero M, Yáñez-Valdés C, Barros-Celume S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814697>
48. **Care of inflammatory bowel disease patients during coronavirus disease-19 pandemic using digital health-care technology.** JGH Open 2021; Ghoshal UC, Sahu S, Biswas SN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821221>
49. **Network bioinformatics analysis provides insight into drug repurposing for COVID-19.** Med Drug Discov 2021:100090Li X, Yu J, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817623>
50. **Medico-legal implications of audiovisual recordings of telehealth encounters.** Med. J. Aust. 2021; Farmer CC, Pang SC, Kevat D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33840094>
51. **COVID-19 Real-time Information System for Preparedness and Epidemic Response (CRISPER).** Med. J. Aust. 2021; Field E, Dyda A, Lau CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837527>
52. **Role of nanotechnology behind the success of mRNA vaccines for COVID-19.** Nano Today 2021:101142Khurana A, Allawadhi P, Khurana I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815564>
53. **Enhancing COVID-19 tracking apps with human activity recognition using a deep convolutional neural network and HAR-images.** Neural Comput Appl 2021:1-17D'Angelo G, Palmieri F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814729>

54. **Data in the time of COVID-19: a general methodology to select and secure a NoSQL DBMS for medical data.** PeerJ Comput Sci 2020; 6:e297EIDahshan KA, AlHabsy AA, Abutaleb GE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816948>
55. **Researching COVID-19 tracing app acceptance: incorporating theory from the technological acceptance model.** PeerJ Comput Sci 2021; 7:e316Velicia-Martin F, Cabrera-Sanchez JP, Gil-Cordero E, Palos-Sanchez PR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816983>
56. **Changes in Google search for "sunburn" during the COVID-19 pandemic.** Photodermatol Photoimmunol Photomed 2021; Boothby-Shoemaker W, Lim HW, Kohli I, Ozog D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830570>
57. **Digital herd immunity and COVID-19.** Phys. Biol. 2021; Bulchandani VB, Shivam S, Moudgalya S, Sondhi SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827059>
58. **Virtual Care in the Veterans Affairs Spinal Cord Injuries and Disorders System of Care During the COVID-19 National Public Health Emergency.** Phys. Med. Rehabil. Clin. N. Am. 2021; 32:207-221Barrows D, Goldstein B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814053>
59. **Telehealth in Rehabilitation Psychology and Neuropsychology.** Phys. Med. Rehabil. Clin. N. Am. 2021; 32:405-418Wells MJ, Dukarm P, Mills A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814065>
60. **An online survey and review about the awareness, coping style, and exercise behavior during the "COVID-19 pandemic situation" by implementing the cloud-based medical treatment technology system in China among the public.** Sci. Prog. 2021; 104:368504211000889Ma C, Ma L, Helwan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827338>
61. **Social work and telehealth: How Patient Aligned Care Team (PACT) social workers in the Veterans Health Administration responded to COVID-19.** Soc. Work Health Care 2021:1-15Cornell PY, Celardo C, Chmelka G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826466>
62. **Models of Incorporating Telehealth into Obstetric Care During the COVID-19 Pandemic, Its Benefits And Barriers: A Scoping Review.** Telemed J E Health 2021; Almuslim H, AlDossary S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819434>
63. **The Impact of Telehealth Implementation on Underserved Populations and No-Show Rates by Medical Specialty During the COVID-19 Pandemic.** Telemed J E Health 2021; Franciosi EB, Tan AJ, Kassamali B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826411>
64. **Primary Care implementation of Germ Defence, a digital behaviour change intervention to improve household infection control during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial.** Trials 2021; 22:263Horwood J, Chalder M, Ainsworth B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836825>
65. **Pandemic trade: COVID-19, remote work and global value chains.** World Econ 2021; Espitia A, Mattoo A, Rocha N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821085>

Other – Miscellaneous (89 articles)

1. **Spatial and temporal variation characteristics of atmospheric NO₂ and SO₂ in the Beijing-Tianjin-Hebei region before and after the COVID-19 outbreak.** Air Qual Atmos Health 2021;1-14 Shen N, Zhao X, Li L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824688>
2. **The Importance of Agriculture in the Economy: Impacts from COVID-19.** Am J Agric Econ 2021; Beckman J, Countryman AM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821008>
3. **Food Consumption and Food Security during the COVID-19 Pandemic in Addis Ababa.** Am J Agric Econ 2021; Hirvonen K, de Brauw A, Abate GT.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821007>
4. **Impact of COVID-19 and Nationwide Lockdowns on Vegetable Prices: Evidence from Wholesale Markets in China.** Am J Agric Econ 2021; Ruan J, Cai Q, Jin S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821009>
5. **Self-efficacy, social distancing, and essential worker status dynamics among SGM people.** Ann LGBTQ Public Popul Health 2020; 1:300-317 Robles G, Sauermilch D, Starks TJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829212>
6. **The Influence of COVID-19-Related Stress on Food Motivation.** Appetite 2021;105233 Smith KR, Jansen E, Thapaliya G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33819527>
7. **COVID-19, Government Transfer Payments, and Investment Decisions in Farming Business: Evidence from Northern India.** Appl Econ Perspect Policy 2021; 43:248-269 Varshney D, Kumar A, Mishra AK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821179>
8. **Changes in the employment status of people with and without disabilities in the United States during the COVID-19 pandemic.** Arch. Phys. Med. Rehabil. 2021; Houtenville AJ, Paul S, Brucker DL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839102>
9. **Effects of containment and closure policies on controlling the COVID-19 pandemic in East Asia.** Asian J Soc Psychol 2021; 24:42-47 Chen SX, Lam BCP, Liu JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821141>
10. **Majority world successes and European and American failure to contain COVID-19: Cultural collectivism and global leadership.** Asian J Soc Psychol 2021; 24:23-29 Liu JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821138>
11. **Continuing the precedent: Financially disadvantaging young people in "unprecedented" COVID-19 times.** Aust J Soc Issues 2021; O'Keeffe P, Johnson B, Daley K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821061>
12. **Capstone during COVID-19: Medical Device Development at Home to Solve Global Health Problems.** Biomed Eng Educ 2021; 1:209-213 Kubelick KP, Gleason RL, Rains JK, Stubbs JB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817695>
13. **Military coup during COVID-19 pandemic and health crisis in Myanmar.** BMJ Glob Health 2021; 6 Han SM, Lwin KS, Swe KT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33836997>
14. **The UK Foot and Ankle COVID-19 National (FAICoN) audit.** Bone Jt Open 2021; 2:216-226 Mangwani J, Malhotra K, Houchen-Wolloff L, Mason L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33829856>

15. **Evolution of physical activity habits after a context change: The case of COVID-19 lockdown.** Br. J. Health Psychol. 2021; Maltagliati S, Rebar A, Fessler L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822454>
16. **[A Mythological Anamnesis: from AIDS Spiders to the Bats of Ebola or Covid-19 - Revised Version of the Paper Presented at the Colloquium "Cultural and Social Perspectives on Epidemics", musée du quai Branly-Jacques-Chirac, June 27, 2019].** Bull. Soc. Pathol. Exot. 2020; 113:222-227Cros M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826269>
17. **The feminist economic geographies of working from home and "digital by default" in Canada before, during, and after COVID-19.** Can Geogr 2021; Cockayne D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821018>
18. **What does the public want police to do during pandemics? A national experiment.** Criminol Public Policy 2021; Nix J, Ivanov S, Pickett JT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821153>
19. **Pilot study of an occupational healthcare program to assess the SARS-CoV-2 infection and immune status of employees in a large pharmaceutical company.** Curr. Med. Res. Opin. 2021:1Moroni-Zentgraf PC, Keller C, Mahmoudi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836626>
20. **The big in the small.** Deutsche Zeitschrift fur Akupunktur 2021; 64Bachmann J.
21. **Impacts of COVID-19 on Global Value Chains.** Dev Econ 2021; Hayakawa K, Mukunoki H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821021>
22. **Letter to the editor in response to: Effect of COVID-19 lockdown on patients with chronic diseases.** Diabetes Metab Syndr 2021; Pathak SK, Salunke AA, Pandey A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814293>
23. **Home alone? Effect of weather-induced behaviour on spread of SARS-CoV-2 in Germany.** Econ. Hum. Biol. 2021; 42:100998Yakubenko S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838616>
24. **Democracy and COVID-19 outcomes.** Econ Lett 2021:109840Karabulut G, Zimmermann KF, Bilgin MH, Doker AC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814654>
25. **Alcohol Use during the COVID-19 Pandemic: Self-Reported Changes and Motives for Change.** Eur. Addict. Res. 2021:1-6Bramness JG, Bye EK, Moan IS, Rossow I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839730>
26. **To what extent are conspiracy theorists concerned for self versus others? A COVID-19 test case.** Eur. J. Soc. Psychol. 2021; Hornsey MJ, Chapman CM, Alvarez B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821057>
27. **No evidence for an effect of working from home on neck pain and neck disability among Swiss office workers: Short-term impact of COVID-19.** Eur. Spine J. 2021; Aegerter AM, Deforth M, Johnston V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817763>
28. **An impact study of COVID-19 on six different industries: Automobile, energy and power, agriculture, education, travel and tourism and consumer electronics.** Expert Syst 2021; Nayak J, Mishra M, Naik B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821074>
29. **The impact of COVID-19 on housing price: Evidence from China.** Financ Res Lett 2021:101944Qian X, Qiu S, Zhang G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821074>

term=33821155

30. **The impact of COVID-19 confinement on the eating habits and lifestyle changes: A cross sectional study.** Food Sci Nutr 2021; Galali Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821183>
31. **Teamwork and Leadership Under Fire at the Epicenter of the COVID-19 Epidemic in the Bronx.** Front Med (Lausanne) 2021; 8:610100Tomer Y, Ng Gong M, Keller MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816518>
32. **The Impact of the COVID-19 Pandemic on Male Strength Athletes Who Use Non-prescribed Anabolic-Androgenic Steroids.** Front Psychiatry 2021; 12:636706Zoob Carter BN, Boardley ID, van de Ven K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828494>
33. **Examining the Psychological State Analysis Relationship Between Bitcoin Prices and COVID-19.** Front. Psychol. 2021; 12:647691Hou J, Liu J, Jie Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828511>
34. **Pandemic Leadership: Sex Differences and Their Evolutionary-Developmental Origins.** Front. Psychol. 2021; 12:633862Luoto S, Varella MAC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33815218>
35. **Collaboration in handling COVID-19 toward people in poverty line: study case in Makassar.** Gac. Sanit. 2021; 35 Suppl 1:S30-s32Latief MI, Hasbi, Amandaria R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33832620>
36. **Narratives of life-maneuvering in reshaping new living space during Covid-19: A case study of women activist in Manggarai Region, Eastern Indonesia.** Gend Work Organ 2021; Regus M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821107>
37. **In This Together: Navigating Ethical Challenges Posed by Family Clustering during the Covid-19 Pandemic.** Hastings Cent Rep 2021; 51:16-21Van Buren NR, Weber E, Bliton MJ, Cunningham TV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33840101>
38. **Environmental correlation and epidemiologic analysis of COVID-19 pandemic in ten regions in five continents.** Heliyon 2021; 7:e06576Sharif N, Sarkar MK, Ahmed SN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817387>
39. **Ghost trains: Australian rail in the early stages of the global COVID-19 pandemic.** Hum Factors Ergon Manuf 2021; Naweed A, Jackson JE, Read GJM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821127>
40. **A systematic review on the impacts of Covid-19 on work: Contributions and a path forward from the perspectives of ergonomics and psychodynamics of work.** Hum Factors Ergon Manuf 2021; Sigahi T, Kawasaki BC, Bolis I, Morioka SN.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821126>
41. **Impact of COVID-19 on health and safety in the construction sector.** Hum Factors Ergon Manuf 2021; Stiles S, Golightly D, Ryan B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821125>
42. **Financial impact of COVID-19 on radiology practice in India.** Indian J. Radiol. Imaging 2021; 31:S31-s37Ahuja G, Verma M, Patkar D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814759>
43. **Changes in the consumption of foods characterising the Mediterranean dietary pattern and major correlates during the COVID-19 confinement in Italy: results from two cohort studies.** Int. J. Food Sci. Nutr. 2021:1-13Ruggiero E,

Mignogna C, Costanzo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823720>

44. **Health workforce management in the context of the COVID-19 pandemic: A survey of physicians in Serbia.** *Int. J. Health Plann. Manage.* 2021; Dinić M, Šantrić Milićević M, Mandić-Rajčević S, Tripković K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817831>
45. **COVID-19 Rumination Scale (C-19RS): Initial psychometric evidence in a sample of Dutch employees.** *Int. J. Health Plann. Manage.* 2021; Nikolova I, Caniëls MCJ, Curseu PL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817832>
46. **Employment outcomes and job satisfaction of international public health professionals: What lessons for public health and COVID-19 pandemic preparedness? Employment outcomes of public health graduates.** *Int. J. Health Plann. Manage.* 2021; Treviño-Reyna G, Czabanowska K, Haque S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817807>
47. **Outcomes for Implemented Macroeconomic Policy Responses and Multilateral Collaboration Strategies for Economic Recovery After a Crisis: A Rapid Scoping Review.** *Int J Health Serv* 2021:207314211007100 Embrett M, Bielska IA, Manis DR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819129>
48. **Being an accountant, cook, entertainer and teacher-all at the same time: Changes in employees' work and work-related well-being during the coronavirus (COVID-19) pandemic.** *Int. J. Psychol.* 2021; Syrek C, Kühnel J, Vahle-Hinz T, de Bloom J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826148>
49. **Unequal but essential: How subsistence consumer-entrepreneurs negotiate unprecedented shock with extraordinary resilience during COVID-19.** *J Consum Aff* 2021; 55:151-178 Viswanathan M, Faruque Aly H, Duncan R, Mandhan N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821035>
50. **Recognition and the Development Potential of Mobile Shopping of Customized Cosmetic on Untact COVID19 Period: Focused on 40's to 60's Women in Seoul, Republic of Korea.** *J Cosmet Dermatol* 2021; Lee J, Kwon KH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834593>
51. **Career Services in the Post-COVID-19 Era: A Paradigm for Career Counseling Unemployed Individuals.** *J Employ Couns* 2021; 58:36-48 Drosos N, Theodoroulakis M, Antoniou AS, Rajter IC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821036>
52. **Mobility Change and COVID-19 in Japan: Mobile Data Analysis of Locations of Infection.** *J. Epidemiol.* 2021; Nagata S, Nakaya T, Adachi Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814508>
53. **Worried of Not COVID-19 but Fear of Hunger and Starvation: Challenges of the Poor Nigerians.** *J Evid Based Soc Work (2019)* 2021:1-16 Nwatu UL, Nwafor NF, Odo CO, Onalu CE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827381>
54. **Effect of the COVID-19 Lockdown on Ambient Air Quality in Major Cities of Nepal.** *J Health Pollut* 2021; 11:210211 Baral BD, Thapa K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815898>
55. **IL-6 modulation for COVID-19: the right patients at the right time?** *J Immunother Cancer* 2021; 9 Ascierto PA, Fu B, Wei H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837054>

56. **"We also deserve help during the pandemic": The effect of the COVID-19 pandemic on foreign domestic workers in Hong Kong.** J Migr Health 2021; 3:100037Lui ID, Vandan N, Davies SE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817682>
57. **Countering social stigma and discrimination during the COVID-19 pandemic through solidarity.** J Public Health (Oxf) 2021; Balingue AC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823029>
58. **Celebrating holy week practices at home during the COVID-19 pandemic in the Philippines.** J Public Health (Oxf) 2021; Gozum IEA, Nucum J, Noriega PJD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839795>
59. **Effect of COVID-19 on air quality and pollution in different countries.** J Transp Health 2021; 21:101061Albayati N, Waisi B, Al-Furaiji M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816115>
60. **The COVID-19 pandemic and the role of responsible leadership in health care: thinking beyond employee well-being and organisational sustainability.** Leadersh Health Serv (Bradford Engl) 2021; 34:52-68Haque A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818971>
61. **Impacts of the COVID-19 pandemic on mammals at tourism destinations: a systematic review.** Mamm Rev 2021; Usui R, Sheeran LK, Asbury AM, Blackson M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821078>
62. **Devastating urban flooding and dengue outbreak during the COVID-19 pandemic in Pakistan.** Med. J. Islam. Repub. Iran 2020; 34:169Junaid Tahir M, Rizwan Siddiqi A, Ullah I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816368>
63. **Opportunity cost and COVID-19: A perspective from health economics.** Med. J. Islam. Repub. Iran 2020; 34:177Olivera MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816376>
64. **Effects of the COVID-19 Emergency and National Lockdown on Italian Citizens' Economic Concerns, Government Trust, and Health Engagement: Evidence From a Two-Wave Panel Study.** Milbank Q. 2021; Graffigna G, Palamenghi L, Savarese M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822424>
65. **Is politics forgetting COVID-19 therapeutic agents? - Biotech companies ask for funding.** MMW-Fortschritte der Medizin 2020; 162:80Patzner KH.
66. **UK food and nutrition security during and after the COVID-19 pandemic.** Nutr. Bull. 2021; 46:88-97Rivington M, King R, Duckett D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821148>
67. **Meteorological factors and incidence of COVID-19 during the first wave of the pandemic in Catalonia (Spain): A multi-county study.** One Health 2021; 12:100239Tobías A, Molina T, Rodrigo M, Saez M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816746>
68. **Assessing the risks of SARS-CoV-2 in wildlife.** One Health Outlook 2021; 3:7Delahay RJ, de la Fuente J, Smith GC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834160>
69. **Forecasting major impacts of COVID-19 pandemic on country-driven sectors: challenges, lessons, and future roadmap.** Pers Ubiquitous Comput 2021:1-

24Kumar S, Viral R, Deep V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815032>

70. **Taxation in the COVID-19 Pandemic: to Pay or Not to Pay.** *Philosophia (Ramat Gan)* 2021;1-13Abumere FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814644>
71. **Covid-19 and Football: Crisis Creates Opportunity.** *Polit Q* 2021; 92:132-138Maguire K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821038>
72. **What medical waste management system may cope With COVID-19 pandemic: Lessons from Wuhan.** *Resour Conserv Recycl* 2021; 170:105600Chen C, Chen J, Fang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821099>
73. **Labour Market Dynamics in South Africa at the Onset of the COVID-19 Pandemic.** *S Afr J Econ* 2021; 89:44-62Ranchhod V, Daniels RC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821045>
74. **An application of probability density function for the analysis of PM2.5 concentration during the COVID-19 lockdown period.** *Sci Total Environ* 2021; 782:146681Mishra G, Ghosh K, Dwivedi AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836380>
75. **Social policy in the face of a global pandemic: Policy responses to the COVID-19 crisis in Central and Eastern Europe.** *Soc Policy Adm* 2021; 55:358-373Aidukaite J, Saxonberg S, Szelewa D, Szikra D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821058>
76. **The political economy of the COVID-19 pandemic.** *South Econ J* 2021; Boettke P, Powell B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821055>
77. **Separation of power and expertise: Evidence of the tyranny of experts in Sweden's COVID-19 responses.** *South Econ J* 2021; Bylund PL, Packard MD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821054>
78. **The political economy of state responses to infectious disease.** *South Econ J* 2021; Coyne CJ, Duncan TK, Hall AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821053>
79. **Externality and COVID-19.** *South Econ J* 2021; Leeson PT, Rouanet L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821050>
80. **The political economy of drug and alcohol regulation during the COVID-19 pandemic.** *South Econ J* 2021; Redford A, Dills AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821052>
81. **Economic lessons for COVID-19 pandemic policies.** *South Econ J* 2021; Viscusi WK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821048>
82. **Does Airborne Pollen Influence COVID-19 Outbreak?** *Sustain Cities Soc* 2021;102887Khairwal R, Goyal A, Mor S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816082>
83. **Smart City Projects Against COVID-19: Quantitative Evidence from China.** *Sustain Cities Soc* 2021; 70:102897Yang S, Chong Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824851>
84. **Measuring Progress of Regulatory Convergence and Cooperation Among Asia-Pacific Economic Cooperation (APEC) Member Economies in the Context of the COVID-19 Pandemic.** *Ther Innov Regul Sci* 2021; Chong SSF, Kim M, Limoli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33840083>

85. **Prediction of COVID-19 cases using the weather integrated deep learning approach for India.** Transbound Emerg Dis 2021; Bhimala KR, Patra GK, Mopuri R, Mutheneneni SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837675>
86. **Sustainable Border Control Policy in the COVID-19 Pandemic: A Math Modeling Study.** Travel Med Infect Dis 2021; 41:102044Zhu Z, Weber E, Strohsal T, Serhan D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838318>
87. **Comparative life cycle assessment of emergency disposal scenarios for medical waste during the COVID-19 pandemic in China.** Waste Manag 2021; 126:388-399Zhao H, Liu H, Wei G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827006>
88. **Trade policy responses to the COVID-19 pandemic crisis: Evidence from a new data set.** World Econ 2021; Evenett S, Fiorini M, Fritz J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821084>
89. **COVID-19, public procurement regimes and trade policy.** World Econ 2021; Hoekman B, Shingal A, Eknath V, Ereshchenko V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821083>

Pathology (4 articles)

1. **The challenges and risk of laboratory handling on a histology specimen during COVID-19 pandemic.** Ann Med Surg_(Lond) 2021; 64:102242Amri MF, Azizan N, Hussain FA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815787>
2. **Histopathologic Evaluation of COVID-19 Patients with Peripheral Arterial Thromboembolism: Does clot composition make any sense?** Ann. Vasc. Surg. 2021; Yesilkaya N, Tellioglu TM, Unay FC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819598>
3. **Characterisation of cardiac pathology in 23 autopsies of lethal COVID-19.** J Pathol Clin Res 2021; Haslbauer JD, Tzankov A, Mertz KD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837673>
4. **Pathophysiology of light phenotype SARS-CoV-2 interstitial pneumonia: from histopathological features to clinical presentations.** Pulmonology 2021; Oldani S, Ravaglia C, Bensai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832850>

Protection (27 articles)

1. **Review of the Breathability and Filtration Efficiency of Common Household Materials for Face Masks.** ACS Nano 2021; Kwong LH, Wilson R, Kumar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822580>
2. **Adherence to Social Distancing Guidelines Throughout the COVID-19 Pandemic: The Roles of Pseudoscientific Beliefs, Trust, Political Party Affiliation, and Risk Perceptions.** Ann. Behav. Med. 2021; Gratz KL, Richmond JR, Woods SE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830215>
3. **Face mask use during the Covid-19 pandemic - the significance of culture and the symbolic meaning of behaviour.** Ann. Epidemiol. 2021; Timpka T, Nyce JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836290>

4. **The challenges and risk of laboratory handling on a histology specimen during COVID-19 pandemic.** Ann Med Surg.(Lond) 2021; 64:102242Amri MF, Azizan N, Hussain FA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815787>
5. **Pharmacists self-perceived role competence in prevention and containment of COVID-19: A cross-sectional study.** Ann Med Surg.(Lond) 2021; 64:102243Muflih S, Al-Azzam S, Lafferty L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815788>
6. **Telling people to "rely on their reasoning" increases intentions to wear a face covering to slow down COVID-19 transmission.** Appl. Cogn. Psychol. 2021; Capraro V, Barcelo H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821089>
7. **Fluid-repellent surgical mask (FRSM) fit - one size does not fit all.** Clin Med (Lond) 2021; Russell L, Campani L, Jones J, Healy B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824138>
8. **Working short and working long: can primary healthcare be protected as a public good in Lebanon today?** Confl Health 2021; 15:23Hamadeh RS, Kdouh O, Hammoud R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827637>
9. **Simultaneous monitoring of SARS-CoV-2, bacteria, and fungi in indoor air of hospital: a study on Hajar Hospital in Shahrekord, Iran.** Environ. Sci. Pollut. Res. Int. 2021; Hemati S, Mobini GR, Heidari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837940>
10. **"Face mask dermatitis" due to compulsory facial masks during the SARS-CoV-2 pandemic: data from 550 health care and non-health care workers in Germany.** Eur. J. Dermatol. 2021; Niesert AC, Oppel EM, Nellessen T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814358>
11. **Proactive Measures to Combat a SARS-CoV-2 Transmission Among High Risk Patients and Health Care Workers in an Outpatient Dialysis Facility.** Front. Pharmacol. 2020; 11:600364Pillai J, Motloba P, Motaung KSC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833677>
12. **The Status of Occupational Protection During COVID-19 Pandemic: Knowledge, Attitudes, and Practice of Healthcare Workers in Endoscopy Units, China.** Front Public Health 2021; 9:632608Tian Y, Nian B, Ma Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829007>
13. **Protection Motivation During COVID-19: A Cross-Sectional Study of Family Health, Media, and Economic Influences.** Health Educ. Behav. 2021:10901981211000318Hanson CL, Crandall A, Barnes MD, Novilla ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823626>
14. **Genomics in Patient Care and Workforce Decisions in High-Level Isolation Units: A Survey of Healthcare Workers.** Health Secur 2021; Gerber JE, Geller G, Boyce A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826422>
15. **Case study into the successful emergency production and certification of a filtering facepiece respirator for Belgian hospitals during the COVID-19 pandemic.** J Manuf Syst 2021; Vanhooydonck A, Van Goethem S, Van Loon J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814674>
16. **Laser plume containment during flexible transnasal laryngoscopy.** Laryngoscope Investig Otolaryngol 2021; Hoffman HT, Walsh JE, Pratt A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821216>

17. **N95 or P2 respirator fit testing policy in Australia: implementation issues to consider.** Med. J. Aust. 2021; Ganesan A, Parker J, Chapman D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33837543>
18. **The 3 P's model enhancing patient safety during the COVID-19 pandemic.** Oral Surg 2021; Nathwani S, Rahman N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821170>
19. **Airflow dispersion during common neonatal resuscitation procedures: A simulation study.** Pediatr Pulmonol 2021; Kwok TC, Swaby R, Sharkey D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33826802>
20. **School opening during the SARS-CoV-2 pandemic: Public acceptance of wearing fabric masks in class.** Public Health Pract (Oxf) 2021; 2:100115Betsch C, Korn L, Felgendreiff L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817681>
21. **Development of a new aerosol barrier mask for mitigation of spread of SARS-CoV-2 and other infectious pathogens.** Respir. Med. 2021; 181:106381Abi Karam K, Hota P, Mora SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819714>
22. **[Prevention measures to avoid COVID-19 spreading by: from the everyday to the technical-scientific actions.].** Rev. Esp. Salud Publica 2021; 95Romero-Saritama JM, Simaluiza J, Fernandez H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833213>
23. **How to use laser safely in times of COVID-19: Systematic review.** Spec. Care Dentist. 2021; Lago ADN, Cordon R, Gonçalves LM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33822391>
24. **The Use of Modified Snorkel Masks as Personal Protective Equipment During Aerosol-Generating Procedures: COVID-19 Necessity.** Surg. Innov. 2021:15533506211003528Matsevyich OY, Koto MZ, Balabyeki M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33830809>
25. **Face-touching behavior as a possible correlate of mask-wearing: A video observational study of public place incidents during the COVID-19 pandemic.** Transbound Emerg Dis 2021; Liebst LS, Ejbye-Ernst P, de Bruin M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817991>
26. **Predictive Analyses of COVID-19 Case Data to Estimate the Effectiveness of Nationwide Face Cover.** World Med Health Policy 2021; Kim H, Simpson J, Park B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821197>
27. **[Hygiene measures against COVID-19 in routine outpatient care : Acceptance by the patients?].** Z. Rheumatol. 2021:1-5Ehrenstein B, Schwarz T, Fleck M, Günther F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822255>

Pulmonary disease (13 articles)

1. **COVID-19 severe pneumonia: Prospective multicentre study on demands on intensive care capacities.** Cent. Eur. J. Public Health 2021; 29:3-8Džupová O, Moravec M, Bartoš H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831279>
2. **Interstitial lung abnormalities and pulmonary fibrosis in COVID-19 patients: a short-term follow-up case series.** Clin Imaging 2021; 77:180-186Gulati A, Lakhani P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836413>

3. **A Case of Suspected Radiation Recall Pneumonitis After a COVID-19 Infection.** Cureus 2021; 13:e13688Kurosaki H, Utsumi N, Miura K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824832>
4. **Assessment of pulmonary arterial circulation 3 months after hospitalization for SARS-CoV-2 pneumonia: Dual-energy CT (DECT) angiographic study in 55 patients.** EClinicalMedicine 2021; 34:100778Remy-Jardin M, Duthoit L, Perez T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817609>
5. **Virus-Induced Changes of the Respiratory Tract Environment Promote Secondary Infections With *Streptococcus pneumoniae*.** Front Cell Infect Microbiol 2021; 11:643326Sender V, Hentrich K, Henriques-Normark B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828999>
6. **The incidence of pleural effusion in COVID-19 pneumonia: State-of-the-art review.** Heart Lung 2021; 50:481-490Chong WH, Saha BK, Conuel E, Chopra A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33831700>
7. **Lung Fibrosis Sequelae After Recovery from COVID-19 Infection.** J Infect Dev Ctries 2021; 15:360-365Susanto AD, Triyoga PA, Isbaniah F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33839710>
8. **Broad SARS-CoV-2 cell tropism and immunopathology in lung tissues from fatal COVID-19.** J Infect Dis 2021; Ramos da Silva S, Ju E, Meng W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33837392>
9. **Spontaneous hemopneumothorax in an adolescent with COVID-19.** J Pediatr Surg Case Rep 2021; 69:101852Montgomery AB, Finck C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828949>
10. **A mechanism for matrikine regulation in acute inflammatory lung injury.** JCI Insight 2021; 6Robison SW, Li J, Viera L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33830084>
11. **Letter from the Philippines.** Respirology 2021; Wi JA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33830610>
12. **Does Airborne Pollen Influence COVID-19 Outbreak?** Sustain Cities Soc 2021;102887Khaiwal R, Goyal A, Mor S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816082>
13. **Improved asthma control during the COVID-19 pandemic: are there lessons to be learnt?** Thorax 2021; Skene IP, Pfeffer PE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33837141>

Renal disease (13 articles)

1. **Epidemiology of COVID-19 Infection in Hospitalized End-Stage Kidney Disease Patients in a Predominantly African-American Population.** Am. J. Nephrol. 2021;1-9Navarrete JE, Tong DC, Cobb J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33827078>
2. **Syndemics at play: chronic kidney disease, diabetes and COVID-19 in Pakistan.** Ann. Med. 2021; 53:581-586Ali I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825598>
3. **Kidney transplantation and COVID-19 renal and patient prognosis.** Clin Kidney J 2021; 14:i21-i29Toapanta N, Torres IB, Sellarés J *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33815780>

4. **SARS-CoV-2 vaccines - What the nephrologist should know.** Deutsche Medizinische Wochenschrift 2021; 146:466-470Heine GH, Becker SL, Scheuer AL, Schirmer SH.
5. **Comparing the Value of Cystatin C and Serum Creatinine for Evaluating the Renal Function and Predicting the Prognosis of COVID-19 Patients.** Front. Pharmacol. 2021; 12:587816Chen S, Li J, Liu Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33828483>
6. **Proactive Measures to Combat a SARS-CoV-2 Transmission Among High Risk Patients and Health Care Workers in an Outpatient Dialysis Facility.** Front. Pharmacol. 2020; 11:600364Pillai J, Motloba P, Motaung KSC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33833677>
7. **Initial Effects of COVID-19 on Patients with ESKD.** J Am Soc Nephrol 2021; Weinhandl ED, Wetmore JB, Peng Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833076>
8. **Incorporation of Urinary Neutrophil Gelatinase-Associated Lipocalin and Computed Tomography Quantification to Predict Acute Kidney Injury and In-Hospital Death in COVID-19 Patients.** Kidney Dis (Basel) 2021; 7:120-130He L, Zhang Q, Li Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824868>
9. **Renal Injury by SARS-CoV-2 Infection: A Systematic Review.** Kidney Dis (Basel) 2021; 7:100-110Wang M, Xiong H, Chen H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821207>
10. **Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19.** Kidney Int Rep 2021; 6:905-915Hardenberg JB, Stockmann H, Aigner A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817450>
11. **[Covid-19 in kidney transplantation: Lessons from the French Registry].** Nephrol. Ther. 2021; Caillard S, Thaumat O, Hazzan M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33836957>
12. **[New coronavirus infection (COVID-19) associated with kidney infarction in a seventeen-year-old child].** Urologija 2021;84-88Kagantsov IM, Sizonov VV, Shelegin RV, Svarich VG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818941>
13. **Siblings with coronavirus disease 2019 infection and opposite outcome-the hemodialysis's better outcome paradox: Two case reports.** World J Nephrol 2021; 10:21-28Bacharaki D, Chrysanthopoulou E, Grigoropoulou S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816154>

Reviews (48 articles)

1. **A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing.** 3 Biotech 2021; 11:198Kumar SU, Priya NM, Nithya SR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816047>
2. **Comprehensive Review of Cardiovascular Involvement in COVID-19.** AACN Adv. Crit. Care 2021:e1-e19Macale Cajanding RJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33836538>

3. **Update in COVID-19.** Am J Respir Crit Care Med 2021; Chotirmall SH, Leither LM, Çoruh B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835905>
4. **Considerations and perspectives on digestive diseases during the COVID-19 pandemic: a narrative review.** Ann Palliat Med 2021; Li J, Li C, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832321>
5. **Nutritional determinants and COVID-19 outcomes of older patients with COVID-19: A systematic review.** Arch. Gerontol. Geriatr. 2021; 95:104411Damayanthi H, Prabani KIP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836322>
6. **Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection.** Biochemistry (Mosc.) 2021; 86:257-261Letarov AV, Babenko VV, Kulikov EE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838638>
7. **The role of extracorporeal membrane oxygenation in critically ill patients with COVID-19: a narrative review.** BMC Pulm. Med. 2021; 21:116Huang S, Zhao S, Luo H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832474>
8. **A scoping review of COVID-19 experiences of people living with dementia.** Can. J. Public Health. 2021; Bacsu JR, O'Connell ME, Webster C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825134>
9. **Current opinion in neurological manifestations of SARS-CoV-2 infection.** Curr Opin Toxicol 2021; Engin AB, Engin ED, Engin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817451>
10. **COVID-19 and diabetes: Analysis of the scientific production indexed in Scopus.** Diabetes Metab Syndr 2021; 15:765-770Corrales-Reyes IE, Hernández-García F, Mejía CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831772>
11. **Drugs intervention study in COVID-19 management.** Drug Metab Pers Ther 2021; Taher M, Tik N, Susanti D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818031>
12. **Vitamin D sufficiency and COVID-19: is vitamin D binding protein (and its polymorphism) the missing link?** Endocr. Pract. 2021; Speeckaert MM, Speeckaert R, Delanghe JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819636>
13. **Novel coronavirus disease 2019 (COVID-19) pandemic: From transmission to control with an interdisciplinary vision.** Environ. Res. 2021:111126Anand U, Cabrerós C, Mal J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831411>
14. **Determining the communicable period of SARS-CoV-2: A rapid review of the literature, March to September 2020.** Euro Surveill 2021; 26Park M, Pawliuk C, Nguyen T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834961>
15. **The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review.** Front. Endocrinol. (Lausanne) 2021; 12:645194Zangiabadian M, Nejadghaderi SA, Zahmatkesh MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815295>
16. **COVID-19-A Theory of Autoimmunity Against ACE-2 Explained.** Front. Immunol. 2021; 12:582166McMillan P, Dexhiemer T, Neubig RR, Uhal BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833750>
17. **Characteristics of Children With Kawasaki Disease-Like Signs in COVID-19 Pandemic: A Systematic Review.** Front Pediatr 2021; 9:625377Mardi P, Esmaeili

- M, Iravani P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816398>
18. **COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.** Front. Pharmacol. 2021; 12:633680Malone RW, Tisdall P, Fremont-Smith P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833683>
 19. **A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa.** Global Health 2021; 17:42Amimo F, Lambert B, Magit A, Hashizume M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832487>
 20. **A scoping review of international policy responses to mental health recovery during the COVID-19 pandemic.** Health Res. Policy Syst. 2021; 19:58McCartan C, Adell T, Cameron J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823855>
 21. **Responding to pandemics and other disease outbreaks in homeless populations: A review of the literature and content analysis.** Health Soc Care Community 2021; Babando J, Quesnel DA, Woodmass K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825271>
 22. **The incidence of pleural effusion in COVID-19 pneumonia: State-of-the-art review.** Heart Lung 2021; 50:481-490Chong WH, Saha BK, Conuel E, Chopra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831700>
 23. **A systematic review on the impacts of Covid-19 on work: Contributions and a path forward from the perspectives of ergonomics and psychodynamics of work.** Hum Factors Ergon Manuf 2021; Sigahi T, Kawasaki BC, Bolis I, Morioka SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821126>
 24. **Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review.** Indian J. Clin. Biochem. 2021;1-13Kaur RJ, Dutta S, Bhardwaj P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814753>
 25. **Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.** Indian J Med Res 2021; 153:64-85Khaire NS, Jindal N, Yaddanapudi LN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818467>
 26. **Health Systems and Services During COVID-19: Lessons and Evidence From Previous Crises: A Rapid Scoping Review to Inform the United Nations Research Roadmap for the COVID-19 Recovery.** Int J Health Serv 2021;20731421997088Baral P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827309>
 27. **Pathomechanism and Management of Stroke in COVID-19: Review of Immunopathogenesis, Coagulopathy, Endothelial Dysfunction, and Downregulation of ACE2.** J. Clin. Neurol. 2021; 17:155-163Rahmawati PL, Tini K, Susilawathi NM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835735>
 28. **Discharge Practices for COVID-19 Patients: Rapid Review of Published Guidance and Synthesis of Documents and Practices at 22 US Academic Medical Centers.** J Gen Intern Med 2021;1-7Greysen SR, Auerbach AD, Mitchell MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835314>
 29. **Anxiety impact during COVID-19: a systematic review.** J Infect Dev Ctries 2021; 15:320-325Batista P, Duque V, Luzio-Vaz A, Pereira A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839704>

30. **Structural and physiological changes of the human body upon SARS-CoV-2 infection.** J Zhejiang Univ Sci B 2021; 22:310-317Wu Z, Zhang Q, Ye G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835765>
31. **Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.** JMIR Public Health Surveill 2021; 7:e25500Peng HT, Rhind SG, Beckett A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825689>
32. **Renal Injury by SARS-CoV-2 Infection: A Systematic Review.** Kidney Dis (Basel) 2021; 7:100-110Wang M, Xiong H, Chen H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821207>
33. **Impacts of the COVID-19 pandemic on mammals at tourism destinations: a systematic review.** Mamm Rev 2021; Usui R, Sheeran LK, Asbury AM, Blackson M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821078>
34. **Repurposing antiviral drugs on recently emerged viral infections: A review article.** Mater Today Proc 2021; Swathi K, Nikitha B, Chandrakala B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816131>
35. **Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials.** Medwave 2021; 21:e8105Meza N, Pérez-Bracchiglione J, Pérez I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830976>
36. **An Update on COVID-19 Related Ophthalmic Manifestations.** Ocul Immunol Inflamm 2021;1-6Jevnikar K, Jaki Mekjavic P, Vidovic Valentincic N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826465>
37. **[Antiviral and anti-inflammatory therapies in COVID-19].** Orv. Hetil. 2021; 162:643-651Szekanecz Z, Bogos K, Constantin T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838023>
38. **Epidemics, the Ising-model and percolation theory: A comprehensive review focussed on Covid-19.** Physica A 2021:125963Mello IF, Squillante L, Gomes GO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814681>
39. **Complementary and alternative medicine therapies and COVID-19: a systematic review.** Rev. Environ. Health 2021; Badakhsh M, Dastras M, Sarchahi Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838089>
40. **Hypercoagulability in COVID-19: A review of the potential mechanisms underlying clotting disorders.** SAGE Open Med 2021; 9:20503121211002996Alam W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815798>
41. **COVID-19 and the perioperative neuroscience - A narrative review.** Saudi J. Anaesth. 2021; 15:19-26Kapoor I, Mahajan C, Prabhakar H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824638>
42. **Models of Incorporating Telehealth into Obstetric Care During the COVID-19 Pandemic, Its Benefits And Barriers: A Scoping Review.** Telemed J E Health 2021; Almuslim H, AlDossary S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819434>
43. **Bioethical Perspective of Convalescent Plasma Therapy for COVID-19: A Systematic Review.** Transfus. Clin. Biol. 2021; Munir MA, Tandiang PA, Setyawati T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839300>

44. **Slowing the spread of COVID-19: Review of "Social distancing" interventions deployed by public transit in the United States and Canada.** Transp Policy (Oxf). 2021; 106:25-36Kamga C, Eickemeyer P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814735>
45. **Assessment and management of asymptomatic COVID-19 infection: A Systematic Review.** Travel Med Infect Dis 2021; 41:102058Barboza JJ, Chambergo-Michilot D, Velasquez-Sotomayor M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838319>
46. **Coronavirus disease-2019 and the intestinal tract: An overview.** World J. Gastroenterol. 2021; 27:1255-1266Alberca GGF, Solis-Castro RL, Solis-Castro ME, Alberca RW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833480>
47. **Radiological and clinical spectrum of COVID-19: A major concern for public health.** World J Radiol 2021; 13:53-63Verma HK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815683>
48. **A Call for the World Health Organization to Create International Classification of Disease Diagnostic Codes for Post-Intensive Care Syndrome in the Age of COVID-19.** World Med Health Policy 2021; Peach BC, Valenti M, Sole ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821196>

Risk factors (62 articles)

1. **Genomic Insights into the Human Susceptibility to SARS-CoV-2 Infection.** Acta Med Port 2021; Magalhães AC, Pedro N, Pereira L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821785>
2. **The role of the BUN/albumin ratio in predicting mortality in COVID-19 patients in the emergency department.** Am J Emerg Med 2021; 48:33-37Küçükceran K, Ayrancı MK, Girişgin AS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838471>
3. **Covid-19, hypokalaemia and the renin-angiotensin-aldosterone system.** Ann Med Surg (Lond) 2021:102261Mandal AKJ, Wenban C, Heer RS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815782>
4. **A meta-analysis: Proton pump inhibitors current use and the risk of Coronavirus Infectious Disease 2019 development and its related mortality.** Arch Med Res 2021; Toubasi AA, AbuAnzeh RB, Khraisat BR *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814207>
5. **Gender disparity in COVID-19: Role of sex steroid hormones.** Asian Pac. J. Trop. Med. 2021; 14:5-9Lipsa A, Prabhu JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828641>
6. **Quantifying the association between ethnicity and COVID-19 mortality: a national cohort study protocol.** BMJ Open 2021; 11:e045286Dambha-Miller H, Tan PS, Saatci D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827839>
7. **Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USA.** BMJ Open 2021; 11:e047121Incerti D, Rizzo S, Li X *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827848>
8. **Annual influenza vaccination effect on the susceptibility to COVID-19 infection.** Cent. Eur. J. Public Health 2021; 29:14-17Erismis B, Karabela SN, Eksi F

et al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831281>

9. **Inflammatory and Prothrombotic Biomarkers Associated With the Severity of COVID-19 Infection.** Clin. Appl. Thromb. Hemost. 2021; 27:1076029621999099Lopez-Castaneda S, García-Larragoiti N, Cano-Mendez A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835872>
10. **Vitamin D and COVID-19 in an immunocompromised patient with multiple comorbidities-A Case Report.** Clin Case Rep 2021; Kralj M, Jakovac H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821193>
11. **Racial and Ethnic Differences and Clinical Outcomes of COVID-19 Patients Presenting to the Emergency Department.** Clin Infect Dis 2021; Wiley Z, Ross-Driscoll K, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822023>
12. **Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19?** Clin Rheumatol 2021; Castillo-Martínez D, Torres Z, Amezcua-Guerra LM, Pineda C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826045>
13. **Development and Validation of a Clinical Symptom-based Scoring System for Diagnostic Evaluation of COVID-19 Patients Presenting to Outpatient Department in a Pandemic Situation.** Cureus 2021; 13:e13681Bhattacharya A, Ranjan P, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833907>
14. **Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19.** Cureus 2021; 13:e13687Salvador P, Oliveira P, Costa T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833912>
15. **A Mechanistic Link Between Selenium and Coronavirus Disease 2019 (COVID-19).** Curr Nutr Rep 2021:1-12Khatiwada S, Subedi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835432>
16. **Vitamin D Status: Can It Affect the Risk of Infection and the Severity of COVID-19 Symptoms?** Curr Trop Med Rep 2021:1-8Paiz N, Alonso P, Portillo AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816060>
17. **IL-6 and IL-10 are associated with disease severity and higher comorbidity in adults with COVID-19.** Cytokine 2021:155507Luporini RL, Rodolpho JMA, Kubota LT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839002>
18. **Impact of the vitamin D deficiency on COVID-19 infection and morality in Asian countries.** Diabetes Metab Syndr 2021; 15:757-764Jayawardena R, Jeyakumar DT, Francis TV, Misra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823331>
19. **Impact of the vitamin D deficiency on COVID-19 infection and mortality in Asian countries.** Diabetes Metab Syndr 2021; 15:757-764Jayawardena R, Jeyakumar DT, Francis TV, Misra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823331>
20. **Evaluation of simple and cost-effective immuno- haematological markers to predict outcome in hospitalized severe COVID-19 patients, with a focus on diabetes mellitus - A retrospective study in Andhra Pradesh, India.** Diabetes Metab Syndr 2021; 15:739-745Ramesh J, Reddy SLS, Rajesh M, Varghese J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819728>
21. **Letter to the Editor in response to article: Hypocalcemia is associated with severe COVID-19: A systematic review and meta-analysis (Martha et al.).**

Diabetes Metab Syndr 2021; Siniorakis EE, Arvanitakis SG, Elkouris MJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814294>

22. **SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru.** EClinicalMedicine 2021; 34:100801Reyes-Vega MF, Soto-Cabezas MG, Cárdenas F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817611>
23. **Is sickle cell disease a risk factor for severe COVID-19 outcomes in hospitalized patients? A multicenter national retrospective cohort study.** EJHaem 2021; Abdulrahman A, Wael M, AlAmmadi F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821258>
24. **E-cigarette Vape and Lung ACE2 Expression: Implications for coronavirus vulnerability.** Environ. Toxicol. Pharmacol. 2021:103656Lallai V, Manca L, Fowler CD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838329>
25. **How Does SARS-CoV-2 Infection Affect Survival of Emergency Cardiovascular Patients? A Cohort Study From a German Insurance Claims Database.** Eur. J. Vasc. Endovasc. Surg. 2021; Behrendt CA, Seiffert M, Gerloff C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824066>
26. **Characteristics and risk factors for SARS-CoV-2 in children tested in the early phase of the pandemic: a cross-sectional study, Italy, 23 February to 24 May 2020.** Euro Surveill 2021; 26Lazzerini M, Sforzi I, Trapani S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33834960>
27. **Genomic Variations in SARS-CoV-2 Genomes From Gujarat: Underlying Role of Variants in Disease Epidemiology.** Front Genet 2021; 12:586569Joshi M, Puvar A, Kumar D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815459>
28. **Red Cell Distribution Width Upon Hospital Admission Predicts Short-Term Mortality in Hospitalized Patients With COVID-19: A Single-Center Experience.** Front Med (Lausanne) 2021; 8:652707Kaufmann CC, Ahmed A, Brunner U *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816532>
29. **On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases.** Front. Microbiol. 2021; 12:646679Trunfio M, Longo BM, Alladio F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33815334>
30. **COVID-19 and Smoking: What Evidence Needs Our Attention?** Front. Physiol. 2021; 12:603850Xie J, Zhong R, Wang W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33815131>
31. **Higher Temperatures, Higher Solar Radiation, and Less Humidity Is Associated With Poor Clinical and Laboratory Outcomes in COVID-19 Patients.** Front Public Health 2021; 9:618828Hachim MY, Hachim IY, Naeem K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816417>
32. **Comparison of Clinical Features and Outcomes of Medically Attended COVID-19 and Influenza Patients in a Defined Population in the 2020 Respiratory Virus Season.** Front Public Health 2021; 9:587425Liu L, Zeng F, Rao J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33834012>
33. **High-Minority Nursing Homes Disproportionately Affected by COVID-19 Deaths.** Front Public Health 2021; 9:606364Weech-Maldonado R, Lord J, Davlyatov

G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829006>

34. **Interferon-induced transmembrane protein-3 genetic variant rs12252 is associated with COVID-19 mortality.** *Genomics* 2021; Alghamdi J, Alaamery M, Barhoumi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838280>
35. **SARS-CoV-2 molecular identification and clinical data analysis of associated risk factors from a COVID-19 testing laboratory of a coastal region in Bangladesh.** *Heliyon* 2021; 7:e06650 Ali MR, Chowdhury MR, Mas-Ud MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817359>
36. **CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity.** *Infection* 2021; Doehn JM, Tabeling C, Biesen R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825125>
37. **Early hematological indicators of severe COVID-19 disease in hospitalized patients: Data from a South Asian population.** *Int. J. Lab. Hematol.* 2021; Sharif F, Khan S, Junaid A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837662>
38. **Classification and analysis of outcome predictors in non-critically ill COVID-19 patients.** *Intern. Med. J.* 2021; Venturini S, Orso D, Cugini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835685>
39. **ECG markers of malignant arrhythmias and in-hospital outcome of COVID-19 pneumonia.** *J Arrhythm* 2021; Shaghee F, Nafakhi H, Alareedh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821177>
40. **Vitamin D and Vitamin D binding protein: the inseparable duo in COVID-19.** *J. Endocrinol. Invest.* 2021; Speeckaert MM, Speeckaert R, Delanghe JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33840080>
41. **Retrospective analysis of vitamin D status on inflammatory markers and course of the disease in patients with COVID-19 infection.** *J. Endocrinol. Invest.* 2021; Ünsal YA, Gül Ö, Cander S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818731>
42. **Does Macrophage Migration Inhibitory Factor predict the prognosis of COVID-19 disease?** *J Infect Dev Ctries* 2021; 15:398-403 Dheir H, Yaylaci S, Sipahi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839715>
43. **The PaO₂/FiO₂ ratio on admission is independently associated with prolonged hospitalization in COVID-19 patients.** *J Infect Dev Ctries* 2021; 15:353-359 Zinellu A, De Vito A, Scano V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839709>
44. **IgG immune complexes may contribute to neutrophil activation in the course of severe COVID-19.** *J Infect Dis* 2021; Mazzitelli I, Bleichmar L, Ludueña MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822045>
45. **Association between the HLA genotype and the severity of COVID-19 infection among South Asians.** *J Med Virol* 2021; Naemi FMA, Al-Adwani S, Al-Khatibi H, Al-Nazawi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830530>
46. **Red Cell Distribution Width is Associated with Mortality in Non-Anemic Patients with COVID-19.** *J Med Virol* 2021; Rapp JL, Tremblay D, Alpert N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837966>
47. **Hyponatremia is associated with poor outcome in COVID-19.** *J Nephrol* 2021; De Carvalho H, Letellier T, Karakachoff M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826113>

48. **Analysis of Risk Factors in COVID-19 Adult Mortality in Russia.** J. Prim. Care Community Health 2021; 12:21501327211008050Kirillov Y, Timofeev S, Avdalyan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829916>
49. **Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality.** J Thromb Haemost 2021; Smadja DM, Philippe A, Bory O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830623>
50. **Sex Differences in Coronavirus Disease 2019 (COVID-19) Hospitalization and Mortality.** J Womens Health (Larchmt) 2021; Gomez JMD, Du-Fay-de-Lavallaz JM, Fugar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826864>
51. **Development and validation of an individualized nomogram for early prediction of the duration of SARS-CoV-2 shedding in COVID-19 patients with non-severe disease.** J Zhejiang Univ Sci B 2021; 22:318-329Yuan S, Pan Y, Xia Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835766>
52. **Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19.** Med Clin (Engl Ed) 2021; 156:324-331Deng F, Zhang L, Lyu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824908>
53. **Construction of a risk map to understand the vulnerability of various types of cancer patients to COVID-19 infection.** MedComm (Beijing) 2021; 2:69-81He J, Yang X, Wang H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821252>
54. **Investigating the ACE2 polymorphisms in COVID-19 susceptibility: An in silico analysis.** Mol Genet Genomic Med 2021:e1672Pouladi N, Abdolahi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818000>
55. **Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease.** Open Heart 2021; 8Tessitore E, Carballo D, Poncet A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833064>
56. **Deaf adults at higher risk for severe illness: COVID-19 information preference and perceived health consequences.** Patient Educ. Couns. 2021; Moreland CJ, Paludneviciene R, Park JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824053>
57. **Dyslipidaemia and mortality in COVID-19 patients - a meta-analysis.** QJM 2021; Zuin M, Rigatelli G, Bilato C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822215>
58. **Chest CT severity score and radiological patterns as predictors of disease severity, ICU admission, and viral positivity in COVID-19 patients.** Respir Investig 2021; Bellos I, Tavernaraki K, Stefanidis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820751>
59. **Does Airborne Pollen Influence COVID-19 Outbreak?** Sustain Cities Soc 2021:102887Khairwal R, Goyal A, Mor S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816082>
60. **COVID-19 and ethnicity:has history repeated itself?** Thorax 2021; Learoyd AE, Douiri A, Hart N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837142>
61. **Citizen science initiative points at childhood BCG vaccination as a risk factor for COVID-19.** Transbound Emerg Dis 2021; de la Fuente J, Armas O, Sánchez-Rodríguez L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825348>
62. **Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide**

survey. World J. Gastroenterol. 2021; 27:1226-1239Queiroz NSF, Teixeira FV, Motta MP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828396>

Safety (27 articles)

1. **Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials.** Am. J. Cardiovasc. Dis. 2021; 11:93-107Eze P, Mezue KN, Nduka CU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815925>
2. **Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.** Am J Kidney Dis 2021; Lebedev L, Sapojnikov M, Wechsler A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839200>
3. **Disproportionality Analysis of Anaphylactic Reactions after Vaccination with mRNA COVID-19 Vaccines in the United States.** Ann. Allergy. Asthma. Immunol. 2021; Rodriguez-Nava G, Egoryan G, Trelles-Garcia DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838338>
4. **Re: Unilateral axillary adenopathy in the setting of COVID-19 vaccine, Clinical Imaging, January 2021.** Clin Imaging 2021; Finnegan J, Govender P, Torreggiani WC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838977>
5. **Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon.** Clin Immunol 2021;108721Akinosoglou K, Tzivaki I, Marangos M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823270>
6. **Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test.** Contact Dermatitis 2021; Stingeni L, Francisci D, Bianchi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834491>
7. **Untimely Myocardial Infarction or COVID-19 Vaccine Side Effect.** Cureus 2021; 13:e13651Boivin Z, Martin J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824804>
8. **SARS-CoV-2 vaccines - What the nephrologist should know.** Deutsche Medizinische Wochenschrift 2021; 146:466-470Heine GH, Becker SL, Scheuer AL, Schirmer SH.
9. **Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.** Eur J Hosp Pharm 2021; Skalafouris C, Samer C, Stirnemann J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832918>
10. **Delirium triggered by COVID-19 vaccine in an elderly patient.** Geriatr Gerontol Int 2021; Zavala-Jonguitud LF, Pérez-García CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829614>
11. **Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review.** Indian J. Clin. Biochem. 2021:1-13Kaur RJ, Dutta S, Bhardwaj P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814753>
12. **Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis.** Indian J Med Res 2021; 153:219-226Faruqui AR, Xavier D, Kamat SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818480>
13. **mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability.** Int. J. Pharm. 2021:120586Schoenmaker L, Witzigmann D, Kulkarni JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839230>

14. **COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).** J Allergy Clin Immunol Pract 2021; Bonadonna P, Brockow K, Niedoszytko M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831618>
15. **Cutaneous Reactions Reported after Moderna and Pfizer COVID-19 Vaccination: A Registry-Based Study of 414 Cases.** J Am Acad Dermatol 2021; McMahon DE, Amerson E, Rosenbach M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838206>
16. **Vaccination for Covid-19 and relationship to osteoporosis care: Current evidence and suggested approaches.** J. Bone Miner. Res. 2021; Tsourdi E, Yu EW, Jan de Beur SM, Drake MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831269>
17. **Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single centre case series.** J Eur Acad Dermatol Venereol 2021; Corbeddu M, Diociaiuti A, Vinci MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834563>
18. **Good tolerance of hyaluronic acid injections during the period of the Covid-19 pandemic: observing a cohort of 1093 patients in a prospective, observational real-life study.** J Eur Acad Dermatol Venereol 2021; Naouri M, Dahan S, Le Pillouer Prost A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834559>
19. **Combined intravenous immunoglobulin and baricitinib treatment for severe COVID-19 with rhabdomyolysis: A case report.** J Formos Med Assoc 2021; Wu HY, Pan CT, Cheng CF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838985>
20. **Interferon- λ 3 Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis.** J Inflamm Res 2021; 14:1257-1270 Read SA, Gloss BS, Liddle C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833547>
21. **Adverse effects of COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.** J Med Virol 2021; Kadali RAK, Janagama R, Peruru S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822361>
22. **Reactive Axillary Lymphadenopathy to COVID-19 Vaccination on F18-FDG PET/CT.** J. Nucl. Med. Technol. 2021; Smith MV, Yang M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820864>
23. **United States internet searches for "infertility" following COVID-19 vaccine misinformation.** J Osteopath Med 2021; Sajjadi NB, Nowlin W, Nowlin R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838086>
24. **Efficacy and safety of chloroquine and hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies.** Med. J. Islam. Repub. Iran 2020; 34:171 Barzkar F, Ranjbar M, Sioofy-Khojine AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816370>
25. **Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications.** Neurologia 2021; Caronna E, José Gallardo V, Alpuente A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832802>

26. **Use of Remdesivir in Myasthenia Gravis and COVID-19.** Pharmacotherapy 2021; Peters BJ, Rabinstein AA, DuBrock HM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835512>
27. **COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER).** Vaccine 2021; Kochhar S, Dubé E, Graham J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836897>

Treatment options (92 articles)

1. **Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era.** ACS Nano 2021; Serrano-Aroca Á, Takayama K, Tuñón-Molina A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826850>
2. **Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.** Acta Med Indones 2021; 53:86-95 Hosseini P, Rahimi H, Najafabadi MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818411>
3. **Capturing Cytokines with Advanced Materials: A Potential Strategy to Tackle COVID-19 Cytokine Storm.** Adv Mater 2021:e2100012 Meng QF, Tian R, Long H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837596>
4. **SARS-CoV-2: the "Uncensored" Truth about Its Origin and Adipose-Derived Mesenchymal Stem Cells as New Potential Immune-Modulatory Weapon.** Aging Dis 2021; 12:330-344 Gentile P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815867>
5. **Mesenchymal Stem Cells for the Compassionate Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID 19.** Aging Dis 2021; 12:360-370 Iglesias M, Butrón P, Torre-Villalvazo I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815870>
6. **Global Sex Disparity of COVID-19: A Descriptive Review of Sex Hormones and Consideration for the Potential Therapeutic Use of Hormone Replacement Therapy in Older Adults.** Aging Dis 2021; 12:671-683 Okpechi SC, Fong JT, Gill SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815890>
7. **Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation.** Allergy 2021; Khaitov M, Nikonova A, Shilovskiy I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837568>
8. **Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials.** Am. J. Cardiovasc. Dis. 2021; 11:93-107 Eze P, Mezue KN, Nduka CU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815925>
9. **Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study.** Am. J. Otolaryngol. 2021; 42:103033 Rashid RA, Zgair A, Al-Ani RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839489>
10. **Investigation into molecular mechanisms and high-frequency core TCM for pulmonary fibrosis secondary to COVID-19 based on network pharmacology and data mining.** Ann Palliat Med 2021; Yu MX, Song X, Ma XQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832291>

11. **Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor.** Biochem Biophys Rep 2021; 26:100982Ahsan T, Sajib AA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817352>
12. **Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay.** Bioorg. Med. Chem. 2021; 38:116119Sun H, Wang Y, Chen CZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831697>
13. **Elderberry for prevention and treatment of viral respiratory illnesses: a systematic review.** BMC Complement Med Ther 2021; 21:112Wieland LS, Piechotta V, Feinberg T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827515>
14. **Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.** BMC Infect. Dis. 2021; 21:337Ranjbar K, Moghadami M, Mirahmadizadeh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838657>
15. **Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too.** BMJ Glob Health 2021; 6Perhudoff K, t Hoen E, Boulet P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827793>
16. **Encephalopathy responsive to thiamine in severe COVID-19 patients.** Brain Behav Immun Health 2021; 14:100252Branco de Oliveira MV, Irikura S, Lourenço FHB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817670>
17. **Bioinformatics and machine learning approach identifies potential drug targets and pathways in COVID-19.** Brief. Bioinform. 2021; Auwul MR, Rahman MR, Gov E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839760>
18. **Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.** Cardiovasc. Toxicol. 2021:1-6Ferrara F, Vitiello A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33835386>
19. **TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.** Cell 2021; Ho JSY, Mok BW, Campisi L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33836156>
20. **Electrospun Aspirin/Eudragit/Lipid Hybrid Nanofibers for Colon-targeted Delivery Using an Energy-saving Process.** Chem. Res. Chin. Univ. 2021:1-7Wang Y, Tian L, Zhu T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814861>
21. **COVID-19 into Chemical Science Perspective: Chemical Preventive Measures and Drug Development.** ChemistrySelect 2021; 6:2010-2028Adhikari B, Sahu N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33821213>
22. **Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 M(pro) for pharmacological interventions in COVID-19 pandemic.** Chronobiol. Int. 2021:1-15Sultan A, Ali R, Sultan T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33820462>
23. **Combination of convalescent plasma therapy and repurposed drugs to treat severe COVID-19 patient with multimorbidity.** Clin Case Rep 2021; Das SK, Ranabhat K, Bhattarai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821192>
24. **Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.** Clin Immunol 2021:108723Kenig A, Ishay Y, Kharouf F, Rubin L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838340>

25. **Fast recovery of cardiac function in PIMS-TS patients early using intravenous anti-IL-1 treatment.** Crit Care 2021; 25:131 Mastrolia MV, Marrani E, Calabri GB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827651>
26. **C-Phycocyanin-derived Phycocyanobilin as a Potential Nutraceutical Approach for Major Neurodegenerative Disorders and COVID-19-induced Damage to the Nervous System.** Curr. Neuropharmacol. 2021; Pentón-Rol G, Marín-Prida J, McCarty MF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829974>
27. **COVID-19: Evidence-based treatment options.** Deutsches Arzteblatt International 2020; 117:A2340-A2345 Karagiannidis C, Mikolajewska A, Uhrig A *et al.*
28. **Anti-Inflammation, Immunomodulation and Therapeutic Repair in Current Clinical Trials for the Management of COVID-19.** Drug Des. Devel. Ther. 2021; 15:1345-1356 Li C, Zhao H, Cheng L, Wang B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824579>
29. **Regulatory status quo and prospects for biosurfactants in pharmaceutical applications.** Drug Discov Today 2021; Ruba I, Zain B, Ildikó C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831583>
30. **Drugs intervention study in COVID-19 management.** Drug Metab Pers Ther 2021; Taher M, Tik N, Susanti D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818031>
31. **The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study.** Drugs Context 2021; 10 Efimov SV, Matsiyeuskaya NV, Boytsova OV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828607>
32. **New insights into application of nanoparticles in the diagnosis and screening of novel coronavirus (SARS-CoV-2).** Emergent Mater 2021:1-17 Tharayil A, Rajakumari R, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817553>
33. **Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.** Eur J Hosp Pharm 2021; Skalaforis C, Samer C, Stirnemann J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832918>
34. **Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19.** Eur J Intern Med 2021; Dalekos GN, Stefanos A, Georgiadou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820686>
35. **Evidence that Maackia amurensis seed lectin (MASL) exerts pleiotropic actions on oral squamous cells with potential to inhibit SARS-CoV-2 infection and COVID-19 disease progression.** Exp. Cell Res. 2021:112594 Sheehan SA, Hamilton KL, Retzbach EP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823179>
36. **A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.** Expert Opin Biol Ther 2021:1-12 Kumar S, De Souza R, Nadkar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835886>
37. **Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.** Expert Rev. Clin. Immunol. 2021:1-

- 13Rezaei S, Fatemi B, Karimi Majd Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823733>
38. **Recent efforts for drug identification from phytochemicals against SARS-CoV-2: Exploration of the chemical space to identify druggable leads.** Food Chem. Toxicol. 2021;112:160Joshi G, Sindhu J, Thakur S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823228>
39. **Bovine Coronavirus Immune Milk Against COVID-19.** Front. Immunol. 2021; 12:637152Arenas A, Borge C, Carbonero A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833758>
40. **Corrigendum: High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China.** Front. Immunol. 2021; 12:671443Cao W, Liu X, Hong K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831136>
41. **Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients.** Front. Immunol. 2021; 12:613070Caracciolo M, Correale P, Mangano C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815368>
42. **Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19.** Front Med (Lausanne) 2021; 8:620990Issa H, Eid AH, Berry B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816521>
43. **Case Report: Administration of Amniotic Fluid-Derived Nanoparticles in Three Severely Ill COVID-19 Patients.** Front Med (Lausanne) 2021; 8:583842Mitrani MI, Bellio MA, Sagel A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816515>
44. **Fever and Antipyretic Supported by Traditional Chinese Medicine: A Multi-Pathway Regulation.** Front. Pharmacol. 2021; 12:583279Ma LL, Liu HM, Luo CH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828481>
45. **COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.** Front. Pharmacol. 2021; 12:633680Malone RW, Tisdall P, Fremont-Smith P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833683>
46. **Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug.** Front. Pharmacol. 2021; 12:649532Uckun FM, Saund S, Windlass H, Trieu V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815126>
47. **A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa.** Global Health 2021; 17:42Amimo F, Lambert B, Magit A, Hashizume M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832487>
48. **Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study.** Glycobiology 2021; Šmak P, Chandrabose S, Tvaroška I, Koča J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822042>
49. **Design and Identification of Novel Annomontine Analogues Against SARS-CoV-2: An In-Silico Approach.** Heliyon 2021:e06657Waidha K, Saxena A, Kumar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824915>
50. **Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study.** Indian J. Anaesth. 2021; 65:S41-

s46Mahajan L, Singh AP, Gifty. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814589>

51. **Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach.** *Indian J Med Res* 2021; 153:132-143 Behera SK, Mahapatra N, Tripathy CS, Pati S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818470>
52. **Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.** *Indian J Med Res* 2021; 153:64-85 Khaire NS, Jindal N, Yaddanapudi LN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818467>
53. **Emerging trends from COVID-19 research registered in the Clinical Trials Registry - India.** *Indian J Med Res* 2021; 153:26-63 Rao MVV, Juneja A, Maulik M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818466>
54. **Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial.** *Indian J Med Res* 2021; 153:151-158 Thakar A, Panda S, Sakthivel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818472>
55. **Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomized control clinical trial.** *Int J Antimicrob Agents* 2021:106334 Faqih F, Alharthy A, Abdulaziz S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838224>
56. **Antiviral potential of plant polysaccharide nanoparticles actuating non-specific immunity.** *Int. J. Biol. Macromol.* 2021; Stovbun SV, Kalinina TS, Zlenko DV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831450>
57. **Comment to the manuscript by William P. Hausdorff and Jorge Flores: Low-dose and oral exposure to SARS-CoV-2 may help us understand and prevent severe COVID-19, IJID 103 (2021) 37-41.** *Int J Infect Dis* 2021; Bauer G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819603>
58. **A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm.** *Intern Emerg Med* 2021; Pouladzadeh M, Safdarian M, Eshghi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837906>
59. **The impact of COVID-19 on a cohort of patients treated with clozapine.** *Ir. J. Psychol. Med.* 2021:1-24 Fahy Y, Dineen B, McDonald C, Hallahan B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818330>
60. **Potential anti-COVID-19 agents, Cepharranthine and Nelfinavir, and their usage for combination treatment.** *iScience* 2021:102367 Ohashi H, Watashi K, Saso W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817567>
61. **A novel anti-human IL-1R7 antibody reduces IL-18-mediated inflammatory signaling.** *J Biol Chem* 2021:100630 Li S, Jiang L, Beckmann K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823154>
62. **Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression.** *J Diabetes Metab Disord* 2021:1-8 Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816358>
63. **The use of medicinal plants to prevent COVID-19 in Nepal.** *J Ethnobiol Ethnomed* 2021; 17:26 Khadka D, Dhamala MK, Li F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832492>

64. **Immunomodulatory and anti-inflammatory potential of crocin in COVID-19 treatment.** J. Food Biochem. 2021:e13718Ghasemnejad-Berenji M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817822>
65. **Combined intravenous immunoglobulin and baricitinib treatment for severe COVID-19 with rhabdomyolysis: A case report.** J Formos Med Assoc 2021; Wu HY, Pan CT, Cheng CF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838985>
66. **Interferon- λ 3 Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis.** J Inflamm Res 2021; 14:1257-1270Read SA, Gloss BS, Liddle C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833547>
67. **Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection.** J Inflamm Res 2021; 14:1195-1206Shrivastava R, Shrivastava R, Johansen B, Allain T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833542>
68. **A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers.** J. Pharm. Biomed. Anal. 2021; 199:114057Morsy MI, Nouman EG, Abdallah YM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831737>
69. **N-acetylcysteine and coronavirus disease 2019: May it work as a beneficial preventive and adjuvant therapy? A comprehensive review study.** J. Res. Med. Sci. 2020; 25:109Atefi N, Behrangi E, Mozafarpour S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824674>
70. **Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.** JMIR Public Health Surveill 2021; 7:e25500Peng HT, Rhind SG, Beckett A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825689>
71. **Repurposing antiviral drugs on recently emerged viral infections: A review article.** Mater Today Proc 2021; Swathi K, Nikitha B, Chandrakala B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816131>
72. **Anti-Inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort.** Mayo Clin Proc Innov Qual Outcomes 2021; Hayek ME, Mansour M, Ndetan H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817559>
73. **Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19.** Med. Hypotheses 2021; 150:110564Sanghavi DK, Titus A, Caulfield TR, David Freeman W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823371>
74. **Efficacy and safety of chloroquine and hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies.** Med. J. Islam. Repub. Iran 2020; 34:171Barzkar F, Ranjbar M, Sioofy-Khojine AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816370>
75. **An EUA for bamlanivimab and etesevimab for COVID-19.** Med. Lett. Drugs Ther. 2021; 63:49-50. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830966>
76. **Investigation of angucycline compounds as potential drug candidates against SARS Cov-2 main protease using docking and molecular dynamic**

- approaches.** *Mol. Divers.* 2021; Al-Bustany HA, Ercan S, Ince E, Pirinccioglu N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837893>
77. **Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications.** *Neurologia* 2021; Caronna E, José Gallardo V, Alpuente A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832802>
 78. **Antivirális és gyulladásellenes kezelési lehetőségek COVID-19-ben.** *Orv. Hetil.* 2021; 162:643-651 Szekanecz Z, Bogos K, Constantin T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838023>
 79. **[Antiviral and anti-inflammatory therapies in COVID-19].** *Orv. Hetil.* 2021; 162:643-651 Szekanecz Z, Bogos K, Constantin T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838023>
 80. **Use of Remdesivir in Myasthenia Gravis and COVID-19.** *Pharmacotherapy* 2021; Peters BJ, Rabinstein AA, DuBrock HM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835512>
 81. **Focused Role of Nanoparticles Against COVID-19: Diagnosis and Treatment.** *Photodiagnosis Photodyn. Ther.* 2021:102287 Dheyab MA, Khaniabadi PM, Aziz AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836276>
 82. **Robust antimicrobial photodynamic therapy with Curcumin-Poly (Lactic-co-Glycolic Acid) nanoparticles against COVID-19: A preliminary in vitro study in Vero cell line as a model.** *Photodiagnosis Photodyn. Ther.* 2021:102286 Pourhajbagher M, Azimi M, Haddadi-Asl V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838311>
 83. **Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property.** *Phytother. Res.* 2021; Palit P, Mukhopadhyay A, Chattopadhyay D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817867>
 84. **Adhatoda Vasica attenuates inflammatory and hypoxic responses in preclinical mouse models: potential for repurposing in COVID-19-like conditions.** *Respir Res* 2021; 22:99 Gheware A, Dholakia D, Kannan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823870>
 85. **Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection.** *Rev. Esp. Quimioter.* 2021; Moreno-García E, Rico E, Albiach L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829722>
 86. **Therapeutic plasma exchange: A potential management strategy for critically ill MIS-C patients in the pediatric intensive care unit.** *Transfus. Apher. Sci.* 2021:103119 Emeksiz S, Özcan S, Perk O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836934>
 87. **Bioethical Perspective of Convalescent Plasma Therapy for COVID-19: A Systematic Review.** *Transfus. Clin. Biol.* 2021; Munir MA, Tandiabang PA, Setyawati T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839300>
 88. **What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis.** *Transfus. Clin. Biol.* 2021; Zeng J, Yin S, Du X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839301>

89. **Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.** *Trials* 2021; 22:262Garcia PJ, Mundaca H, Ugarte-Gil C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836826>
90. **Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19.** *World J Virol* 2021; 10:34-52Dominari A, Hathaway Iii D, Kapasi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816149>
91. **Trends in the management of infectious disease under SARS-CoV-2 era: From pathophysiological comparison of COVID-19 and influenza.** *World J Virol* 2021; 10:62-68Seki M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816151>
92. **Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review.** *World J Virol* 2021; 10:53-61Spera AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=3381615>

Trials (17 articles)

1. **Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.** *BMC Infect. Dis.* 2021; 21:337Ranjbar K, Moghadami M, Mirahmadizadeh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838657>
2. **Anti-Inflammation, Immunomodulation and Therapeutic Repair in Current Clinical Trials for the Management of COVID-19.** *Drug Des. Devel. Ther.* 2021; 15:1345-1356Li C, Zhao H, Cheng L, Wang B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824579>
3. **The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study.** *Drugs Context* 2021; 10Efimov SV, Matsiyeuskaya NV, Boytsova OV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828607>
4. **SARS-CoV-2 Human Challenge Trials: Rethinking the Recruitment of Healthy Young Adults First.** *Ethics Hum Res* 2021; Matsui K, Inoue Y, Yamamoto K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821569>
5. **A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.** *Expert Opin Biol Ther* 2021;1-12Kumar S, De Souza R, Nadkar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835886>
6. **Latin-American Registry of Cardiovascular Disease and COVID-19: Rationale and Design of the CARDIO COVID 19-20 Registry.** *Glob Heart* 2021; 16:14Gómez-Mesa JE, Galindo-Coral S, Montes MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833938>
7. **Ambulatory Patients with Cardiometabolic Disease and Without Evidence of COVID-19 During the Pandemic. The CorCOVID LATAM Study.** *Glob Heart* 2021; 16:15Santi RL, Márquez MF, Piskorz D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833939>

8. **Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study.** Indian J. Anaesth. 2021; 65:S41-s46 Mahajan L, Singh AP, Gifty. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814589>
9. **Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial.** Indian J Med Res 2021; 153:151-158 Thakar A, Panda S, Sakthivel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818472>
10. **Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomized control clinical trial.** Int J Antimicrob Agents 2021:106334 Faqih F, Alharthy A, Abdulaziz S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838224>
11. **The willingness of the Saudi Arabian population to participate in the COVID-19 vaccine trial: A case-control study.** J Taibah Univ Med Sci 2021; Felemban RM, Tashkandi EM, Mohorjy DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815034>
12. **Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials.** Medwave 2021; 21:e8105 Meza N, Pérez-Bracchiglione J, Pérez I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830976>
13. **Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression.** Nutr. Metab. Cardiovasc. Dis. 2021; Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838992>
14. **Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants.** Prev Med Rep 2021; 22:101350 Sun S, Lin D, Operario D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816087>
15. **Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.** Trials 2021; 22:262 Garcia PJ, Mundaca H, Ugarte-Gil C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836826>
16. **Primary Care implementation of Germ Defence, a digital behaviour change intervention to improve household infection control during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial.** Trials 2021; 22:263 Horwood J, Chalder M, Ainsworth B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836825>
17. **The COVID-19 pandemic and new clinical trial activations.** Trials 2021; 22:260 Unger JM, Xiao H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832534>

Vaccines (62 articles)

1. **COVID-19 Vaccine for Elderly: Should We Be Reactive or Proactive?** Acta Med Indones 2021; 53:1-4 Setiati S, Marsigit J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818400>
2. **Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.** Am J Kidney Dis 2021; Lebedev L, Sapojnikov M, Wechsler A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839200>

3. **Disproportionality Analysis of Anaphylactic Reactions after Vaccination with mRNA COVID-19 Vaccines in the United States.** Ann. Allergy. Asthma. Immunol. 2021; Rodriguez-Nava G, Egoryan G, Trelles-Garcia DP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33838338>
4. **RNAi Technology and Investigation on Possible Vaccines to Combat SARS-CoV-2 Infection.** Appl. Biochem. Biotechnol. 2021; Talukder P, Chanda S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33826068>
5. **The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.** Arch Razi Inst 2021; 76:1-6Amanpour S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33818952>
6. **Common low complexity regions for SARS-CoV-2 and human proteomes as potential multidirectional risk factor in vaccine development.** BMC Bioinformatics 2021; 22:182Gruca A, Ziemska-Legiecka J, Jarnot P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33832440>
7. **Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.** Clin Chem Lab Med 2021; Danese E, Montagnana M, Salvagno GL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33838087>
8. **Re: Unilateral axillary adenopathy in the setting of COVID-19 vaccine, Clinical Imaging, January 2021.** Clin Imaging 2021; Finnegan J, Govender P, Torreggiani WC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838977>
9. **Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon.** Clin Immunol 2021;108721Akinosoglou K, Tzivaki I, Marangos M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33823270>
10. **Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.** Clin J Am Soc Nephrol 2021; Grupper A, Sharon N, Finn T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824157>
11. **Untimely Myocardial Infarction or COVID-19 Vaccine Side Effect.** Cureus 2021; 13:e13651Boivin Z, Martin J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824804>
12. **SARS-CoV-2 vaccines - What the nephrologist should know.** Deutsche Medizinische Wochenschrift 2021; 146:466-470Heine GH, Becker SL, Scheuer AL, Schirmer SH.
13. **Roll out of COVID-19 vaccination in India: A SWOT analysis.** Disaster Med Public Health Prep 2021;1-13Sharma P, Pardeshi G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33820581>
14. **Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.** Drug Dev. Ind. Pharm. 2021;1-12Nascimento Júnior JAC, Santos AM, Cavalcante RCM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826439>
15. **Postvaccination COVID-19 among Healthcare Workers, Israel.** Emerg Infect Dis 2021; 27Yousaf Z, Mushtaq K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829986>
16. **Toward the Impact of Non-pharmaceutical Interventions and Vaccination on the COVID-19 Pandemic With Time-Dependent SEIR Model.** Front Artif Intell 2021; 4:648579Li Y, Ge L, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817630>

17. **Addressing Parental Vaccine Hesitancy and Other Barriers to Childhood/Adolescent Vaccination Uptake During the Coronavirus (COVID-19) Pandemic.** Front. Immunol. 2021; 12:663074 Olusanya OA, Bednarczyk RA, Davis RL, Shaban-Nejad A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815424>
18. **A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.** Front. Pharmacol. 2020; 11:590154 Dash P, Mohapatra S, Ghosh S, Nayak B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815095>
19. **Delirium triggered by COVID-19 vaccine in an elderly patient.** Geriatr Gerontol Int 2021; Zavala-Jonguitud LF, Pérez-García CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829614>
20. **A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa.** Global Health 2021; 17:42 Amimo F, Lambert B, Magit A, Hashizume M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832487>
21. **Hospitalist perspectives on barriers to recommend and potential benefit of the COVID-19 vaccine.** Hosp Pract (1995) 2021; Dugani SB, Geyer HL, Maniaci MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826433>
22. **Positive aspects of the mRNA platform for SARS-CoV-2 vaccines.** Hum Vaccin Immunother 2021:1-3 Hajissa K, Mussa A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830862>
23. **Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review.** Indian J. Clin. Biochem. 2021:1-13 Kaur RJ, Dutta S, Bhardwaj P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814753>
24. **mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability.** Int. J. Pharm. 2021:120586 Schoenmaker L, Witzigmann D, Kulkarni JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839230>
25. **National Study of Youth Opinions on Vaccination for COVID-19 in the U.S.** J. Adolesc. Health 2021; Brandt EJ, Rosenberg J, Waselewski ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824070>
26. **No psychological vaccination: Vaccine hesitancy is associated with negative psychiatric outcomes among Israelis who received COVID-19 vaccination.** J. Affect. Disord. 2021; 287:352-353 Palgi Y, Bergman YS, Ben-David B, Bodner E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819733>
27. **COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).** J Allergy Clin Immunol Pract 2021; Bonadonna P, Brockow K, Niedoszytko M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831618>
28. **Cutaneous Reactions Reported after Moderna and Pfizer COVID-19 Vaccination: A Registry-Based Study of 414 Cases.** J Am Acad Dermatol 2021; McMahon DE, Amerson E, Rosenbach M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838206>
29. **Vaccination for Covid-19 and relationship to osteoporosis care: Current evidence and suggested approaches.** J. Bone Miner. Res. 2021; Tsourdi E, Yu

EW, Jan de Beur SM, Drake MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33831269>

30. **SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.** J. Clin. Invest. 2021; Woldemeskel BA, Garliss CC, Blankson JN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822770>
31. **Clinical Equipoise in COVID-19 Vaccine Candidates Trials.** J. Clin. Pharmacol. 2021; Dal-Ré R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826784>
32. **Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single centre case series.** J Eur Acad Dermatol Venereol 2021; Corbeddu M, Diociaiuti A, Vinci MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834563>
33. **WHO's allocation framework for COVAX: is it fair?** J. Med. Ethics 2021; Sharma S, Kawa N, Gomber A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837046>
34. **Priority vaccination for mental illness, developmental or intellectual disability.** J. Med. Ethics 2021; Shevzov-Zebrun N, Caplan AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33827909>
35. **Adverse effects of COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.** J Med Virol 2021; Kadali RAK, Janagama R, Peruru S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822361>
36. **Reactive Axillary Lymphadenopathy to COVID-19 Vaccination on F18-FDG PET/CT.** J. Nucl. Med. Technol. 2021; Smith MV, Yang M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33820864>
37. **United States internet searches for "infertility" following COVID-19 vaccine misinformation.** J Osteopath Med 2021; Sajjadi NB, Nowlin W, Nowlin R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838086>
38. **Considering Needle Phobia among Adult Patients During Mass COVID-19 Vaccinations.** J. Prim. Care Community Health 2021; 12:21501327211007393 Love AS, Love RJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33813931>
39. **No-jab, no-job clause: ethical issues and legal impediments.** J Public Health (Oxf) 2021; Corpuz JCG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825879>
40. **Faster than warp speed: early attention to COVID-19 by anti-vaccine groups on Facebook.** J Public Health (Oxf) 2021; Kalichman SC, Eaton LA, Earnshaw VA, Brousseau N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837428>
41. **Social trauma as a contributory factor in Filipino's vaccine hesitancy.** J Public Health (Oxf) 2021; Vergara RJD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837432>
42. **The willingness of the Saudi Arabian population to participate in the COVID-19 vaccine trial: A case-control study.** J Taibah Univ Med Sci 2021; Felemban RM, Tashkandi EM, Mohorjy DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815034>
43. **Timing of COVID-19 Vaccine in the setting of anti-CD20 Therapy: A Primer for Nephrologists.** Kidney Int Rep 2021; Kant S, Kronbichler A, Salas A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821223>
44. **Current questions regarding Covid-19 vaccination for specific populations - an overview of the state of research.** MMW-Fortschritte der Medizin 2021; 163:48-

49Sönmez S, Huenges B, Vollmar HC.

45. **Role of nanotechnology behind the success of mRNA vaccines for COVID-19.** Nano Today 2021;101142Khurana A, Allawadhi P, Khurana I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33815564>
46. **An Informative Discussion for School Nurses on COVID-19 mRNA Vaccine.** NASN Sch. Nurse 2021;1942602x21999606Gordon J, Reynolds M, Barnby E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33825584>
47. **The prospective COVID-19 vaccine: willingness to pay and perception of community members in Ibadan, Nigeria.** PeerJ 2021; 9:e11153Ilesanmi O, Afolabi A, Uchendu O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828927>
48. **Attitudes towards COVID-19 vaccination, vaccine hesitancy and intention to take the vaccine.** Pharm. Pract. (Granada) 2021; 19:2317Cordina M, Lauri MA, Lauri J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828623>
49. **Determinants of COVID-19 vaccine acceptance in a high infection-rate country: a cross-sectional study in Russia.** Pharm. Pract. (Granada) 2021; 19:2276Tran VD, Pak TV, Gribkova EI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33828622>
50. **How to best handle vaccine decliners: scientific facts and psychological approach.** Postgrad. Med. J. 2021; Xantus GZ, Burke D, Kanizsai P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33837130>
51. **Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants.** Prev Med Rep 2021; 22:101350Sun S, Lin D, Operario D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816087>
52. **GP confidence in counselling patients about COVID-19 vaccines: A cross-sectional survey.** Public Health Pract (Oxf) 2021; 2:100113Armitage R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33817680>
53. **[In the United Kingdom, volunteer caregivers to reinforce COVID vaccination teams].** Rev. Infirm. 2021; 70:33-34Young G, Hodgson J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33832727>
54. **Value of influenza vaccines in cancer patients during the coronavirus (COVID-19) pandemic: a cross-sectional study.** Support. Care Cancer 2021; Aznab M, Eskandari Roozbahani N, Moazen H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33837848>
55. **A two-step vaccination technique to limit COVID-19 spread using mobile data.** Sustain Cities Soc 2021; 70:102886Jadidi M, Jamshidiha S, Masroori I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33816084>
56. **Models of Incorporating Telehealth into Obstetric Care During the COVID-19 Pandemic, Its Benefits And Barriers: A Scoping Review.** Telemed J E Health 2021; Almuslim H, AlDossary S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33819434>
57. **Citizen science initiative points at childhood BCG vaccination as a risk factor for COVID-19.** Transbound Emerg Dis 2021; de la Fuente J, Armas O, Sánchez-Rodríguez L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825348>
58. **Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients.** Vaccine 2021; Azzi L, Focosi D, Dentali F *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33824042>

59. **COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER).** Vaccine 2021; Kochhar S, Dubé E, Graham J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33836897>
60. **Cancelled routine vaccination appointments due to COVID-19 pandemic in Germany.** Vaccine X 2021; 100094 Katharina Schmid-Küpke N, Matysiak-Klose D, Siedler A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821245>
61. **Cancelled routine vaccination appointments due to COVID-19 pandemic in Germany.** Vaccine X 2021; 8:100094 Schmid-Küpke NK, Matysiak-Klose D, Siedler A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821245>
62. **Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates.** Virol Sin 2021; 1-11 Yao YF, Wang ZJ, Jiang RD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33835391>

Women – pregnancy (33 articles)

1. **Global Sex Disparity of COVID-19: A Descriptive Review of Sex Hormones and Consideration for the Potential Therapeutic Use of Hormone Replacement Therapy in Older Adults.** Aging Dis 2021; 12:671-683 Okpechi SC, Fong JT, Gill SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33815890>
2. **The COVID-19 outbreak increases maternal stress during pregnancy, but not the risk for postpartum depression.** Arch Womens Ment Health 2021; Boekhorst M, Muskens L, Hulsbosch LP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33830373>
3. **Challenges and opportunities of the COVID-19 pandemic for perinatal mental health care: a mixed-methods study of mental health care staff.** Arch Womens Ment Health 2021; Wilson CA, Dalton-Locke C, Johnson S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33830374>
4. **Effects of the COVID pandemic on pregnancy outcomes.** Best Pract. Res. Clin. Obstet. Gynaecol. 2021; Elsaddig M, Khalil A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33832868>
5. **Maternal medicine in the COVID era.** Best Pract. Res. Clin. Obstet. Gynaecol. 2021; Relph S, Thangaratinam S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33839044>
6. **Emerging responses implemented to prevent and respond to violence against women and children in WHO European member states during the COVID-19 pandemic: a scoping review of online media reports.** BMJ Open 2021; 11:e045872 Pearson I, Butler N, Yelgezekova Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33827844>
7. **COVID-19 and immunomodulation treatment for women with reproductive failures.** Cas. Lek. Cesk. 2021; 160:33-36 Sedláčková L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33823602>
8. **Pulmonary embolism in pregnancy with COVID-19 infection: A case report.** Clin Case Rep 2021; Goudarzi S, Firouzabadi FD, Mahmoudzadeh F, Aminimoghaddam S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821188>

9. **A neonate born to an infected COVID-19 mother was tested positive just 24 hours after its birth.** Clin Case Rep 2021; Huseynova RA, L ABM, Huseynov O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821189>
10. **Mobile-Assisted Virtual Bonding Enables Breast Milk Supply in Critically Ill Mothers With COVID-19: A Reflection on the Feasibility of Telelactation.** Cureus 2021; 13:e13699Farhadi R, Mehrpisheh S, Philip RK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33833919>
11. **Prevalence of Preterm Birth Rate During COVID-19 Lockdown in a Tertiary Care Hospital, Riyadh.** Cureus 2021; 13:e13634Huseynova R, Bin Mahmoud L, Abdelrahim A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816033>
12. **Treatment of Women with Multiple Sclerosis Planning Pregnancy.** Curr. Treat. Options Neurol. 2021; 23:11Krysko KM, Bove R, Dobson R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814892>
13. **Analysis of Ovarian Injury Associated With COVID-19 Disease in Reproductive-Aged Women in Wuhan, China: An Observational Study.** Front Med (Lausanne) 2021; 8:635255Ding T, Wang T, Zhang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33816526>
14. **Berlin, December 22, 2020 - Ensuring the protection of pregnant women and neonates.** Geburtshilfe Frauenheilkd. 2021; 81:147-148.
15. **"There are absolutely no incontestable truths, and if there were any, they would be boring" - Theodor Fontane, 1819-1898.** Geburtshilfe Frauenheilkd. 2021; 81:107-108Scharl AJ.
16. **Impact of COVID-19 on Gynaecological oncology; a global perspective.** Heliyon 2021; 7:e06658O'Neill D, El-Ghobashy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829116>
17. **The exacerbation of violence against women as a form of discrimination in the period of the COVID-19 pandemic.** Heliyon 2021; 7:e06491Valencia Londoño PA, Nateras González ME, Bruno Solera C, Paz PS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33817371>
18. **The severity of COVID-19 among pregnant women and the risk of adverse maternal outcomes.** Int J Gynaecol Obstet 2021; Samadi P, Alipour Z, Ghaedrahmati M, Ahangari R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33834499>
19. **Characteristics and outcomes of COVID-19 pneumonia in pregnancy compared with infected nonpregnant women.** Int J Gynaecol Obstet 2021; Vizheh M, Muhidin S, Aghajani F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33829492>
20. **Postpartum during COVID-19 pandemic: Portuguese mothers' mental health, mindful parenting, and mother-infant bonding.** J. Clin. Psychol. 2021; Fernandes DV, Canavarro MC, Moreira H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33822369>
21. **Domestic violence during COVID-19 pandemic: The case for Indian women.** J. Community Appl. Soc. Psychol. 2021; Maji S, Bansod S, Singh T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821118>
22. **Cervical abscess caused by methicillin-susceptible Staphylococcus aureus in an infant infected with SARS-CoV-2: Diagnostic dilemma.** J Infect Chemother

- 2021; Yildirim Arslan S, Sahbudak Bal Z, Guner Ozenen G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33814352>
23. **Experiences in Electronic Consultation (eConsult) Service in Gynecology from a Quaternary Academic Medical Center.** *J Med Syst* 2021; 45:58Corbetta-Rastelli CM, Morgan TK, Homaifar N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33825075>
24. **Anxiety Levels and Solution-Focused Thinking Skills of Nurses and Midwives Working in Primary Care during the COVID-19 Pandemic: A Descriptive Correlational Study.** *J. Nurs. Manag.* 2021; Selçuk Tosun A, Akgül Gündoğdu N, Taş F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33838066>
25. **Maternal and perinatal outcomes and placental pathologic examination of 29 SARS-CoV-2 infected patients in the third trimester of gestation.** *J. Obstet. Gynaecol. Res.* 2021; Blasco Santana L, Miraval Wong E, Álvarez-Troncoso J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33821521>
26. **Community-Acquired Neonatal SARS-CoV-2 Infection Associated with Neurological Symptoms in Colombia.** *J. Trop. Pediatr.* 2021; 67Alvarado-Socarras JL, Theurel-Martin D, Cruz-Hernandez M, Rodriguez-Morales AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33823049>
27. **Sex Differences in Coronavirus Disease 2019 (COVID-19) Hospitalization and Mortality.** *J Womens Health (Larchmt)* 2021; Gomez JMD, Du-Fay-de-Lavallaz JM, Fugar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826864>
28. **Airflow dispersion during common neonatal resuscitation procedures: A simulation study.** *Pediatr Pulmonol* 2021; Kwok TC, Swaby R, Sharkey D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33826802>
29. **Depression and anxiety in pregnancy during COVID-19: A rapid review and meta-analysis.** *Psychiatry Res* 2021; 300:113912Tomfohr-Madsen LM, Racine N, Giesbrecht GF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33836471>
30. **Absence of SARS-CoV-2 (COVID-19 virus) within the IVF laboratory using strict patient screening and safety criteria.** *Reprod. Biomed. Online* 2021; Rajput SK, Khan SA, Goheen BB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33814309>
31. **Emergency cesarean section in a COVID-19 patient: A case report.** *Saudi J. Anaesth.* 2021; 15:40-42Al Harbi M, Elkouny A, Babbain B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33824641>

to subscribe click [here](#)

mailing address is:
lansberg@gmail.com

